INDEX TO VOLUME 59—1991
AUTHOR INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

Ab, B. K., (A) 511
Abalos, R. M., (O) 25
Abbot, N. C., (O) 537
Abdullah, A. K., (A) 689
Abebe, M., (A) 508
Abel, L., (A) 171, 522
Abhayambika, K., (A) 501
Abou-Zeid, C., (A) 698
Abraham, A., (A) 348
Abraham, B., (O) 68, 76
Abramova, Z. P., (A) 183
Abrams, J., (A) 713
Accolla, R. S., (A) 678
Adams, L., (A) 198, 711, 712
Adiga, R. B., (A) 681
Adnani, M. A., (A) 172
Affronti, L. F., (A) 374
Agarwal, A., (A) 517
Agarwal, J. K., (A) 151
Agarwal, U. S., (A) 504
Agrawal, J. S., (A) 149
Aguas, A. P., (A) 510
Aguis, G., (A) 354
Aiderous, A. H., (A) 371
Air, G. M., (A) 515
Akiyama, T., (A) 194
Al Atiyah, R., (A) 531
Al-Abyad, S., (A) 371
Al-Anezi, A., (A) 371
Al-Aska, A. K., (A) 175
Al-Hajjaj, M. S., (A) 689
Al-Kandari, S., (A) 371
Al-Kassimi, F. A., (A) 689
Al-Majed, S., (A) 689
Al-Mofleh, I., (A) 175
Al-Orainey, I. O., (A) 689, 689
Al-Qasaf, F., (A) 371
Al-Qubati, Y., (A) 155
Al-Shareef, N., (A) 175
Al-Shimali, B., (A) 163, 374
Al-Tameem, M., (A) 175
Al-Wazzan, A., (A) 689
Alaoui, B., (A) 172
Alekseev, L. P., (A) 363
Alfaro-Bustamante, F., (C) 480
Alford, P. L., (O) 450
Alland, D., (A) 710
Alley, P., (A) 673
Allison, J. W., (A) 692
Almeida, S. M. R., (A) 158
Alonso, T. P., (A) 362
Ambrosio, R. E., (A) 689
Amerio, N., (A) 353
Amicosante, G., (A) 374
Amin, S. S., (C) 337
Amiruddin, M. D., (A) 199, 721
Amital-Teplizki, H., (A) 176
Anandan, D., (A) 523
Ananthan, D., (A) 348
Andersen, A. B., (A) 186
Andersen, B. R., (O) 41, (A) 683
Andersen, P., (O) 58, (A) 689
Anderson, D. C., (A) 352, 508
Anderson, R., (A) 165
Andrade, H. F., Jr., (O) 12
Andrade, V. L., (C) 125
Andrew, P. W., (A) 166
Annamma, M., (A) 690
Annichino-Bizzacchi, J. M., (A) 674
Antia, N. H., (A) 525, 686
Antsey, N., (A) 518
Apt, S. D., (A) 184
Arce, P., (O) 605
Archana, (A) 675
Arnoldi, J., (A) 353
Ashtekar, D. R., (A) 694
Askgaard, D., (A) 689
Atkin, S. L., (A) 348
Auffray, C., (A) 678
Augustine, S. M., (C) 479
Ausina, V., (A) 521
Avelleira, J. C., (C) 125
Avila, J. M., (A) 357
Avinoach, I., (A) 176
Awasthi, S. K., (A) 504
Azadeh, B., (A) 524
Azulay, R. D., (A) 156

Bach, M.-A., (A) 170, 515, (O) 582
Bachhawat, B. K., (A) 697
Backstrom, B. T., (A) 510, 682
Badukshanova, N. M., (A) 187, 374
Baelden, M.-C., (A) 176
Bagga, A., (O) 248
Bahnassy, A., (A) 371
Bahr, G. M., (A) 163, 374, 518
Bailey, C. C., (A) 180
Baird, D. B., (A) 145
Bajardi, A. C., (A) 710
Bajpai, H. S., (A) 151
Bal, V., (A) 160
Balakrishnan, K., (A) 698

Balakrishnan, S., (O) 20
Balasubramanian, R., (A) 375
Baliarsing, A., (A) 525
Balybin, E. S., (A) 164
Band, H., (A) 197, 678
Banerjee, B. D., (A) 523
Banerjee, D. K., (A) 169
Banerjee, R., (A) 369, 523
Banzato, C. E. M., (C) 486
Baodebiligc, *et al.*, (A) 687
Barbieri, G., (A) 360
Barker, J., (A) 513
Barker, R. H., Jr., (A) 201
Barnes, P. F., (A) 721
Barrera, L. F., (A) 162
Barry, M. E., (A) 352, 508
Baskin, G. B., (O) 618, (A) 686
Bassily, S., (A) 700
Basten, A., (A) 355
Basu, M. K., (A) 697
Bates, J. H., (A) 692
Baya-Tsika, N., (A) 524
Bechelli, L. M., (A) 159, 504
Beck, B., (A) 364
Beck, J. S., (O) 537, (A) 690, 697
Becx-Bleumink, M., (A) 158, (O) 292, (A) 511, 516, (O) 558
Behbehan, K., (A) 374
Behbehani, K., (A) 163
Behrens, R. H., (A) 693
Belisle, J., (A) 200
Bell, D. A., (A) 358
Bellahmer, F., (A) 172
Bellein, M., (A) 151
Bello, I., (A) 362
Belurkar, L. S., (A) 500
Benar, A. B., (A) 689
Bennedsen, J., (A) 165, 689
Bentzon, M. W., (O) 58, (A) 529, 530
Berche, P., (A) 693
Bercovier, H., (A) 380, 684
Berhe, D., (A) 173
Bermudez, L. E. M., (A) 176
Bernheimer, H., (O) 441, 590
Best, M., (A) 177
Bharadwaj, V. P., (A) 163, 519
Bhargava, A., (A) 530
Bhargava, S. K., (A) 508
Bhat, H. R., (A) 352
Bhatia, A. S., (A) 679
Bhatia, V., (O) 426
Bhatia, V. N., (O) 20, (A) 348, 365, 520, 523
Bhatnagar, S., (O) 398
Bhattacharya, S. N., (C) 323
Bhoopat, L., (A) 363
Bhutani, L. K., (A) 511, 511, (O) 576
Bijlsma, J. W. J., (A) 187
Bill, R., (A) 531
Birke, J. A., (A) 372
Blackwell, J. M., (A) 507
Blanchard, D. K., (A) 375, 690
Bliss, L., (O) 221
Blocker, H., (A) 177
Blok, L. M., (A) 672
Blom-Potar, M.-C., (A) 379, 379
Bloom, B. R., (A) 157, 167, 196, 197, 200, 518, 682, 710, 713, 715
Bloos, L. J., (A) 672
Blum, L., (A) 515, (O) 582
Bobrovnik, S. A., (A) 691, 696
Bock, K., (A) 166
Boddinghaus, B., (A) 177, 375
Boddingius, J., (A) 369
Boerrigter, G., (O) 255, (A) 373
Bohme, K.-H., (A) 181
Bola, N., (A) 172
Bonerandi, J.-J., (A) 350
Bonnetblanc, J.-M., (A) 185
Bonney, G. E., (A) 522
Boog, C. J. P., (A) 680
Booth, R. J., (A) 168
Boschloo, J. G., (A) 365
Bosecker, B. A., (A) 196, 509
Bottasso, O. A., (A) 157, 353
Bottger, E. C., (A) 177, 375
Boughton, E., (A) 180
Boulnois, G. J., (A) 166
Bourdillon, C., (N) 138
Bourland, J., (A) 687
Bourrel, P., (A) 174
Boutin, J.-P., (A) 672
Bowden, R. E. M., (A) 373
Boylan, C. T., (A) 531
Bozic, C. M., (A) 202, 678, 715
Brahmajothi, V., (A) 691, 698
Branch, R. A., (A) 346
Brasseaux, D. M., (A) 372
Breckenridge, A. M., (A) 146, 501
Bremerich, A., (A) 519
Brennan, P. J., (O) 25, (A) 167, 200, 202, 678, 710, 715
Brenner, M. B., (A) 678
Brett, S. J., (A) 697
Brightmer, M. I., (A) 172
Britton, W., (A) 503
Britton, W. J., (A) 513, 676, 681
Brown, B. A., (A) 378, 533
Brown, I. N., (A) 694
Brown, R. A., (O) 537
Bryan, L. E., (A) 693
Bubochkin, B. P., (A) 691
Buchanan, T. M., (A) 517
Buckner, C. B., (A) 692
Bulmer, K., (A) 685
Burkhardt, R. A., (A) 361, 513
Burnham, G., (A) 378
Buschauer, A., (A) 184
Butler, W. R., (A) 177
Butlin, C. R., (O) 537
Byass, P., (A) 693

Byrd, S. R., (A) 345, 674
Byrne, M., (A) 347

Cadou, S., (O) 278
Caiazzo, T., (A) 358
Cairns, E., (A) 358
Cakiner, T., (A) 505, 505, 506, 675
Callihan, D. R., (A) 527
Cameron, L. J., (A) 674
Campbell, H., (A) 693
Campos-Outcalt, D., (A) 500
Cantrell, C., (O) 618
Capdepuy, M., (A) 528
Cariappa, A., (O) 68, 76
Carlone, G. M., (A) 367
Carolina, J.-C., (O) 242
Carrazana Hernandez, G. B., (A) 349, 349, 353
Cartel, J.-L., (A) 349, 354, 672
Castaño Hernández, S. T., (A) 349
Castel, O., (A) 354
Castells Rodellas, A., (A) 678
Castets, M., (A) 354
Catty, D., (A) 181, 530
Cave, M. D., (A) 692
Cellona, R. V., (O) 25
Cen, Y., *et al.*, (A) 172
Centeno, M., (O) 405
Cernoch, P., (A) 378
Chacko, A., (A) 501
Chacko, C. J. G., (O) 68
Chae, G.-T., (A) 514
Chagla, A. H., (A) 175
Chakrabarty, A. N., (A) 166, 366, 683
Chandra, A. K., (A) 166
Chang, C.-H., (A) 184
Chanpongsri, A., (A) 699
Chanteau, S., (A) 349, 354
Charles, I., (A) 365
Charvin, M., (A) 684
Chatterjee, D., (A) 202, 678
Chattopadhya, D., (A) 372
Chaturvedi, V., (O) 32, (A) 679
Chau, P. Y., (A) 188
Chaudhary, S. D., (A) 352, 675
Chaudhury, S., (A) 369, 523
Chaumeil, J. C., (A) 185
Chedid, L., (A) 374
Chen, J.-L., *et al.*, (A) 354
Cheng, J., *et al.*, (A) 146
Cherian, A., (A) 673
Chernousova, L. N., (A) 695
Chiang, T. J., (A) 517
Chin-A-Lien, R. A. M., (A) 676
Cho, S.-N., (O) 25, (A) 676
Chopra, N. K., (A) 149
Choudhary, A., (O) 398
Choudhury, A. M., (A) 199, 721
Choy, A. M., (A) 501
Christian, M., (A) 500
Chugh, K. S., (A) 509, 686
Chugh, T. D., (A) 163, 374
Chujor, C. S. N., (O) 441, 590
Chukanova, V. P., (A) 182
Cisse, M. F., (A) 354
Clark-Curtiss, J. E., (A) 196, 509, 684, 715
Claudy, A., (A) 185
Clavel-Sérès, S., (A) 520, 695
Clayberger, C., (A) 713
Cline, J. M., (A) 527
Coates, P. J., (A) 532
Cocito, C., (A) 176
Coddy-Zitsamele, R., (A) 524
Coelmo, A. A. M., (A) 169
Coffazo, S., (A) 362
Coghill, G., (A) 697
Cohen, I. R., (A) 679
Cohn, Z. A., (A) 158, 198, 511, 513, 680
Cole, S. T., (A) 369
Coleman, M. D., (A) 146, 501
Coleman, W. C., (A) 372
Colley, J., (A) 187
Collins, D. M., (A) 178
Collins, F. M., (A) 694
Colston, M. J., (A) 157, 168
Constant-Desportes, M., (A) 151, (O) 242
Content, J., (A) 178
Converse, P., (A) 158, (C) 320, (A) 512
Convit, J., (O) 405, (A) 518
Cope, A., (A) 348
Corcoran, M., (A) 347
Cossermelli, W., (A) 531
Costa, H. C., (A) 167, 169
Cottenot, F., (A) 150, 524
Courtright, P., (A) 149
Cowley, S. A., (A) 373
Crawford, J. T., (A) 692
Cree, I. A., (O) 537
Cricks, B., (A) 185
Crowle, A. J., (A) 376, 527
Cruaud, P., (A) 158, (C) 332
Cua, V. V., (A) 171

D'Khissy, L., (A) 172
da Costa, C. A., (A) 696
da Silva, M. G., (A) 169
Daffe, M., (A) 182
Dale, J. W., (A) 181, 530, 694
Dallac, S., (A) 185
Dandapat, M. C., (A) 525
Danilevskaya, I. M., (A) 376
Das, N., (A) 697
Das, R. K., (A) 147, 149
Das, S., (A) 166
Dash, B. M., (A) 677
Dastidar, S. G., (A) 166, 366, 683
Dastur, D. K., (C) 122
David, H. L., (A) 158, (C) 332, (A) 520, 527, (O) 569, (A) 695
Davis, E. O., (A) 168
Davis, J., (A) 378

Dawson, D. J., (A) 186
Dayal, S. S., (A) 517
de Bont, J. A. M., (A) 365
De Brito, T., (O) 12
de Campos, F. P. F., (A) 531
de Carvalho, E. F., (A) 196, 509
De Carvalho, F. F., (A) 380
de Chastellier, C., (A) 693
de Fatima Maroja, M., (C) 332
De Jonge, N., (A) 700
de la Cuvellerie, A., (A) 178
de la Rocha, A. D., (A) 362
de Lima, M. O., (A) 380
de Lisle, G. W., (A) 178
de Oliveira, R. M., (A) 531
de Oliveria Lima, A., (A) 696
de Rojas y Lopez del Rincon, V, (A) 523
de Soldenhoff, R., (A) 503, 517
de Souza, L. C. D., (A) 167
de Vries, R. R. P., (A) 352, 356, 357, 508, 680, 698
de Wit, M. Y. L., (A) 159, 178, 514, 520
Deans, R., (A) 197
Deelder, A. M., (A) 700
del Giudice, A. C., (A) 167
dela Cruz, E. C., (O) 25
Den Otter, W., (A) 187
Denath, F. M., (A) 374
Denis, F., (A) 155, 351, 508
Denis, M., (A) 510, 692
Deo, M. G., (C) 482
Desikan, K. V., (A) 160, (O) 385
Destree, A., (A) 358
Deuskar, N. J., (C) 482
Devadoss, P. O., (A) 692
Deverchin, J., (A) 172, 524
Dhandayudapani, S., (O) 426
Dhandayuthapani, S., (A) 348, 523
Dhar, N., (A) 504
Dhople, A. M., (O) 548, (A) 672, 684, 685
Diabate, N., (A) 678
Diament, J., (A) 531
Diamond, B., (A) 358
Diamond, E. L., (O) 229
Dias, M., (A) 696
Diaz, J. M., (A) 174, 523
Diaz, M. A., (A) 362
Dick, W. C., (A) 348
Dickinson, J. M., (A) 376
Dieng, M., (A) 176
Dietz, M., (A) 158, (O) 262, 548
Dieye, A., (A) 515, (O) 582
Dijkman, H., (A) 369
Dimitrova, D. B., (A) 148
Dindinaud, G., (A) 354
Disdier, P., (A) 350
Diver, J. M., (A) 693
Dixit, V. B., (A) 352, 677
Djeu, J. Y., (A) 375, 690
Dockrell, H., (A) 680
Doherty, T. M., (A) 510, 682
Dong, L., *et al.*, (A) 150
Dongre, V. V., (A) 347
Donnelly, M., (A) 196
Dorozhkova, I. R., (A) 178, 187, 527
Doua, F., (A) 155
Dougan, G., (A) 365
Douglas, J. T., (A) 355, 520
Dovgalyuk, I. F., (A) 376
Dowlati, Y., (A) 518
Drabick, J. J., (A) 178
Drain, V., (E) 116, (A) 169
Drazek, F. J., (A) 527
Drexhage, H. A., (A) 186
Due, L. K., (A) 171
Duerksen, F., (A) 174, 175
Duffy, P. E., (A) 178
Dumas, J.-L., (A) 351
Dumas, M., (A) 519
Dutt, A. K., (A) 179
Dutta Banik, N. D., (A) 372
Dutta, A., (O) 426
Dutta, R. K., (A) 504
Duysen, E., (A) 715

Easmon, C. S. F., (A) 694
Edorh, A. A., (A) 371
Eeckhout, E., (A) 172, 524
Eichberg, J. W., (O) 450
Eisenach, K. D., (A) 692
Ekambaram, V., (A) 672
El-Ghobarey, A., (A) 348
Elangeswaran, N., (A) 716
Elango, T. V., (A) 365
Elavia, J. F., (C) 122
Elkins, N., (A) 527
Ellard, G. A., (E) 82
Emori, M., (A) 503
Emre, S., (A) 528
English, D., (A) 683
Eozenou, P., (A) 524
Ersoy, N., (A) 675
Esaguy, N., (A) 510
Escande, J. P., (A) 180
Esquenazi, D. A., (A) 158
Esser, R. E., (A) 509
Estes, M., (A) 528
Evans, D. J., (A) 158

Faber, W. R., (O) 392, (A) 520
Fadeeva, N. I., (A) 374
Fafutis-Morris, M., (C) 480
Failbus, S. S., (A) 503, 676, 681
Fajardo, T. T., Jr., (O) 25, (A) 355
Fandinho, F. C. O., (O) 569
Fann, M. C, (A) 187
Farhi, D. C., (A) 694
Farthing, M. J. G., (A) 532
Fattorini, L., (A) 374
Ferra Torres, T. M., (A) 349, 353
Ferra Zalazar, C., (A) 184

Festenstein, H., (A) 517
Feuillet, A., (A) 380
ffytche, T. J., (A) 504, 505
Fikri, M., (A) 172
Filali, B., (A) 172
Fine, P. E. M., (A) 154, (O) 221, 255, (A) 373, 507, 680
Fiocchi, F., (A) 501
Fiss, E. H., (A) 184
Flad, H.-D., (A) 353
Flageul, B., (A) 150
Fleischer, A. B., Jr., (A) 145
Fleming, A. F., (A) 150
Fleury, R. N., (A) 151
Flohr, T., (A) 177
Flory, C. M., (A) 694
Flowers, F. P., (A) 505
Fofana, Y., (A) 678
Fonseca, L. S., (A) 169, 362
Ford, E., (A) 696
Forget, A., (A) 370
Forster, A., (O) 537
Forster, D., (A) 693
Foss, N. T., (A) 159
Foster, R., (A) 674
Foulkes, J., (A) 674
Fourche, J., (A) 528
Fournie, J.-J., (A) 355
Franceschini, N., (A) 374
Frankel, E. H., (A) 671
Franzblau, S. G., (A) 198, 684, 719
Freeman, R. G., (A) 364
Frehel, C., (A) 162, 693
Freitag, C. S., (A) 690
Frelier, P. F., (A) 528
Frere, J.-M., (A) 374
Friedland, I. R., (A) 179
Fries, J. W. U., (A) 179
Friese-Kimmel, A., (A) 184
Fritschi, E. P., (A) 506
Frommel, D., (A) 508
Fujiwara, T., (A) 199, 199
Fukutomi, Y., (A) 711, 712
Fumo, G., (A) 360
Furtado-Mendonca, L. L., (A) 531

Gabric, D. M., (A) 178
Gabriel, M., (A) 163, 374
Gadi, S., (A) 372
Gallo, M. E. N., (A) 158, 362
Ganapati, R., (A) 500, 518
Gangadharam, P. R. J., (A) 694
Ganguly, N. K., (A) 183, 686
Ganjam, K., (A) 196, 200
Ganju, L., (A) 356
Garbe, T., (A) 365
Garcia, L. F., (A) 162
Garcia, S., (A) 174, 523
Garcia, V., (O) 405
Gardner, G. D., (A) 672
Garg, R., (A) 151
Gatrill, A. J., (A) 359
Gave, A., (A) 155
Gazzard, B., (A) 188
Gebre, N., (A) 359
Gehanno, P., (A) 180
Gelas, H., (A) 524
Gelber, R. H., (A) 147, 168, 193, 345, 345, 522, 673, 674, 717
George, J., (O) 20
George, S., (O) 237
Gerardin, M., (A) 371
Gerdes, J., (A) 353
Gergert, V. Y., (A) 183
Gerovich, L. M., (A) 164
Ghazi Saidi, K., (A) 518
Gibson, S. J., (A) 169
Gidoh, M., (A) 673
Gigli, I., (A) 164
Gikas, A., (A) 378, 698
Gilbody, J. S., (E) 458
Gilburd, B. S., (A) 695
Gilleron, M., (A) 377
Gillis, T. P., (A) 168, (E) 311, (A) 368, 719
Ginda, S. S., (A) 377, 695
Girdhar, A., (A) 151, 160, 352, 360, 360, (O) 385
Girdhar, B. K., (O) 32, (A) 151, 160, 160, 161, 346, 352, 360, 360, 361, (O) 385, (C) 487, (A) 679
Go-Estrada, K. L., (A) 671
Goh, K. S., (A) 380
Gole, D. H., (A) 347
Golyshevskaya, V. I., (A) 182
Gontijo Filho, P. P., (A) 169, 362 (O) 569
Gonzalez, A. B., (A) 356
Gonzalez-Abreu, E., (A) 356
Gonzalez Castro, U., (A) 678
Gonzalez-Mendoza, A., (C) 480
Gonzalez Segredo, A., (A) 681
Goodless, D. R., (A) 145, 505
Gorin, I., (A) 180
Gormus, B. J., (A) 370, (O) 450, 618, (A) 686
Gosselin, D., (A) 169
Goto, M., (A) 195
Govoni, M., (A) 501
Graham, S. L., (A) 372
Grange, J. M., (A) 180, 377, (O) 537
Grant, A., (A) 697
Grau, G. E., (A) 506
Griffo, W., (A) 361
Grillone, S., (A) 687
Groenen, G., (A) 673
Grollier, G., (A) 354
Gronberg, A., (A) 700
Grosset, J.-H., (A) 171, (O) 242, (A) 346, 349, 378, 501, 533, 698
Groves, M. J., (A) 184, 692
Gruer, P. J. K., (A) 154
Gschmeissner, S. E., (A) 373, 681
Guardiola, J., (A) 678
Guelpa-Lauras, C.-C., (O) 242

Guido, L. S., (A) 355
Guillama, E., (A) 362
Guillaume, J.-C., (A) 185
Guillet, G., (A) 151
Guillet, M., (A) 151
Gupta, A. B., (A) 350
Gupta, H. P., (C) 317
Gupta, R. S., (A) 519
Gupta, S., (A) 374
Gupta, S. C., (A) 523
Gupte, M. D., (A) 350

Haanen, J. B. A. G., (A) 356
Haas, M., (O) 262, 548
Hadley, W. K., (A) 381
Haimanot, R. T., (A) 173
Halapi, E., (A) 512, 700
Haldar, B., (A) 350
Hammond, C., (A) 506
Hancock, G. E., (A) 158, 511, 513
Handa, A. K., (A) 504
Hane, A. A., (A) 354
Hanks, J. H., (E) 304
Hans, P., (A) 185
Hanyaloglu, E., (A) 506
Harano, Y., (A) 531
Harboe, M., (A) 165
Harding, D. R. K., (A) 510
Harle, J.-R., (A) 350
Harris, E., (A) 171
Harris, Y., (A) 689
Hartskeerl, R. A., (A) 159, 167, 514, 520
Hasan, R. S., (A) 517
Hashizume, C., (A) 174
Haslov, K., (O) 58
Hastings, R. C., (E) 102, 116, (B) 144, (A) 147, 169, (B) 499, 670, (A) 719
Hatano, K., (A) 721
Hatfull, G. F., (A) 196
Hati, A. K., (A) 369, 523
Havican, K., (A) 358
Hawkins, D., (A) 188
He, H., (A) 709
Heikens, W., (A) 375
Hellio, R., (O) 278, (A) 366
Hellyer, T. J., (A) 694
Hengy, C., (A) 524
Hennigan, S., (A) 701
Henry, D., (A) 180
Henry, P., (A) 519
Hermans, C. J., (A) 167
Hermans, J., (A) 365
Hermans, P. W. M., (A) 181, 530
Heron, I., (O) 58, (A) 689
Hibbs, J., (A) 198
Hidaka, T., (A) 503
Hioki, K., (A) 722
Hirata, T., (A) 159, 195
Hirsch, D. S., (A) 355
Hirunpetcharat, C., (A) 362

Hnizdo, E., (A) 348
Hoaksey, P. E., (A) 146
Hoffner, S. E., (A) 181
Hogervorst, E. J. M., (A) 680
Hogeweg, M., (O) 392, (A) 674, 675
Holloway, B. P, (A) 367
Holzer, T. J., (O) 41
Hong, J., (A) 528
Horhold, C., (A) 181
Hornsten, P., (A) 152
Horwitz, M. A., (A) 719
Hosoe, K., (A) 503
Houssaini-Iraqui, M., (A) 695
Hu, Y., *et al.*, (A) 152
Hua, C. Y., (A) 199
Hubbard, G. B., (O) 450, (A) 686
Hubbard, R. D., (A) 694
Huber-Bruning, O., (A) 187
Huchzermeyer, H. F. A. K., (A) 689
Hugon, J., (A) 155, 351
Huly, M., (A) 151
Humne, A. Y., (A) 523
Hunegnaw, M., (O) 432
Hunter, S. W., (A) 167, 202
Husain, S., (A) 352
Hussain, R., (A) 520
Hussein, N., (A) 370
Hvidt, T, (A) 166

Ibrahim, M. A., (A) 371
Ide, M., (A) 709
Ilangumaran, S., (A) 518
Inamitsu, T., (A) 200
Ingole, D. L., (A) 523
Inouye, T., (A) 722
Iranmanesh, A., (A) 717
Isenberg, D. A., (A) 176
Ishaque, M., (A) 365
Ishikawa, S., (A) 678
Ishikawa, Y., (A) 697
Islas-Rodriguez, A. E., (C) 480
Ivanova, E. S., (A) 691
Ivanyi, J., (A) 158, 697
Iyengar, B., (E) 645
Iyer, R. R., (A) 511, 511
Izumi, S., (A) 195, 199, 199, 709, 721, 722

Jacob, M., (O) 237
Jacobs, N. J., (A) 701
Jacobs, W. R., Jr., (A) 196, 200, 367, 699
Jacobson, R. R., (E) 116, (A) 147, 345
Jadhav, M. V., (A) 151
Jadhav, V. H., (A) 151, 350
Jain, R. C., (A) 185
Jain, S., (C) 323
Jain, V. K., (A) 352, 675
Jakubovic, H. R., (A) 350
Janda, J. M., (A) 696
Janier, M., (A) 185

Jannin, J., (A) 524
Janson, A., (A) 508
Janson, A. A. M., (A) 352, 698
Janssens, L., (A) 673
Jawahar, M. S., (A) 375
Jayalakshmi, P., (A) 147
Jayasingh, K., (A) 348
Jenkins, D., (A) 350
Jenkins, P. A., (O) 221
Jenner, P. J., (A) 168
Jesudasan, K., (A) 500
Jeyakumar, L. H., (A) 168
Jha, P. K., (A) 675
Ji, B., (A) 346, 501, 533
Ji, F., (A) 148
Jirillo, E., (A) 360
Jittinandana, A., (A) 181
Job, C. K., (E) 116, (B) 144, (A) 147, 169, 361, 513, (B) 670
Joesoef, M. R., (A) 181
Joginder, (A) 154, 351
Johnson, A. H., (A) 145
Jones, C., (A) 365
Jones, W. D., Jr., (A) 377, 699
Joshi, P. B., (A) 151

Kagawa, H., (A) 533
Kakeze, C., (A) 687
Kakkanaiah, V. N., (A) 691
Kaklamani, E., (A) 512
Kaleab, B., (A) 512
Kallenius, G., (A) 181
Kalmykova, G. N., (A) 182
Kamat, R. S., (O) 49
Kamel, M., (A) 348
Kanaujia, G. V., (A) 695
Kanetsuna, S., (A) 709
Kannan, K. B., (A) 163, 519
Kannan, S., (A) 350
Kaplan, G., (A) 158, 198, 361, 511, 513, 680, 714
Kaplanski, G., (A) 350
Kar, S., (A) 169
Karachunsky, M. A., (A) 178
Karacorlu, M. A., (A) 505, 505, 506, 675
Karanth, S. S., (A) 169
Kashima, K., (A) 709
Kashiwabara, Y., (A) 722
Kassirskaya, N. G., (A) 187
Kato, L., (A) 145
Katoch, K., (O) 5, (A) 162, (O) 248, (C) 487, (A) 516, 679
Katoch, V. M., (A) 163, (O) 248, (A) 519, 695
Katsouyanni, K., (A) 512
Kaufmann, S. H. E., (A) 359, 513, 519, 681
Kaur, G., (O) 385
Kaur, J., (O) 576
Kaur, S., (A) 348, 373, 686
Kawatsu, K., (A) 199, 721
Kawazu, K., (A) 722
Kazda, J., (A) 182, (C) 649
Kebede, B., (A) 516
Keisu, M., (A) 152
Kelly, P., (A) 378
Kelman, R., (A) 187
Kennedy, M. E., (A) 177
Kesava Reddy, P., (A) 673
Keystone, J. S., (A) 500
Khaldi, M., (A) 172
Khanna, V. N., (A) 508
Khare, S., (O) 576
Khin, M. A., (A) 188
Khodorkovskaya, V. A., (A) 187
Khomenko, A. G., (A) 182, 182
Khuller, G K., (A) 186
Kienle, R. D., (A) 528
Kieser, T., (A) 367
Kiessling, R., (A) 158, 511, 512, 514, 700
Kilburn, J. O., (A) 177
Kim, J.-D., (O) 25
Kioshka, V. S., (A) 695
Kiran, K. U., (A) 674, 675
Kivits, M., (A) 172
Klareskog, L., (A) 514, 700
Klatser, P. R., (A) 159, 167, 355, (O) 416, (A) 514, 520
Klegerman, M. E., (A) 184, 692
Kleinau, S., (A) 514
Klene, C., (A) 185
Klenerman, P., (A) 506
Klyshev, T. L., (A) 695
Kobayashi, K., (A) 359, 709
Kochetkova, E. Y., (A) 178
Koga, T., (A) 531
Kohli, K. K., (A) 183
Kohli, M., (A) 686
Kohsaka, K., (A) 197, (O) 598
Kolk, A. H. J., (A) 514
Komatsu, A., (A) 195, 716
Komissarenko, S. V., (A) 696
Koning, F., (A) 357
Kordy, M. N., (A) 371
Koslov, V. A., (A) 699
Kossiy, N. M., (A) 183
Koumandaki, Y., (A) 512
Kpadenou, Y. K., (A) 371
Krahenbuhl, J. L., (A) 198, 514, 711, 712
Krasnoproshina, L. I., (A) 374
Kremsner, P., (A) 164
Krieg, S. R., (A) 520
Krishnamurthy, P., (O) 426, (A) 687
Krudu, V. N., (A) 527
Kulkarni, V. N., (A) 506, 525
Kumar, A., (C) 317
Kumar, B., (C) 334
Kumar, R. P., (A) 500
Kumar, S., (N) 133, (A) 183
Kumar, V., (A) 160
Kuperman, O., (A) 176
Kuykens, L., (A) 673
Kwan, S. Y.-L., (A) 188, 188

Laal, S., (A) 515
Labrousse, V., (A) 502
Lacave, C., (A) 183
Lachenmayr, F., (A) 184
Lagrange, P., (A) 171
Lai A Fat, R. F. M., (A) 356
Lakhdar-Ghazal, F., (A) 368
Lakshmi, V., (A) 372
Lal, H., (A) 675
Lamb, F. I., (A) 168
Lamb, J. R., (A) 160
Lamba, P. A., (A) 152, 154
Lamoureux, L C., (A) 684
Laneelle, G., (A) 183, 368, 521
Laneelle, M.-A., (A) 521
Lang, C. C., (A) 501
Langer, B., (A) 531
Lap, V. D., (A) 171
Larsson, H., (A) 529
Larsson, L. O., (A) 529, 530
Larsson, S., (A) 529
Laszlo, A., (A) 377
Lau, Y. J., (A) 187
Launois, P., (A) 515, (O) 582
Lavania, R. K., (A) 151, 160
Lavender, M., (A) 681
Laver, W. G., (A) 515
Lazaro-Medina, A., (A) 357
Lazraq, R., (A) 520, 695
Le Moigne, F., (A) 528
Leboutet, M. J., (A) 519
Lee, B. L., (A) 531
Lee, D. R., (O) 450
Lee, H. S., (A) 149
Lee, J., (A) 188
Lee, M. H., (A) 196
Lefford, M. J., (C) 122, (O) 432, (A) 516
Leithiser, R. E., (A) 692
Lemieux, S., (A) 169
Leonard, G., (A) 155, 351
Leoture, A., (O) 242
Levine, S., (A) 515
Levis, W. R., (A) 361, (O) 441, 590
Levy, L., (A) 380
Lévy-Frébault, V. V., (A) 684
Lewallen, S., (A) 149
Lewis, I. J., (A) 180
Li, H., *et al.,* (A) 160
Li, M.-H., *et al.,* (A) 516
Li, S. G., (A) 357
Li, W., *et al.,* (A) 147
Li, W.-H., (A) 148
Liang, Z., *et al.,* (A) 161
Liesack, W., (A) 167, 684
Lim, S. D., (A) 696
Lind, A., (A) 529, 530
Lindner, B., (O) 262, 548
Litvinov, V I., (A) 182, 695
Ljungqvist, L., (O) 58, (A) 689
Locniskar, M., (A) 517
Looker, D., (A) 168
Lopez, J., (A) 696
Lopez-Calahorra, F., (A) 521
Lopez del Rincon, F., (A) 174
Lopez-Saura, P., (A) 362
Louis, J. P., (A) 524
Lourdusamy, G., (A) 350
Love, S. G., (A) 510
Lu, B., *et al.,* (A) 152
Lucas, S. B., (O) 221, (A) 364, 518, 520
Lucksaon, J. M., (O) 221
Luelmo Aguilar, J., (A) 678
Luo, J., (A) 148
Luo, Y.-R., *et al.,* (A) 351
Luquin, M., (A) 521
Lusignan, Y., (A) 169
Ly, H. M., (A) 518
Lyashchenko, K. P., (A) 691, 696
Lyons, J., (A) 358
Lyu, S., (A) 713

M'Boup, S., (A) 351
Ma, W. K., (A) 188
Maa, J.-S., (A) 184
Macedo, H. W., (A) 516
Machado, T. F. G. S., (A) 674
Mackworth-Young, C. G., (A) 358
Maeda, Y., (A) 721
Maekura, R., (A) 709
Maestre Mesa, J. L., (A) 681
Magalhaes, P. A., (A) 696
Magna, L. A., (C) 486
Magnusson, M., (A) 529, 530
Mahadevan, K., (A) 501
Mahadevan, P. R., (A) 359
Mahato, S. B., (A) 697
Mahmoud, S. F., (A) 524
Mahon, A. C., (A) 359, 516
Mahr, A., (A) 358
Maine, N., (A) 154
Majumdar, S., (C) 334
Mak, T., (A) 357
Makino, M., (A) 711
Makokha, S., (A) 502
Malaty, R., (O) 618
Malaviya, G. N., (A) 151, 160, 161, 352, 360, (O) 385, (A) 525
Malhotra, Y. K., (C) 337
Manghani, D. K., (C) 122
Manjunath, N., (A) 530
Manku, M. S., (O) 271
Manrique, X., (O) 405
Mansour, M. M., (A) 700
Marchand, C., (A) 185
Maroja, F., (A) 158
Maroja, J. de F., (A) 380
Maroja, M. F., (O) 569
Marques, A., (C) 125
Martin, L. N., (O) 618
Martini, J. P. D., (A) 167

Martino-Albernas, J., (A) 166
Maslova, L. I., (A) 182
Massicotte, H. J., (A) 358
Mat, C., (A) 506
Mathai, R., (O) 237
Mathur, D., (A) 504
Mathur, N. K., (A) 504
Matsuo, E., (A) 195, 716
Matsuo, K., (A) 200, 359, 533
Matsuoka, M., (A) 716
Maugein, J., (A) 528
Maxwell, B. A., (A) 145
May, D. G., (A) 346
May, M. H., (A) 376
Mayer, L.W., (A) 367
Mayrink, W., (A) 696
Mayurnath, S., (A) 696
McAdam, K. P. W. J., (A) 517
McAdam, R. A., (A) 181, 530
McBride, M. E., (A) 378
McClosky, D. J., (A) 517
McDermot, P. F., (A) 692
McDermott-Lancaster, R. D., (A) 170
McDougall, A. C., (A) 170
McGrath, S., (A) 347
McIean, J., (A) 678
McKenzie, S., (A) 358
McNeil, M., (A) 202, 678
Mecklenburg, M., (A) 186
Medda, S., (A) 697
Medeiros, M. A., (A) 362
Meeker, H. C., (O) 590
Mehlert, A., (A) 160
Mehra, V., (A) 167, 715
Mehra, V. L., (A) 710
Mehta, J., (N) 133
Mehta, J. M., (A) 350, 506, 525
Mehta, R. D., (A) 504
Meijer, C. J. L. M., (A) 186
Meindl, W., (A) 184, 672
Melo, M. N., (A) 696
Melton, R. E., (A) 367
Mendes, M. F., (A) 199, 721
Mendez, P., (O) 605
Mendez-Samperio, P., (A) 160
Menini, C., (A) 501
Merini, J. C., (A) 353
Meuwissen, S. G. M., (A) 186
Meyers, W. M., (O) 450, 618, (A) 686
Mezebish, D. S., (A) 506
Mezhlumova, M. B., (A) 184
Miao, Z.-H., *et al.*, (A) 347
Michalick, M. S. M., (A) 696
Michel, J. C., (O) 582
Michelini-Norris, M. B., (A) 375, 690
Milan, J., (A) 351
Millan, J., (A) 515, 519, (O) 582
Miller, R. A., (E) 639
Mills, J., (A) 531
Mineta, T., (A) 709
Minnikin, D. E., (A) 182
Miorner, H., (A) 186
Mishra, R. S., (A) 515
Misra, R. S., (O) 1, (A) 154, 351, (E) 645, (A) 676, 677
Mistry, Y., (A) 686
Mitchison, D. A., (A) 376
Mittal, A., (A) 504
Modlin, R. L., (A) 197, 678, 682, 710, 712, 713, 721
Moers, D., (A) 179
Molloy, A., (A) 511, 513
Momotani, E., (A) 697
Montreewasuwat, N., (A) 520
Mora, N., (A) 356
Morales, M. C., (A) 362
Morales-Ortiz, R., (C) 480
Moreira, A. L., (A) 158
Moretti, M., (A) 501
Mori, T., (A) 716
Morini, J. C., (A) 157
Morita, C., (A) 197
Morita, C. T., (A) 678
Moroz, A. M., (A) 184
Morse, N., (O) 271
Moudgil, K. D., (A) 185
Mputu, L. B., (A) 673
Mukherjee, A., (O) 1, (A) 154, 351, (O) 385, (A) 676, 677
Mukherjee, L. M., (A) 525
Mukherjee, R., (A) 356, 364, 532, 686
Mulhollan, T. J., (A) 364
Muliyil, J., (O) 229
Mullins, R. J., (A) 355
Muminov, T. A., (A) 695
Mundayoor, S., (A) 202
Munk, M. E., (A) 359
Munno, I., (A) 360
Murakami, M., (A) 716
Murray, L., (A) 717
Murray, L. P., (A) 345, 522, 673
Murtaza, A., (A) 515
Mustafa, S., (A) 367
Muthukkaruppan, V. R., (A) 518
Muthuswami, T. C., (C) 479
Muthuveeralakshmi, R., (A) 698
Mutis, T., (A) 161

N'Deli, L., (A) 349
N'Gaporo, I., (A) 155, 351
Naafs, B., (A) 676
Nacheva, R. N., (A) 148
Nagai, S., (A) 165, 200, 533
Nagaraju, B., (A) 350
Naik, S. S., (A) 347
Nair, B. K. H., (A) 687
Najeeb, O. M., (A) 501
Nakajima, Y., (A) 697
Nakamura, K., (A) 722
Nakamura, M., (A) 531
Nakuci, M., (A) 363
Narayanan, R. B., (A) 160, 161, 360, 360

Narulla, A. K., (A) 507
Nascimento, E., (A) 696
Nassos, P. S., (A) 381
Natarajan, M., (O) 248
Nath, I., (A) 515, (E) 645
Nathan, C., (A) 361
Neelan, P. N., (O) 426, (A) 687
Neet, M. R., (A) 347
Nelson, K. E., (O) 41, 229
Nery, J. A., (A) 506
Neu, H. C., (A) 534
Neupane, K. P., (A) 676
Niculescu, D., (A) 381
Niemczyk, S., (A) 701
Nigam, P. K., (A) 153
Nikonenko, B. V., (A) 184
Nilsson, E., (A) 700
Nishimura, Y., (A) 200, 361
Nogueira, L. A. D., (A) 153
Nomaguchi, H., (A) 197, 200
Nomura, T., (A) 722
Norton, P., (A) 158
Novick, A., (A) 372
Nsansi, B. N., (A) 524
Nurlign, A., (A) 359, 516
Nusrat, A. R., (A) 361
Nyawalo, J., (A) 502

O'Connor, S. P., (A) 367
O'Kennedy, R., (A) 347
O'Sullivan, J. F., (A) 165
O'Sullivan, S., (A) 347
Oberti, J., (A) 171
Obregon Fuentes, A. M., (A) 184
Obura, M., (A) 502
Obvala, D., (A) 524
Ochoa, C., (A) 362
Offredo, C., (A) 693
Ohara, N., (A) 709
Ohman, R., (C) 320
Ohmen, J., (A) 721
Ojha, V., (A) 183
Oka, S., (A) 709
Okelo, C., (A) 502
Okuku, P., (A) 502
Olivares, R., (A) 356
Olofson, J., (A) 529, 530
Olsen, W. P., (A) 184
Olsson-Liljequist, B., (A) 181
Oltra, A., (O) 605
Onyi, G. O., (A) 533
Ooms, J., (A) 178
Opromolla, D. V. A., (A) 146, 151, 167
Oratore, A., (A) 374
Orefici, G., (A) 374
Orege, P. A., (A) 502
Orrell, J. M., (A) 697
Orsi-Souza, A. T., (A) 158
Orsini, D. L. M., (A) 698
Osawa, N., (A) 194
Ostler, B., (A) 370
Ottenhoff, T. H. M., (A) 158, 161, 356, 357, 361, 512, 715
Ovcharova, G. D., (A) 148
Owen, J. P., (A) 348
Oxborrow, S. M., (O) 221
Oyaski, M., (A) 196

Pagnano, P. M. G., (A) 159, 504
Pahlavani, M. A., (A) 517
Pahuja, O. P., (A) 504
Pahwa, V. K., (A) 677
Pai, R. R., (A) 500
Pal, D., (A) 366
Pal, N. K., (A) 683
Palande, D. D., (A) 681
Palanimurugan, K., (A) 691
Panchamoorthy, G., (A) 678
Panda, C., (A) 525
Pandhi, R. K., (A) 508
Pandya, P. G., (A) 149
Pane, L., (A) 200
Panicall, D., (A) 358
Pannikar, V. K., (A) 506
Panvelkar, V., (A) 675
Pao, C. C., (A) 184
Papa, F., (A) 158
Papp, K., (A) 350
Paramasivan, C. N., (A) 375, 691
Parimalam, S., (C) 479
Park, A. V., (A) 695
Park, B. K., (A) 146, 501
Park, I., (A) 197
Parkash, O., (A) 362, 516
Parlett, J. H., (A) 182
Patel, R. J., (A) 179
Path, S., (A) 162
Patil, K. M., (A) 526
Patil, M. A., (A) 695
Patil, S. A., (A) 162, 361
Patki, A. H., (A) 153, 153, (C) 331, (A) 350, (C) 492
Patra, H. V., (A) 356
Pattyn, S. R., (A) 172, 520, 524, (O) 613, (A) 671, 673, 687, 687
Pavithran, K., (C) 120, (A) 153
Pawer, P. L, (A) 500
Pearson, C. A., (A) 690
Pellegrino, M., (A) 360
Pennec, J., (A) 150
Perani, E., (A) 349, 501
Pereira, J. H., (A) 373, 681
Pereira, R. M. R., (A) 531
Perez, R. P., (A) 349
Perrone, C., (A) 378, 698
Peterson, L., (A) 196
Petit, C., (A) 372
Petit, G., (A) 351
Pezeshkpour, G. H., (O) 618
Piessens, W. F., (A) 179
Pike, J. G., (A) 187

Pitchappan, R. M., (A) 691, 698
Pitulle, C., (A) 167, 182, 684
Plichart, R., (A) 354, 672
Plikaytis, B. B., (A) 168, 202, 367
Pocidalo, J.-J., (A) 378, 698
Pokhrel, B. M., (A) 529
Polak, J. M., (A) 169
Poli, H. J., (A) 353
Ponnighaus, I. M., (A) 373
Ponnighaus, J. M., (A) 154, (O) 221, 255, (A) 373, 507, 520
Pope, R. M., (A) 517
Popesku, T. T., (A) 527
Porer, J. A., (A) 346
Porrello, V., (A) 374
Portaels, F., (A) 368
Pospelov, L. E., (A) 182, 379
Potar, M. C., (A) 158
Prabhakar, R., (A) 691, 696
Pradhan, H. M., (A) 513
Prakash, S. K., (A) 351
Praputpittaya, K., (A) 362
Prasad, H. K., (A) 511, 511, 515
Pratap, V. K., (A) 517
Premkumar, R., (A) 506
Prestidge, R. L., (A) 510
Prignot, J., (A) 176
Proctor, S. J., (A) 187
Pugh, R. N. H., (A) 371
Puzo, G., (A) 366, 377

Quemard, A., (A) 183
Quirico-Santos, T., (A) 516

Rabin, H. R., (A) 693
Radford, C., (A) 378
Radhakrishnan, V. V., (A) 690
Radhamani, M. P., (A) 696
Raina, V., (A) 507
Rajan, L., (A) 530
Rajaram, K., (A) 691, 698
Rajendran, M., (A) 348
Rakhimov, A. K., (A) 379
Ralhan, R., (A) 517
Ramachandran, R., (A) 375
Ramalingam, A., (A) 350
Ramanathan, U., (O) 5
Ramanathan, V. D., (O) 5, (A) 362
Ramesh, V., (O) 1, (A) 154, (C) 322, (A) 351, 676, 677
Ramos, G., (A) 157
Ramos-Caro, F. A., (A) 505
Ramu, G., (O) 5, 20, (A) 162, 362, (Ob) 494, (A) 518
Ramu, S., (A) 691
Rao, D. N., (A) 511, 511, (O) 576
Rao, K. N., (A) 372
Rao, M. K., (A) 672
Rao, P. S., (A) 172, (O) 426, (A) 687
Rao, S., (A) 365
Rappoport, S., (A) 361
Rasheed, F. N., (A) 517
Rastogi, N., (A) 162, (O) 278, (A) 366, 379, 379, 380, 502, 684
Ratledge, C., (A) 367, 685
Rav, S. D., (A) 517
Raveendranathan, O., (A) 687
Ravi, S., (O) 1, (E) 645
Rea, T. H., (A) 193, 197, 345, 712, 717, 721
Reddy, B. N., (O) 426, (A) 687
Reddy, N. B. B., (A) 361
Rees, R. J. W., (Ob) 127, (A) 345
Regele, H., (O) 590
Remington, P. L., (A) 181
Ren, X.-W., *et al.*, (A) 524
Res, P. C. M., (A) 698
Resnick, M., (A) 380
Restrepo, L. M., (A) 162
Revankar, C. R., (A) 500
Revuz, J., (A) 185
Rey, J. L., (A) 155, 351
Reyes Maldonado, E., (C) 325, 652
Ridell, M., (C) 320
Ridley, D. S., (A) 364, 364
Ridley, M. J., (A) 521
Riviere, M., (A) 377
Rivoire, B., (A) 167, 202, 715
Roberts, G. D., (A) 532
Robinson, P., (A) 359
Roca Miralles, M., (A) 678
Roch, F., (A) 170
Roche, P. W., (A) 503, 513, 676, 681
Rodrigues, C. J., (A) 531
Rodriguez Cano, L., (A) 678
Rodriquez Idigoras, M. I., (A) 372
Rogall, T., (A) 177
Roguel-Resnick, N., (A) 380
Rohatgi, J., (A) 152
Rojas-Espinosa, O., (C) 325, (O) 605, (C) 652
Rollier, B., (A) 172
Rollier, R., (A) 172
Rook, G. A. W., (A) 163, 163, 374, 518, 531
Rose, P., (A) 517
Rosen, E. U., (A) 185
Rothbard, J. B., (A) 160
Rottenberg, M., (A) 512
Roudaut, M. M., (A) 151
Roussel, J., (A) 521
Roux, J., (A) 349, 354
Roux, J.-F., (A) 672
Roy, A., (A) 517
Roy, B., (A) 147, 149
Royston, J. P., (A) 169
Rudolph, A. H., (A) 378
Rungruengthanakit, K., (A) 362
Russell, J., (A) 373
Rybakova, A. M., (A) 187
Rydard, K. J., (A) 181

Saad, M. H. F., (A) 362
Sabbaga, J., (A) 358
Safrin, S., (A) 531

Sagaro Delgado, B., (A) 362
Saha, K., (A) 372
Sahu, D. M., (A) 525
Sai Baba, K. S. S., (A) 185
Sailer, D., (A) 517
Sainis, K. B., (O) 49
Saito, H., (A) 186, 193, 503, 718
Saito, M., (A) 722
Saito, T., (A) 716
Sakamoto, Y., (A) 199, 716, 722
Sakhuja, V., (A) 509
Sakla, A., (A) 348
Salem, J. I., (A) 380, (O) 569
Salgado, A., (O) 405
Salgame, P., (A) 518, 682, 713
Saltzman, A., (A) 515
Saluja, S., (A) 530
Samlaska, C. P., (A) 178
Sampaio, E. P., (A) 158, 714
Sampson, C., (O) 405
Sampson, J. S., (A) 367
Samson, P. D., (O) 537
Sanchez, A., (A) 674
Sanchez, E., (A) 361
Sanchez, R. M., (A) 169
Sancho-Garnier, H., (A) 185
Sanders, C. A., (A) 381
Sangare, A., (A) 155, 351
Sangared, D., (A) 678
Sano, S., (A) 197
Sansarricq, H., (O) 242
Santi, D. V., (A) 699
Sapatnekar, S. M., (A) 151
Sareen, M., (A) 186
Sarno, E. N., (A) 158, 506
Sarojini, P. A., (A) 687
Saroyants, L. V., (A) 363
Sarthou, J. L., (A) 515, (O) 582
Sasaki, N., (A) 195, 716
Sasazuki, T., (A) 200, 361
Sashidhar, M., (A) 691
Sassou-Guesseau, E., (A) 155, 351
Sathish, M., (A) 509, 711
Sato, K., (A) 186, 503, 718
Sattar, S. A., (A) 177
Sattler, F. R., (A) 531
Satyawan, I., (A) 676
Savage, J., (A) 165
Saxena, N., (A) 154
Saxena, U., (O) 1, (A) 154, 351, 676, 677
Saylan, T., (A) 505, 505, 506, 675
Schechter, M., (C) 125
Scherbenske, J. M., (A) 178
Schlafer, D. W., (A) 527
Schlesinger, L. S., (A) 719
Schoenenberger, H., (A) 672
Schollaardt, T., (A) 693
Schuitema, A. R. J., (A) 181
Schunack, W., (A) 184
Schwartz, R. S., (A) 358
Schwerer, B., (O) 441, 590
Scollard, D. M., (A) 363, 682
Scott, A. K., (A) 501
Sedratti, O., (A) 172
Segal-Eiras, A., (A) 157
Segatore, B., (A) 374
Sehgal, P., (A) 677
Sehgal, V. N., (A) 154, 154, (C) 323, (A) 351
Sekkat, A., (A) 172
Sela, S., (A) 196, 509, 684, 684, 715
Seldenrijk, C. A., (A) 186
Seledtsova, G. V., (A) 699
Selvakumar, N., (A) 375
Selvi, G. T., (C) 479
Semilutskaya, I. B., (A) 376
Sen, R., (A) 352, 677
Sengupta, S. R., (O) 49
Sengupta, U., (O) 5, 32, (A) 161, 162, 361, 362, (O) 385, (C) 487, (A) 516, 679
Servin, P., (A) 377
Seth, S., (A) 675
Seydel, U., (O) 262, 548
Shaaban, M. A., (A) 163, 374
Shafer, R. W., (A) 699
Shafik, A., (C) 649
Shahin, A., (A) 163, 374
Shankar, P., (A) 530
Shannon, E. J., (A) 171
Sharma, N. K., (A) 517
Sharma, R. P., (A) 154
Sharma, V. D., (A) 695
Sharma, V. K., (A) 348, 351, 373, 381, 686
Sharma, Y., (A) 677
Sharma, Y. D., (A) 515
Sharmanoy, A. T., (A) 695
Shaw, M.-A., (O) 221, (A) 507
Sheela, R., (A) 518
Sherwin, S., (A) 361
Shi, C., *et al.,* (A) 155
Shi, Z., *et al.,* (A) 170
Shi, Z.-R., *et al.,* (A) 507
Shibata, T., (A) 174
Shiffman, N., (A) 350
Shinkareva, T. I., (A) 695
Shinnick, T. M., (A) 168, 202, 203, 711
Shiv, V. K., (A) 508
Shivannavar, C. T., (A) 695
Shobha, S., (A) 690
Shoenfeld, Y., (A) 176
Shoukrallah, I., (A) 348
Shrestha, K. B., (A) 529
Shrestha, M. P., (A) 529
Shriniwas, (A) 530
Shroff, K. E., (O) 49
Shu, H.-W., *et al.,* (A) 688
Sibley, L. D., (A) 514
Siddique, Z., (A) 163, 374
Silva, M. T., (A) 510
Simoes, A. L., (A) 159
Singer, D. S, (A) 678

Singh, G., (A) 151, 153, 504
Singh, I. G., (A) 532
Singh, K., (A) 507
Singh, K. P., (A) 162, 361
Singh, N. B., (C) 317, (O) 398
Singh, R., (A) 507
Singh, S., (A) 515
Singh, U., (A) 677
Singh, V. S., (A) 154
Sinha, S., (O) 32, (A) 679
Sinos, C., (A) 358
Siqueira, S., (O) 12
Sirawaraporn, R., (A) 699
Sirawaraporn, W., (A) 699
Sirugue, S., (A) 368
Sirumban, P., (A) 172
Siu, P., (A) 345, 522, 717
Sivasubramanian, S., (A) 375
Siwik, E., (O) 432
Sixou, S., (A) 368
Sjobring, U., (A) 186
Sjogren, I., (A) 530
Skinsnes, O. K., (A) 195, 716
Skoogh, B.-E., (A) 529, 530
Smida, J., (A) 182
Smith, K. A., (A) 513
Smith, P. G., (O) 405
Smith-Gill, S. J., (A) 515
Snapper, S. B., (A) 367
Soderstrom, K., (A) 514, 700
Soebono, H., (A) 356, (O) 416
Somasundaram, P. R., (A) 375
Soutevrand, P., (A) 185
Spiegel, A., (A) 354, 672
Spits, H., (A) 356
Springall, D. R., (A) 169
Springthorpe, V. S., (A) 177
Squires, K., (A) 361
Sreevatsa, (A) 352
Srinath, M. S., (A) 526
Srinivasan, H., (Ob) 656
Sritharan, M., (A) 367
Srivastava, A., (C) 317
Srivastava, L. M., (A) 185
Srivastava, S., (C) 317
Stabel, L. F. E. M., (A) 159, 167
Stackebrandt, E., (A) 167, 182, 684
Stanford, J. L., (A) 163, 374, 518
Stavri, D., (A) 381
Stavri, H., (A) 381
Stead, W. W., (A) 179
Steinhoff, U., (A) 519
Stemberger, H., (A) 164
Sterne, J. A. C., (O) 221
Stingl, P., (A) 146
Stoner, G. L., (A) 532
Strannegard, I.-L., (A) 530
Street, M. L., (A) 532
Strong, L. C., (A) 672
Su, W. P. D., (A) 532
Subramanian, M., (O) 426, (A) 687
Subramanyam, P. T., (A) 698
Sudo, T., (A) 200
Sui, P., (A) 673
Sukhova, T. G., (A) 187
Sulcebe, G., (A) 363
Sulochana, G., (A) 508
Sumrani, N., (A) 528
Suneetha, S., (A) 674, 675
Suphawilai, C., (A) 362
Surel, Z., (A) 506, 675
Suresh, M. S., (A) 675
Suri Babu, C. S. S., (A) 163
Suri Babu, S. S., (A) 519
Suriyanon, V., (A) 362
Sut, A., (A) 368
Sutlas, M., (A) 675
Suzuki, Y., (A) 709, 711
Svenson, S. B., (A) 181

Tabaqchali, S., (A) 532
Tada, K., (A) 174
Tadesse, G., (A) 512
Tadesse, T., (A) 173, 508
Taintor, R., (A) 198
Takahashi, M. D., (O) 12
Talwar, G. P., (A) 356, 532
Talwar, S., (A) 675
Tamalet, C., (A) 350
Tanaka, K., (A) 532
Tanaka, M., (A) 194, (O) 598
Tanaka, Y., (A) 194, (O) 598
Taneja, K., (A) 508
Tangri, S., (A) 515
Tao, M.-B., (A) 148
Taranger, J., (A) 529
Tasaka, H., (A) 359
Tausk, F., (A) 164
Tebebe, Y. B., (O) 262, 548
Tedla, T., (A) 173
Tekle-Haimanot, R., (A) 508
Templeton, J. W., (A) 528
Teng, B. P., (A) 671
Terada, M., (A) 716
Terasaka, K., (A) 359
Terencio de las Aguas, J., (A) 678
Thangaraj, H. S., (A) 168
Thankappan, T. P., (A) 508
Thappa, D. M., (A) 373
Theetranont, C., (A) 363
Theuvenet, W. J., (A) 513, 676, 681
Thole, J. E. R., (A) 167, 509, 715
Thomas, B. M., (A) 364
Thomas, J., (C) 479
Thorson, C., (A) 693
Tianco, E. A., (A) 357
Ting, H. C., (A) 147
Tjipthoherijanto, P., (A) 181
Tocanne, J.-F., (A) 368
Todd, J., (A) 696

Toledo, J., (A) 380
Tomioka, H., (A) 186, 193, 503, 718
Tonglet, R., (A) 172, 524
Torgal-Garcia, J., (A) 158
Torres, P., (A) 518
Totsuka, M., (A) 359
Tounkara, A., (A) 678
Tozuka, M., (A) 200
Trebucq, A., (A) 524
Trichopoulos, D., (A) 512
Truffot-Pernot, C., (A) 378, 533, 698
Truman, R. W., (A) 169
Tsang, M., (A) 345, 522, 673, 717
Tschen, J. A., (A) 378
Tschibangu, P., (A) 526
Tselikova, V. A., (A) 376
Tsukamura, M., (A) 685
Tsutsumi, S., (A) 673
Tu, Y., *et al.*, (A) 155
Turcotte, R., (A) 169, 370
Turk, J. L., (A) 373
Turner, A. C., (O) 221, (A) 507
Tutakne, M. A., (A) 350
Tyagi, P., (O) 5, (A) 362, (C) 487
Tyndall, J. A., (A) 364

Uetrecht, J. P., (A) 346
Ulrich, M., (O) 405
Umbert-Miller, I. J., (A) 532
Upadhyay, M. P, (A) 529
Uvarova, O. A., (A) 182
Uyemura, K., (A) 197, 712, 721

Vachula, M., (O) 41
Vadiee, A. R., (A) 171
Vaillant, V., (A) 354
Vaishnavi, C., (A) 686
Valdivia Alvarez, J. A., (A) 184
Vallat, J. M., (A) 519
Vallishayee, R. S., (A) 350, 696
Van Beeumen, J., (A) 374
Van Boom, J. H., (A) 701
Van Den Berg, G., (A) 672
Van den Elsen, P., (A) 357
Van der Zee, R., (A) 680
Van Eden, W., (A) 187, 680
van Embden, J. D. A., (A) 181, 510, 530, 700
Van Laar, J. M., (A) 698
Van Leeuwen, S. H., (A) 701
Van Lieshout, L., (A) 700
van Rens, R. M., (A) 159
Van Roy, J. L. A. M., (A) 187
Van Schooten, W. C. A., (A) 352, 508
van Soolingen, D., (A) 181, 530
van Trier, Y. D. M., (A) 503
Vanaja, G., (A) 365
Vanderelst, B., (A) 176
Vanderwall, D., (A) 527
Varghese, M., (A) 361
Vasanth, B., (A) 348
Veeneman, G. H., (A) 701
Veerman, G. M., (A) 187
Venisse, A., (A) 377
Venkataraman, S., (A) 201
Venner, T. J., (A) 519
Verdier, M., (A) 155, 351, 508
Verez-Bencomo, V., (A) 166
Vianna, F. R., (C) 125
Vidmar, D. A., (A) 506
Vieira, L. M. M., (A) 506
Vignon-Pennamen, M. D., (A) 150
Vijayan, V. K., (A) 375
Vilde, J.-L., (A) 378, 698
Vilette, B., (A) 180
Vinnik, L. A., (A) 164
Vinod Kumar, C. H. D., (A) 348
Virmond, M., (A) 174, 175
Vlasov, G. S., (A) 374
Volc-Platzer, B., (A) 164
von Reyn, C. F., (A) 701
Vorobyev, A. A., (A) 187, 374
Vuillet, F., (A) 526
Vuzevski, V. D., (A) 676

Wagenaar, J. P. A., (A) 680
Wakamatsu, A., (O) 12
Walford, C., (C) 320, (A) 361
Walker, C. W., (A) 692
Walker-Smith, J. A., (A) 532
Wallace, R. J., Jr., (A) 378, 533
Wallach, D., (A) 150
Wallis, R. S., (A) 517
Walsh, G. P., (O) 25, (A) 370, (O) 618, (A) 686
Wand-Wurttenberger, A., (A) 519
Wang, C.-J., (A) 148
Wang, H.-Y., *et al.*, (A) 673
Wang, X.-H., (A) 721
Warndorff, D. K., (A) 173
Warndorff, J. A., (A) 173
Warren, G., (A) 526
Waters, M. F. R., (A) 364, 364
Watson, J. D., (A) 168, 510, 682
Watson, J. M., (A) 175
Wauben, M. H. M., (A) 680
Webster, R. G., (A) 515
Weiller, P.-J., (A) 350
Weiller-Merli, C., (A) 350
Wele, D. S., (A) 348
Weng, C.-Y., *et al.*, (A) 525
Wheeler, P. R., (A) 521, 685
Whitford, H. W., (A) 528
Wiedermann, G., (A) 164
Wiholm, B.-E., (A) 152
Wiker, H. G., (A) 165
Wilbrink, B., (A) 187
Wiley, E. L., (A) 364
Wilkins, E. G. L., (A) 348
Wilkinson, G. R., (A) 346
Wilks, M., (A) 532
Williams, D. L., (A) 168, (E) 311, (A) 368, 719

Williams, P., (A) 696
Wilson, R. J., (O) 255
Wintersteiger, R., (A) 348
Wirth, D. F., (A) 179
Wise, D. L., (A) 694
Wolf, R. H., (A) 370, (O) 618
Wolters, J., (A) 375
Wondimu, A., (A) 158
Wong, P. C., (A) 188
Wood, P. M. D., (A) 187
Woods, S. A., (A) 369
Woosley, J. T., (A) 145
Work Teklemariam, S., (A) 158
Wright, S. G., (A) 175, (O) 271
Wu, C. H., (A) 187
Wu, Q.-X., *et al.*, (A) 520
Wu-Hunter, S., (A) 710, 715

Xu, K., (O) 450, 618

Yadav, S. S., (A) 677
Yajko, D. M., (A) 381
Yamada, T., (A) 200, 359, 533, 709
Yamaguchi, R., (A) 200, 359, 533
Yamamura, M., (A) 712
Yamamura, Y., (A) 709
Yamane, T., (A) 503
Yamashita, K., (A) 503
Yamazaki, A., (A) 200, 359, 533
Yang, Z.-M., (A) 148
Yano, I., (A) 709
Yates, M. D., (A) 180
Ye, G.-Y., (N) 131, (A) 148
Yeager, J. K., (A) 506
Yen, T. S. B., (A) 184
Yew, W. W., (A) 188, 188
Yoder, L., (A) 147
Yogi, Y., (A) 722
Yoshino, T., (A) 697
You, J.-B., (A) 184
Youle, M., (A) 188
Young, D., (A) 365
Young, D. B., (E) 95, (A) 160, 679
Young, L. S., (A) 176
Young, T., (A) 531
Yu, X., *et al.*, (A) 149
Yuasa, Y., (E) 624
Yukitake, H., (A) 359, 709
Yushchenko, A. A., (A) 363

Zainuddin, Z. F., (A) 530
Zaoui, F., (A) 172
Zeis, B. M., (A) 165
Zhang, F., *et al.*, (A) 175
Zhang, G.-C., *et al.*, (A) 688
Zhang, L., (A) 357, 683
Zhang, X., *et al.*, (A) 166
Zhang, Y.-X., (A) 534
Zhou, H.-M., *et al.*, (A) 360
Zhou, S., *et al.*, (A) 156, 173
Zhou, S.-N., *et al.*, (A) 526
Zinin, A. E., (A) 374
Zipori, D., (A) 380
Zuniga, M., (O) 405
Zuurmond, H., (A) 701

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted article (R), abstracts (A), and book reviews (B).

Acid, fatty,
Analysis of cellular fatty acids and proteins by capillary gas chromatography and sodium dodecyl sulphate polyacrylamide gel electrophoresis to differentiate *M. avium, M. intracellulare* and *M. scrofulaceum* (MAIS) complex species. Fourche, J., *et al.* .....(A) 528
Essential fatty acids in plasma of patients with leprosy. Wright, S., *et al.* .....(O) 271
Fatty acid oxidation and the beta-oxidation complex in *M. leprae* and two axenically cultivable mycobacteria that are pathogens. Wheeler, P. R., *et al.* .....(A) 685

Acid-fast bacilli,
Cultivation *in vitro* of acid-fast nocardioform chemoautotrophic bacteria from mouse foot-pads infected with human strains of leprosy bacillus. Chakrabarty, A. N., *et al.* (A) 166

Acquired immunodeficiency syndrome (AIDS),
Leprosy and AIDS: a review of the literature and speculations on the impact of CD4+ lymphocyte depletion on immunity to *M. leprae.* Miller, R. A. .....(E) 639
Opportunistic infections in AIDS in developed and developing countries. Fleming, A. F. .....(A) 150
Plasmid analysis of *M. avium-intracellulare* (MAI) isolated in the United Kingdom from patients with and without AIDS. Hellyer, T. J., *et al.* .....(A) 694
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. Shafer, R. W. and Jones, W. D. .....(A) 699
Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Youle, M., *et al.* .....(A) 188
Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Gorin, I., *et al.* .....(A) 180

Actinomycete(s),
Reactions to antigens from actinomycetes including *M. leprae* in leprosy patients. Ohman, R., *et al.* .....(C) 320

Adenosine triphosphate (ATP),
Intrabacterial sodium-to-potassium ratios and ATP contents of *M. leprae* from ofloxacin-treated patients. Dietz, M., *et al.* .....(O) 548

Africa,
Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink, M. .....(O) 558
Prevalence of HIV infection among patients with leprosy in African countries and Yemen. Leonard, G., *et al.* .....(A) 351
The anatomical distribution of single leprosy lesions in an African population, and its implications for the pathogenesis of leprosy. Ponnighaus, J. M., *et al.* .....(A) 154
WHO Interregional Conference on Leprosy Control in Africa. (Congo Republic) .....(N) 131

American Leprosy Missions (ALM),
ALM International education and training materials. .....(N) 142
Leprosy poster from ALM International and Wellcome. .....(N) 343

Amoxicillin,
Susceptibilities of *M. fortuitum* biovar, *fortuitum* and the two subgroups of *M. chelonae* to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Wallace, R. J., Jr., *et al.* .....(A) 533

Anemia,
Patterns of erythropoeisis and anaemia in leprosy. Sen, R., *et al.* .....(A) 677
Peripheral neuropathy and haemolytic anaemia with cherry red spot on macula in dapsone poisoning. Abhayambika, K., *et al.* .....(A) 501

Rifampicin-induced immune hemolytic anemia: therapeutic relevance of plasma exchange. Govoni, M., *et al.* ..... (A) 501

Antibody,

Anti-phenolic glycolipid 1 IgM antibodies in leprosy patients and their household contacts. Sulcebe, G. and Nakuci, M. ..... (A) 363

Antibodies to human T lymphotrophic virus type 1 in patients with leprosy in tropical areas. Verdier, M., *et al.* ..... (A) 155

Antibodies to phenolic glycolipid-1 of *M. leprae* in urine of leprosy patients. Patil, S. A., *et al.* ..... (A) 162

[Antibody against PG1 and immunocomplex in the sera of leprosy patients with ENL.] Zhang, X., *et al.* ..... (A) 166

Antineural antibodies in sera of leprosy patients. Thomas, B. M. and Mukherjee, R. ..(A) 364

Association of mycobacterial-specific and *M. leprae* specific antibody levels with clinical activity in tuberculoid leprosy: a comparative study of three serological enzyme-immunoassays. Chaturvedi, V., *et al.* ..... (A) 679

Characteristics of antineuronal antibodies in systemic lupus erythematosus patients with and without central nervous system involvement: the role of mycobacterial cross-reacting antigens. Avinoach, I., *et al.* ..... (A) 176

[Characterization of the spectrum of antibody response to *M. tuberculosis* determinants by the method of immunoblotting.] Kioshka, V. S., *et al.* ..... (A) 695

Circulating antispermatozoal antibodies in leprosy. Kumar, B. and Majumdar, S. ..... (C) 334

Detection of antibodies to 35 kD determinant of *M. leprae* in urine and serum of leprosy patients. Path, S. ..... (A) 162

Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Cho, S.-N., *et al.* ..... (O) 25

[Determination of antibodies to leprosy by MTPA.] Li, M.-H., *et al.* ..... (A) 516

Diagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay to detect mycobacterial antigen and antibody in cerebrospinal fluid. Annamma, M., *et al.* ....(A) 690

Distribution of anti-LAM antibodies in leprosy patients and household contacts. Izumi, S., *et al.* ..... (A) 721

Distribution of anti-PGL-I antibody in household contacts from endemic countries. Izumi, S., *et al.* ..... (A) 199

Early infection with *M. leprae* and antibodies to phenolic glycolipid-I in the nine-banded armadillo. Job, C. K., *et al.* ..... (A) 169

IgG and IgM antibodies immunoreacting with a 2,3-diacyl trehalose-2′-sulphate in sera from leprosy patients. Cruaud, P., *et al.* ..... (A) 158

IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Ulrich, M., *et al.* ..... (O) 405

Immunohistochemical study of bovine lymph nodes with antibodies against S100 protein subunits: comparison between lymph nodes of healthy and *M. paratuberculosis*-infected cattle. Momotani, E., *et al.* ..... (A) 697

Leprosy as cause of false-positive results in serological assays for the detection of antibodies to HIV-1. Andrade, V. L., *et al.* ..... (C) 125

Light- and electron-microscopic immunohistochemistry using anti-PGL-I antibody specific for *M. leprae.* Goto, M. and Izumi, S. ..... (A) 195

Mycobacterial antigens and anti-idiotype antibodies revealed by an enzyme-linked immunosorbent assay in tuberculous patient sera. Stavri, D., *et al.* ..... (A) 381

New generation vaccines: does antibody play a directional role in antigen-processing? Watson, J. D., *et al.* ..... (A) 682

On the value of sequential serology with a *M. leprae*-specific antibody competition ELISA in monitoring leprosy chemotherapy. Chaturvedi, V., *et al.* ..... (O) 32

Polyclonal antibodies raised against bacillus Calmette-Guérin, *M. duvalii,* and *M. paratuberculosis* used to detect mycobacteria in tissue with the use of immunohistochemical techniques. Wiley, E. L., *et al.* ..... (A) 364

Production and characterization of antibody against cord factor (trehalose 6,6′-dimycolate) in mice and its application to rapid serodiagnosis of human mycobacteriosis including tuberculosis and leprosy. He, H., *et al.* ..... (A) 709

Quantitative relationship between anti-PGL-I-specific antibody levels and the lepromin reaction. David, H. L., *et al.* ..... (C) 332

Selection and characterization of recombinant clones that produce *M. leprae* antigens recognized by antibodies in sera from household contacts of leprosy patients. Hartskeerl, R. A., *et al.* ..... (A) 159
Serum antibodies against peripheral nervous system antigens in leprosy. Chujor, C. S. N., *et al.* ..... (O) 590
Serum IgA1 and IgM antibodies against *M. leprae*-derived phenolic glycolipid-I: a comparative study in leprosy patients and their contacts. Chujor, C. S. N., *et al.* ..... (O) 441
[Study of blocking agents in ELISA for antibodies to leprosy.] Wu, Q.-X., *et al.* ..... (A) 520
The evolution of antibody response in armadillos inoculated with *M. leprae.* Vadiee, A. R., *et al.* ..... (A) 171
[The role of precipitating antibodies in the serum of tuberculosis patients.] Klyshev, T. L., *et al.* ..... (A) 695
The value of IgM antibodies to PGL-I in the diagnosis of leprosy. Lefford, M. J., *et al.* (O) 432
[Use of the microdot enzyme immunoassay for the determination of antibodies to *M. tuberculosis.*] Badukshanova, N. M., *et al.* ..... (A) 374

Antibodies, monoclonal,
A monoclonal antibody to the mycobacterial 65kDa heat shock protein (ML 30) binds to cells in normal and arthritic joints of rats. Kleinau, S., *et al.* ..... (A) 514
Application of monoclonal antibodies to differentiate the morphological forms of *M. lepraemurium* Hawaiian strain. Elangeswaran, N., *et al.* ..... (A) 716
Comparative study of idiotypes of monoclonal antibodies derived from patients with lupus and leprosy and from normal individuals. Mackworth-Young, C. G., *et al.* ... (A) 358
Correlation between the chemical structure of the carbohydrate part of *M. leprae* PGL-I and its activity to the monoclonal antibodies. Fujiwara, T., *et al.* ..... (A) 199
Detection of *M. leprae* antigens in the sera of leprosy patients by sandwich immunoradiometric assay using monoclonal antibodies. Patil, S. A., *et al.* ..... (A) 361
Immuno-blot analysis of antigens of *Mycobacterium w*: a candidate antileprosy vaccine using monoclonal antibodies and patient sera. Ganju, L., *et al.* ..... (A) 356
In situ demonstration of *M. leprae* in leprosy lesions using monoclonal antibodies. Narayanan, R. B., *et al.* ..... (A) 161
Isolation and structural characteristics of a monoclonal antibody-defined crossreactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J.-J., *et al.* ..... (A) 355

Antigen(s),
An antigenic complex that restores ability in leprosy patients to kill *M. leprae*—the probable molecular events identified in *in vitro* experiments. Mahadevan, P. R. and Robinson, P. ..... (A) 359
Application of HLA-DQ transgenic mice for the analysis of genetic control of the immune response to *M. leprae* antigen. Nishimura, Y., *et al.* ..... (A) 200
Assessment of cure in schistosomiasis patients after chemotherapy with praziquantel by quantitation of circulating anodic antigen (CAA) in urine. Van Lieshout, L., *et al.* .. (A) 700
Biological properties of factors secreted by antigen-reactive suppressor cells in mice infected with *M. lepraemurium.* Forget, A. and Turcotte, R. ..... (A) 370
Carbohydrate epitope structural elucidation of 1H-NMR spectroscopy of a new *M. kansasii* phenolic glycolipid antigen. Gilleron, M., *et al.* ..... (A) 377
Characteristics of antineuronal antibodies in systemic lupus erythematosus patients with and without central nervous system involvement: the role of mycobacterial cross-reacting antigens. Avinoach, I., *et al.* ..... (A) 176
Characterization of cell-wall associated 10-kDa heat-shock protein of *M. leprae* which is a major T-cell antigen. Mehra, V. L., *et al.* ..... (A) 710
Characterization of murine B-cell epitopes on the *M. leprae* proline-rich antigen by use of synthetic peptides. Klatser, P. R., *et al.* ..... (A) 514
Comparison of IgM, IgG and IgA responses to *M. leprae* specific antigens in leprosy. Praputpittaya, K., *et al.* ..... (A) 362
Detection of *M. leprae* antigens in the sera of leprosy patients by sandwich immunoradiometric assay using monoclonal antibodies. Patil, S. A., *et al.* ..... (A) 361
Detection of *M. leprae*-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients. Singh, N. B., *et al.* ..... (O) 398
Detection of mycobacterial antigens in cerebrospinal fluid by enzyme-linked immunosorbent assay. Wu, C. H., *et al.* ..... (A) 187

Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Cho, S.-N., *et al.* ..... (O) 25
[Determination of antigen-specific immune complexes by the method of the enzyme immunoassay.] Bobrovnik, S. A. and Lyashchenko, K. P. ..... (A) 691
[Development of delayed hypersensitivity to mycobacterial antigens.] Lyashchenko, K. P., *et al.* ..... (A) 696
Diagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay to detect mycobacterial antigen and antibody in cerebrospinal fluid. Annamma, M., *et al.* ..... (A) 690
Differential handling of bacterial antigens in macrophages infected with *M. leprae* as studied by immunogold labeling of ultrathin sections. Rastogi, N., *et al.* ..... (O) 278
Diversity in antigen recognition by *M. tuberculosis*-reactive T cell clones from the synovial fluid of rheumatoid arthritis patients. Res, P. C. M., *et al.* ..... (A) 698
Effect of circulating immune complexes of leprosy patients on leukocyte migration inhibition induced by *M. leprae* antigens in healthy volunteers. Tyagi, P., *et al.* ..... (C) 487
Epitopes on protein antigens: misconceptions and realities. Laver, W. G., *et al.* ..... (A) 515
Establishment of a foreign antigen secretion system in mycobacteria. Matsuo, K., *et al.* (A) 359
[Evaluation of an ELISA using A60 antigen from *M. bovis* BCG: specific IgG and IgM during mycobacterial infection.] Cisse, M. F., *et al.* ..... (A) 354
Evidence that coating of *M. leprae* surface antigens reduces its ability to hinder host microbicidal functions. Rastogi, N. and Frehel, C. ..... (A) 162
Evidence that the capsule around mycobacteria grown in axenic media contains mycobacterial antigens: implication at the level of cell envelope architecture. Rastogi, N. and Hellio, R. ..... (A) 366
Expression of antigenic determinants of *M. leprae* in an avirulent *Salmonella typhimurium* vaccine delivery system. Clark-Curtiss, J. E., *et al.* ..... (A) 196
Heat-shock proteins as antigens of pathogenic microorganisms. Shinnick, T. M. ..... (A) 203
Identification, sequencing, and expression of *M. leprae* superoxide dismutase, a major antigen. Thangaraj, H. S., *et al.* ..... (A) 168
IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from *M. leprae* in sera of leprosy patients and their contacts. Saad, M. H. F., *et al.* ..... (A) 362
Immuno-blot analysis of antigens of *Mycobacterium w*: a candidate antileprosy vaccine using monoclonal antibodies and patient sera. Ganju, L., *et al.* ..... (A) 356
Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Converse, P., *et al.* ..... (A) 158
Isolation and structural characteristics of a monoclonal antibody-defined crossreactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J.-J., *et al.* ..... (A) 355
Mycobacterial antigens and anti-idiotype antibodies revealed by an enzyme-linked immunosorbent assay in tuberculous patient sera. Stavri, D., *et al.* ..... (A) 381
Mycobacterial antigens stimulate rheumatoid mononuclear cells to cartilage proteoglycan depletion. Wilbrink, B., *et al.* ..... (A) 187
New generation vaccines: does antibody play a directional role in antigen-processing? Watson, J. D., *et al.* ..... (A) 682
Nucleotide sequence of *htpB,* the *Legionella pneumophila* gene encoding the 58-kDa common antigen, formerly designated the 60-kDa common antigen. Sampson, J. S., *et al.* ..... (A) 367
Nucleotide sequence of the 32 kDa-protein gene (antigen 85A) of *M. bovis* BCG. de Wit, M. Y. L., *et al.* ..... (A) 178
On the pathologic significance of the receptor for Beta-glucuronidase (BGR) of *M. leprae* in relationship to its other antigen. Matsuo, E., *et al.* ..... (A) 716
[Preliminary study of delayed hypersensitivity to leprosy antigen induced by killed leprosy bacilli plus BCG.] Chen, J.-L., *et al.* ..... (A) 354
Proliferative response to seven affinity purified mycobacterial antigens in eight strains of inbred mice. Andersen, P., *et al.* ..... (O) 58
Protein antigens of *M. leprae.* Clark-Curtiss, J. E., *et al.* ..... (A) 509
Quantitative and qualitative studies on the major extracellular antigen of *M. tuberculosis* H37Rv and *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 165
Reactions to antigens from actinomycetes including *M. leprae* in leprosy patients. Ohman, R., *et al.* ..... (C) 320
Recognition of mycobacterial antigens by gamma/delta T cells. Band, H., *et al.* ..... (A) 678
[Relation of sensitization to specific and nonspecific antigens to an individual type of immune reaction in pulmonary tuberculosis patients.] Ginda, S. S. ..... (A) 377

Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ..... (A) 349
Selection and characterization of recombinant clones that produce *M. leprae* antigens recognized by antibodies in sera from household contacts of leprosy patients. Hartskeerl, R. A., *et al.* ..... (A) 159
Serological analysis of human tuberculosis by an ELISA with mycobacterial antigen 60. Baelden, M.-C., *et al.* ..... (A) 176
Serum antibodies against peripheral nervous system antigens in leprosy. Chujor, C. S. N., *et al.* ..... (O) 590
Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones; a novel potentially immunoregulatory T-T cell interaction in man. Ottenhoff, T. H. M. and Mutis, T. ..... (A) 161
Specificity of lymphocytotoxic autoantibodies (LCAbs) found in the serum of leprosy patients: class I MHC antigens. Rasheed, F. N., *et al.* ..... (A) 517
Spectrum of immune reactivity to mycobacterial (BCG) antigens in healthy hospital contacts in South India. Pitchappan, R. M., *et al.* ..... (A) 698
Studies on alpha-antigen gene of *M. leprae*: molecular biological studies of *M. leprae*-specific epitopes of alpha-antigen. Makino, M. and Suzuki, Y. ..... (A) 711
Subcellular localization of *M. leprae*-specific PGL-I antigen in human leprosy lesions and in *M. leprae* isolated from armadillo liver. Boddingius, J. and Dijkman, H. ..... (A) 369
Synthesis of carbohydrate-antigenic structures of *M. tuberculosis* using an iodonium ion promoted glycosidation approach. Veeneman, G. H., *et al.* ..... (A) 701
T cell activation by mycobacterial antigens in inflammatory synovitis. Pope, R. M., *et al.* ..... (A) 517
T-cells bearing gamma delta antigen receptors in leprosy. Uyemura, K., *et al.* ..... (A) 197
The response of human B cells to *M. leprae*. Identification of target antigens following polyclonal activation *in vitro*. Mahon, A. C., *et al.* ..... (A) 359
The response to chemotherapy of serum *M. leprae*-specific antigen in multibacillary leprosy patients. Roche, P. W., *et al.* ..... (A) 676
Toward a thorough resolution and structural definition of the major antigens of *M. leprae*. Brennan, P. J., *et al.* ..... (A) 202
[Trial of a skin test with the soluble antigen of *M. leprae* in a group at risk.] Maestre Mesa, J. L. and Gonzalez Segredo, A. ..... (A) 681

Armadillo(s),

Antileprotic effect of the immunostimulating drug RACA 854 in experimentally infected armadillos. Kazda, J. and Shafik, A. ..... (C) 649
Changes in hydrolytic enzyme activities in armadillos infected with *M. leprae*. Dhople, A. M. ..... (A) 685
Early infection with *M. leprae* and antibodies to phenolic glycolipid-I in the nine-banded armadillo. Job, C. K., *et al.* ..... (A) 169
[Mycobacteria isolated from armadillos (*Dasypus novemcinctus*) inoculated with *M. leprae*.] Coelmo, A. A. M., *et al.* ..... (A) 169
[Phacogenic endophthalmitis in an armadillo experimentally infected with *M. leprae*.] Shi, Z., *et al.* ..... (A) 170
[Severity of leprosy eye lesions in armadillos infected with *M. leprae*.] Zhou, H.-M., *et al.* ..... (A) 360
Subcellular localization of *M. leprae*-specific PGL-I antigen in human leprosy lesions and in *M. leprae* isolated from armadillo liver. Boddingius, J. and Dijkman, H. ..... (A) 369
The evolution of antibody response in armadillos inoculated with *M. leprae*. Vadiee, A. R., *et al.* ..... (A) 171

Arthritis,

Diversity in antigen recognition by *M. tuberculosis*-reactive T cell clones from the synovial fluid of rheumatoid arthritis patients. Res, P. C. M., *et al.* ..... (A) 698
Induction of arthritis in rats by aqueous suspensions of mycobacteria without the use of oil. Levine, S. and Saltzman, A. ..... (A) 515
[Influence of treatment with *M. leprae* on the immune response in rats; its evaluation in a model of experimental arthritis.] Bottasso, O., *et al.* ..... (A) 353

T cell reactivity to an epitope of the mycobacterial 65-kDa heat-shock protein (hsp 65) corresponds with arthritis susceptibility in rats and is regulated by hsp 65-specific cellular responses. Hogervorst, E. J. M., *et al.* ..... (A) 680

Assay(s) (see also ELISA),
Detection of *M. leprae* antigens in the sera of leprosy patients by sandwich immunoradiometric assay using monoclonal antibodies. Patil, S. A., *et al.* ..... (A) 361
Leprosy as cause of false-positive results in serological assays for the detection of antibodies to HIV-1. Andrade, V. L., *et al.* ..... (C) 125
[Monitoring treatment effectiveness in patients with leprosy using solid-phase immunoenzyme assay.] Gonzalez-Abreu, E., *et al.* ..... (A) 356
[Potentiometric procedure for assay of rifampicin.] Ovcharova, G. D., *et al.* ..... (A) 148
Rapid and sensitive detection of *M. leprae* using a nested-primer gene amplification assay. Plikaytis, B. B., *et al.* ..... (A) 168
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186

Bacilli,
Assessment of testicular volume in bacilliferous leprosy; correlation with clinical parameters. Abraham, A., *et al.* ..... (A) 348
Fine structures of macrophages and/or leprosy bacilli in lepromatous leprosy lesions of human skin. Hirata, T. ..... (A) 195
Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Crowle, A. J. and May, M. H. ..... (A) 376
Mycobacteria and human autoimmune disease: direct evidence of cross-reactivity between human lactoferrin and the 65-kilodalton protein of tubercle and leprosy bacilli. Esaguy, N., *et al.* ..... (A) 510
Mycobacteria other than tubercle bacilli in sputum specimens from patients in Manaus (Amazonia, Brazil). Salem, J. I., *et al.* ..... (A) 380
[Preliminary study of delayed hypersensitivity to leprosy antigen induced by killed leprosy bacilli plus BCG.] Chen, J.-L., *et al.* ..... (A) 354
Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. Crowle, A. J. and Elkins, N. ..... (A) 527

BCG (bacille Calmette-Guérin),
A scanning electron microscope study of mycobacterial developmental stages in commercial BCG vaccines. Devadoss, P. O., *et al.* ..... (A) 692
BCG, tuberculosis, and leprosy. Kaklamani, E., *et al.* ..... (A) 512
Cell mass of *M. bovis* BCG estimated by gas chromatography. Olsen, W. P., *et al.* ..... (A) 184
Effect of BCG on the risk of leprosy in an endemic area: a case control study. Muliyil, J., *et al.* ..... (O) 229
[Evaluation of an ELISA using A60 antigen from *M. bovis* BCG: specific IgG and IgM during mycobacterial infections.] Cisse, M. F., *et al.* ..... (A) 354
Fusion protein based epitope mapping of the MPB57 protein from *M. bovis* BCG and its epitope insertion into the native protein. Yamaguchi, R., *et al.* ..... (A) 533
Leprosy and BCG in southern Vietnam. Abel, L., *et al.* ..... (A) 171
Local adoptive transfer of delayed-type hypersensitivity to tuberculin in *M. bovis* (BCG) infected mice. Nikonenko, B. V., *et al.* ..... (A) 184
M. leprae- and BCG-induced chemiluminescence response of monocytes from leprosy patients and healthy subjects: effects of gamma-interferon and GM-CSF. Launois, P., *et al.* ..... (O) 582
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis.* Orrell, J. M., *et al.* ..... (A) 697
New strategies for leprosy and tuberculosis and for development of bacillus Calmette-Guérin into a multivaccine vehicle. Bloom, B. R. ..... (A) 157
Nucleotide sequence of the 32kDa-protein gene (antigen 85A) of *M. bovis* BCG. de Wit, M. Y. L., *et al.* ..... (A) 178
Polyclonal antibodies raised against bacillus Calmette-Guérin, *M. duvalii,* and *M. para-*

tuberculosis used to detect mycobacteria in tissue with the use of immunohistochemical techniques. Wiley, E. L., *et al.* ..... (A) 364
[Preliminary study of delayed hypersensitivity to leprosy antigen induced by killed leprosy bacilli plus BCG.] Chen, J.-L., *et al.* ..... (A) 354
Progress in establishing a recombinant BCG secreting system. Matsuo, K., *et al.* ..... (A) 200
Quantitative and qualitative studies on the major extracellular antigen of *M. tuberculosis* H37Rv and *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 165
Serological monitoring of previously treated lepromatous patients during a course of multiple immunotherapy treatments with heat-killed *M. leprae* and BCG. Douglas, J. T., *et al.* ..... (A) 355
[Specific tuberculosis prophylaxis by BCG vaccine in young subjects.] Bubochkin, B. P. and Ivanova, E. S. ..... (A) 691
Spectrum of immune reactivity to mycobacterial (BCG) antigens in healthy hospital contacts in South India. Pitchappan, R. M., *et al.* ..... (A) 698
Strain differences in mouse cellular responses to *M. lepraemurium* and BCG subcutaneous infections. I. Analysis of cell surface phenotype in local granulomas. Roch, F. and Bach, M.-A. ..... (A) 170
The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. Friedland, I. R. ..... (A) 179
The progress of the study of the ribosomes of BCG vaccine. Suzuki, Y., *et al.* ..... (A) 709
The significance of positive Mantoux reactions in BCG-vaccinated children. Al-Kassimi, F. A., *et al.* ..... (A) 689

Behcet's syndrome,
Treatment of severe colitis in Behcet's syndrome with thalidomide. Larsson, H. ..... (A) 529

Belgium,
Prof. F. Portaels honored. ..... (N) 496

Beta-glucuronidase,
On the pathologic significance of the receptor for beta-glucuronidase (BGR) of *M. leprae* in relationship to its other antigen. Matsuo, E., *et al.* ..... (A) 716
On the possible cross-immunoreactivity of the beta-glucuronidase receptor of *M. scrofulaceum* HI-75 with that in globi in lepromas; an immunohistologic study. Matsuo, E., *et al.* ..... (A) 195

Biopsy,
Skin Biopsy in Leprosy; Histological Interpretation and Clinical Application by Dennis S. Ridley. Job, C. K. ..... (B) 670

Blood,
Determination of different populations of blood lymphocytes in Brazilian patients with hanseniasis. Azulay, R. D. ..... (A) 156
Effect of delays in processing on the survival of *M. avium-M. intracellulare* in the isolator blood culture system. von Reyn, C. F., *et al.* ..... (A) 701
Effect of tuftsin stimulation on the microbicidal activity exerted by blood monocyte-macrophages of leprosy patients. Iyer, R. R., *et al.* ..... (A) 511
Flow cytometric analysis of CD2 modulation on human peripheral blood T lymphocytes by Dharmendra preparation of *M. leprae.* Sheela, R., *et al.* ..... (A) 518
Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Converse, P., *et al.* ..... (A) 158
Profile of blood elements in leprosy patients. Foster, R., *et al.* ..... (A) 674
Synovial cells responding to a 65-kDa mycobacterial heat shock protein have a high proportion of a TcR gamma/delta subtype uncommon in peripheral blood. Soderstrom, K., *et al.* ..... (A) 700

Bone,
Bone marrow cyto-morphological changes in multibacillary leprosy. Sen, R.,*et al.* ..... (A) 352
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vitro.* I. Chromosome analysis in bone marrow and spermatocytes. Das, R. K. and Roy, B. ..... (A) 147
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vivo.* II. Micronucleus test in bone marrow and hepatocytes. Roy, B. and Das, R. K. ..... (A) 149

Book reviews,
Blossoms from the Kalatuchi Tree by Claude V. Reich. Hastings, R. C. ..... (B) 499
Human Paleopathology; Current Syntheses and Future Options, Donald J. Ortner and Arthur C. Aufderheide, eds. Hastings, R. C. ..... (B) 670
Leprosy by Anthony Bryceson and Roy E. Pfaltzgraff. Job, C. K. ..... (B) 144
Leprosy by K. K. Koticha. Hastings, R. C. ..... (B) 144
Skin Biopsy in Leprosy; Histological Interpretation and Clinical Application by Dennis S. Ridley. Job, C. K. ..... (B) 670

Borderline leprosy,
Additional markers for the type I reactional states of borderline leprosy. Lazaro-Medina, A., *et al.* ..... (A) 357
Borderline tuberculoid (BT) leprosy confined to a tattoo. Sehgal, V. N., *et al.* ..... (C) 323
Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Katoch, K., *et al.* ..... (O) 248
Experimental borderline lepromatous leprosy with intraneural erythema nodosum leprosum in a mangabey monkey (*Cercocebus atys*). Baskin, G. B., *et al.* ..... (O) 618
Keratosis spinulosa developing in borderline tuberculoid lesions during type I lepra reaction: two case reports. Thankappan, T. P. and Sulochana, G. ..... (A) 508
Localized borderline lepromatous leprosy. Jha, P. K., *et al.* ..... (A) 675

Brazil,
Determination of different populations of blood lymphocytes in Brazilian patients with hanseniasis. Azulay, R. D. ..... (A) 156
Mycobacteria other than tubercle bacilli in sputum specimens from patients in Manaus (Amazonia, Brazil). Salem, J. I., *et al.* ..... (A) 380
New home-base for *Hansenologia Internationalis.* ..... (N) 131
Reflections on some aspects of leprosy among children in Brazil and in other countries. Bechelli, L. M. and Pagnano, P. M. G. ..... (A) 504

Cefoxitin,
Susceptibilities of *M. fortuitum* biovar, *fortuitum* and the two subgroups of *M. chelonae* to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Wallace, R. J., Jr., *et al.* ..... (A) 533

Cell(s),
A comparative study on the activation of J-774 macrophage-like cells by gamma-interferon, 1,25-dihydroxyvitamin D3 and lipopeptide RP-56142: ability to kill intracellularly multiplying *M. tuberculosis* and *M. avium.* Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
A monoclonal antibody to the mycobacterial 65kDa heat shock protein (ML 30) binds to cells in normal and arthritic joints of rats. Kleinau, S., *et al.* ..... (A) 514
Biological properties of factors secreted by antigen-reactive suppressor cells in mice infected with *M. lepraemurium.* Forget, A. and Turcotte, R. ..... (A) 370
Cell changes and soluble interleukin-2 receptors (Tac peptide) in leprosy reversal reactions using section-induced blisters. Theetranont, C., *et al.* ..... (A) 363
Cell mass of *M. bovis* BCG estimated by gas chromatography. Olsen, W. P., *et al.* ..... (A) 184
Cutaneous lipids and mast cells in murine leprosy. Rojas-Espinosa, O. and Reyes Maldonado, E. ..... (C) 325
Early accumulation of suppressor cell precursors in the spleen of *M. lepraemurium*-infected mice and analysis of their in vitro-induced maturation. Lemieux, S., *et al.* (A) 169
Endoneurial proliferation of perineurial cells in leprosy. Vallat, J. M., *et al.* ..... (A) 519
Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Arnoldi, J., *et al.* ..... (A) 353
Mast cell in leprosy. Rav, S. D., *et al.* ..... (A) 517
Synovial cells responding to a 65-kDa mycobacterial heat shock protein have a high proportion of a TcR gamma/delta subtype uncommon in peripheral blood. Soderstrom, K., *et al.* ..... (A) 700
Target cell lysis and IL-2 secretion by gamma/delta T lymphocytes after activation with bacteria. Munk, M. E., *et al.* ..... (A) 359

Cells, B,
Characterization of murine B-cell epitopes on the *M. leprae* proline-rich antigen by use of synthetic peptides Klatser, P. R., *et al.* ..... (A) 514
Immune responses to the 18-kDa protein *M. leprae*; similar B cell epitopes but different T cell epitopes seen by inbred strains of mice. Doherty, T. M., *et al.* ..... (A) 510
The response of human B cells to *M. leprae*. Identification of target antigens following polyclonal activation *in vitro*. Mahon, A. C., *et al.* ..... (A) 359

Cells, Langerhans' (giant),
CD1-positive epidermal Langerhans cells in regressed tuberculoid and lepromatous leprosy lesions. Narayanan, R. B., *et al.* ..... (A) 360
[Determination of Langerhans' cells in the skin lesions of leprosy cases with immunohistochemical technique using wheat-germ agglutinin.] Liang, Z., *et al.* ..... (A) 161

Cells, mononuclear,
Mycobacterial antigens stimulate rheumatoid mononuclear cells to cartilage proteoglycan depletion.] Wilbrink, B., *et al.* ..... (A) 187
Phenolic glycolipid-I from *M. leprae* inhibits oxygen free radical production by human mononuclear cells. Launois, P., *et al.* ..... (A) 515

Cells, natural killer (NK),
Natural killer cell activity in patients with pulmonary tuberculosis and in healthy controls. Restrepo, L. M., *et al.* ..... (A) 162

Cells, Schwann,
M. leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells. Steinhoff, U., *et al.* ..... (A) 519
Radiolabeling of *M. leprae* lipids with schwannoma cells, a potential drug screening system. Mistry, Y., *et al.* ..... (A) 686

Cells, T,
Characterization of cell-wall associated 10-kDa heat-shock protein of *M. leprae* which is a major T-cell antigen. Mehra, V. L., *et al.* ..... (A) 710
Diversity in antigen recognition by *M. tuberculosis*-reactive T cell clones from the synovial fluid of rheumatoid arthritis patients. Res, P. C. M., *et al.* ..... (A) 698
HLA-DQ molecules and the control of *M. leprae*-specific T cell nonresponsiveness in lepromatous leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 361
Human suppressor T cell clones lack CD28. Li, S. G., *et al.* ..... (A) 357
Immune responses to the 18-kDa protein of *M. leprae*; similar B cell epitopes but different T cell epitopes seen by inbred strains of mice. Doherty, T. M., *et al.* ..... (A) 510
Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. Salgame, P., *et al.* ..... (A) 518
Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Converse, P., *et al.* ..... (A) 158
M. leprae-specific T cells from a tuberculoid leprosy patient suppress HLA-DR3-restricted T cell responses to an immundominant epitope on 65-kDa hsp of mycobacteria. Haanen, J. B. A. G., *et al.* ..... (A) 356
Major histocompatibility complex restriction of T-cell suppression of immune response to mycobacteria. Shroff, K. E., *et al.* ..... (O) 49
Memory T cell-mediated resistance to *M. tuberculosis* infection in innately susceptible and resistant mice. Hubbard, R. D., *et al.* ..... (A) 694
Molecular mapping of interaction between a *M. leprae*-specific T cell epitope, the restricting HLA-DR2 molecule, and two specific T cell receptors. Anderson, D. C., *et al.* ..... (A) 508
Mycobacterial-induced cytoxic T cells as well as nonspecific killer cells derived from healthy individuals and leprosy patients. Kaleab, B., *et al.* ..... (A) 512
On the mechanism of human T cell suppression. Salgame, P., *et al.* ..... (A) 682
Recognition of mycobacterial antigens by gamma/delta T cells. Band, H., *et al.* ..... (A) 678
Recombinant fusion protein identified by lepromatous sera mimics native *M. leprae* in T-cell responses across the leprosy spectrum. Laal, S. *et al.* ..... (A) 515
Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones; a novel potentially immunoregulatory T-T cell interaction in man. Ottenhoff, T. H. M. and Mutis, T. ..... (A) 161

T cell activation by mycobacterial antigens in inflammatory synovitis. Pope, R. M., *et al.* ..... (A) 517
T cell reactivity to an epitope of the mycobacterial 65-kDa heat-shock protein (hsp 65) corresponds with arthritis susceptibility in rats and is regulated by hsp 65-specific cellular responses. Hogervorst, E. J. M., *et al.* ..... (A) 680
T-cells bearing gamma delta antigen receptors in leprosy. Uyemura, K., *et al.* ..... (A) 197
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186
The mycobacterial GroEL stress protein: a common target of T-cell recognition in infection and autoimmunity, Lamb, J. R., *et al.* ..... (A) 160
The T-cell receptor repertoire in mycobacterial infection. Modlin, R. L., *et al.* ..... (A) 721
Use of flanking sequences to study secondary structure-activity correlations of *M. leprae* T cell epitope. Anderson, D. C., *et al.* ..... (A) 352

Cell-mediated immunity (CMI),
Leprosy and cell-mediated immunity. Kaplan, G. and Cohn, Z. A. ..... (A) 680

Chimpanzee(s),
A serologic study of naturally acquired leprosy in chimpanzees. Gormus, B. J., *et al.* ..(O) 450

Chemotherapy (see also Therapy),
Assessment of cure in schistosomiasis patients after chemotherapy with praziquantel by quantitation of circulating anodic antigen (CAA) in urine. Van Lieshout, L., *et al.* ..(A) 700
[Chemotherapeutic efficacy of flurenizid, a new antituberculous pharmaceutical, in an experiment.] Khomenko, A. G., *et al.* ..... (A) 182
Evaluation of PCR analysis in monitoring antileprosy chemotherapy in lepromatous leprosy patients. Williams, D. L., *et al.* ..... (A) 719
Immunotherapy with *M. vaccae* as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Stanford, J. L., *et al.* ..... (A) 163
On the value of sequential serology with a *M. leprae*-specific antibody competition ELISA in monitoring leprosy chemotherapy. Chaturvedi, V., *et al.* ..... (O) 32
Paradoxical response during chemotherapy of tuberculous cervical lymphadenitis: a report of four cases. Al-Aska, A. K., *et al.* ..... (A) 175
Progress in the chemotherapy of leprosy: status, issues and prospects. Gelber, R. H. ...(A) 345
Recent advances in the chemotherapy of leprosy. Ji, B. and Grosset, J.-H. ..... (A) 346
Recent trends in chemotherapy of paucibacillary leprosy. ..... (A) 148
Smear-negative, culture-positive pulmonary tuberculosis; six-month chemotherapy with isoniazid and rifampin. Dutt, A. K., *et al.* ..... (A) 179
Studies on the development of novel antileprous chemotherapeutics using nude mice with special reference to a new quinolone carboxylic acid, AT-4140. Tsutsumi, S. and Gidoh, M. ..... (A) 673
The chemotherapy of leprosy. Part 2. Ellard, G. A. ..... (E) 82
The response to chemotherapy of serum *M. leprae*-specific antigen in multibacillary leprosy patients. Roche, P. W., *et al.* ..... (A) 676

Children,
A study on nutrition, growth and development of a high-risk group of children of urban leprosy patients. Saha, K., *et al.* ..... (A) 372
Cell-mediated and humoral immunity in leprosy in children. Sehgal, V. N., *et al.* .....(A) 351
Reflections on some aspects of leprosy among children in Brazil and in other countries. Bechelli, L. M. and Pagnano, P. M. G. ..... (A) 504
Sensitivity to sensitins and tuberculin in Swedish children. I. A study of school children in an urban area. Lind, A., *et al.* ..... (A) 530
Sensitivity to sensitins and tuberculin in Swedish children. II. A study of preschool children. Larsson, L. O., *et al.* ..... (A) 529
The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. Friedland, I. R. ..... (A) 179
The diagnostic value of an enzyme-linked immune sorbent assay using adsorbed mycobacterial sonicates in children. Rosen, E. U. ..... (A) 185
The significance of positive Mantoux reactions in BCG-vaccinated children. Al-Kassimi, F. A., *et al.* ..... (A) 689

Transmission of health information on leprosy from children to their families: another approach to health education. Kumar, R. P., *et al.* ..... (A) 500

China, People's Republic of,
[Analysis of endemicity of leprosy in Hubei Province.] Zhou, S., *et al.* ..... (A) 173
[Contents of 10 kinds of elements in hair and serum of Tibetan leprosy patients in Gansu Province.] Shi, C., *et al.* ..... (A) 155
[Level of G6PD in the sera of 81 leprosy patients.] Zhou, S., *et al.* ..... (A) 156
National Leprosy Conference held in Nanchang. Ye., G.-Y. ..... (N) 131
[Selenium contents in hair of normal persons and leprosy patients in Qin and Ba Mountain Regions of Shaanxi Province.] Hu, Y., *et al.* ..... (A) 152
[Survey of ocular diseases among 1692 caes of leprosy in Guangdong Province.] Lu, B., *et al.* ..... (A) 152

Cholesterol,
Formation of progesterone and 1-dehydroprogesterone from cholesterol in fermentation cultures of *M. aurum.* Horhold, C. and Bohme, K.-H. ..... (A) 181

Chromatography,
Analysis of cellular fatty acids and proteins by capillary gas chromatography and sodium dodecyl sulphate polyacrylamide gel electrophoresis to differentiate *M. avium, M. intracellulare* and *M. scrofulaceum* (MAIS) complex species. Fourche, J., *et al.* ..... (A) 528
Cell mass of *M. bovis* BCG estimated by gas chromatography. Olsen, W. P., *et al.* ..... (A) 184
High-performance liquid chromatography patterns of mycolic acids as criteria for identification of *M. chelonae, M. fortuitum,* and *M. smegmatis.* Butler W. R. and Kilburn, J. O. ..... (A) 177
[Identification of mycobacteria by gas-liquid chromatography.] Vorobyev, A. A., *et al.* (A) 187

Chromosome(s),
Evaluation of genotoxicity of clofazmine, an antileprosy drug, in mice in vitro. I. Chromosome analysis in bone marrow and spermatocytes. Das, R. K. and Roy, B. ..... (A) 147

Cimetidine,
The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Coleman, M. D., *et al.* ..... (A) 501

Ciprofloxacin,
In vitro susceptibility of *M. avium* complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Yajko, D. M., *et al.* ..... (A) 381
Intracellular bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* H37Rv multiplying in the J-774 macrophage cell line. Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
Persistence mechanisms in *Pseudomonas aeruginosa* from cystic fibrosis patients undergoing ciprofloxacin therapy. Diver, J. M., *et al.* ..... (A) 693

Classification,
Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy.
A comparison of methods based mainly on skin smears as opposed to clinical methods.
Alternative clinical methods for classification of patients. Becx-Bleumink, M. ..... (O) 292
[Leprosy: pathogenesis, classification, diagnosis, and treatment.] Stingl, P. ..... (A) 146
Skin Biopsy in Leprosy; Histological Interpretation and Clinical Application by Dennis S. Ridley. Job, C. K. ..... (B) 670
Southern regional IAL conference on MDT. ..... (N) 662

Clinic(s),
Bombay Leprosy Project starts integrated rehabilitation clinic for leprosy patients. .... (N) 496
Disability index of hands and feet of patients attending an urban leprosy clinic. Thappa, D. M., *et al.* ..... (A) 373

Clinical,
A clinical, immunological, and histological study of neuritic leprosy patients. Kaur, G. *et al.* ..... (O) 385
Adenosine deaminase activity in leprosy. Suri Babu, S. S., *et al.* ..... (A) 519

Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy.
A comparison of methods based mainly on skin smears as opposed to clinical methods. Alternative clinical methods for classification of patients. Becx-Bleumnik, M. .....(O) 292
[Analysis of newly found cases of leprosy in Jiangsu Province from 1983 to 1987.] Ren, X.-W., *et al.* .....(A) 524
Assessment of testicular volume in bacilliferous leprosy; correlation with clinical parameters. Abraham, A., *et al.* .....(A) 348
Association of mycobacterial-specific and *M. leprae* specific antibody levels with clinical activity in tuberculoid leprosy: a comparative study of three serological enzyme-immunoassays. Chaturvedi, V., *et al.* .....(A) 679
Audiovestibular involvement in leprosy. Awasthi, S. K., *et al.* .....(A) 504
Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Katoch, K., *et al.* .....(O) 248
[Clinical importance of HLA phenotype in childhood tuberculosis.] Dovgalyuk, I. F., *et al.* .....(A) 376
Clinical laboratory studies in patients with leprosy and enthesitis. Atkin, S. L., *et al.* ..(A) 348
[Clinical value of *M. tuberculosis* L-form detection in subjects with residual tuberculous changes in the lungs.] Dorozhkova, I. R., *et al.* .....(A) 527
Fibrinolytic phenomenon in leprosy. Jadhav, V. H., *et al.* .....(A) 151
Gamma-glutamyl transpeptide in leprosy. Jain, V. K., *et al.* .....(A) 675
Hansen's disease update. Goodless, D. R. and Johnson, A. H. .....(A) 145
Hypopigmented lesions in early leprosy—a clinical and histological study. Agarwal, U. S., *et al.* .....(A) 504
In-vitro activity of ofloxacin against *M. tuberculosis* and its clinical efficacy in multiple resistant pulmonary tuberculosis. Yew, W. W., *et al.* .....(A) 188
Inter-observer agreement and clinical diagnosis of leprosy for prophylaxis studies. Gupte, M. D., *et al.* .....(A) 350
Is HIV infection a risk factor for leprosy? Ponnighaus, J. M., *et al.* .....(O) 221
Leprosy. Colston, M. J. .....(A) 157
Leprosy and acquired factor VIII inhibitor: a case report. Annichino-Bizzacchi, J. M. and Machado, T. F. G. S. .....(A) 674
Leucocytic alkaline phosphatase activity in leprosy: a possible guide in the follow up of leprosy. Guillet, G., *et al.* .....(A) 151
Non-pruritic eczemas as presenting manifestation of leprosy. Pavithran, K. .....(A) 153
Pattern of leprosy: STUH experience. Go-Estrada, K. L. .....(A) 671
Preliminary observations on myiasis in leprosy patient. Sreevatsa, *et al.* .....(A) 352
Pterygium inversum unguis in a patient with leprosy. Patki, A. H. .....(A) 153
Role of topical phenytoin in trophic ulcers of leprosy in India. Malhotra, Y. K. and Amin, S. S. .....(C) 337
Skin Biopsy in Leprosy; Histological Interpretation and Clinical Application by Dennis S. Ridley. Job, C. K. .....(B) 670
Sub-clinical infection with *M. leprae* in household contacts of leprosy. Bhatia, V. N., *et al.* .....(A) 348
Thalidomide in type-2 lepra reaction—a clinical experience. Jadhav, V. H., *et al.* .....(A) 350
The demystification of leprosy: a multifactorial problem. Kato, L. .....(A) 145
The potential use of thalidomide in the therapy of graft-vs-host disease—a review of clinical and laboratory information. Wood, P. M. D. and Proctor, S. J. .....(A) 187
Thyroid function in leprosy. Garg, R., *et al.* .....(A) 151
Trigeminal trophic syndrome in Hansen's disease. Thomas, J., *et al.* .....(C) 479
Vibration sense and tarsal disintegration. Klenerman, P., *et al.* .....(A) 506

Clofazimine,
Absorption and analysis of clofazimine and its derivatives. O'Sullivan, S., *et al.* .....(A) 347
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vitro*. I. Chromosome analysis in bone marrow and spermatocytes. Das, R. K. and Roy B. .....(A) 147
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vivo*. II. Micronucleus test in bone marrow and hepatocytes. Roy, B. and Das, R. K. .....(A) 149
Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. Job, C. K., *et al.* .....(A) 147

Cloning,
Cloning and characterization of the aroA gene from *M. tuberculosis.* Garbe, T., *et al.* ..(A) 365
Cloning and characterization of the *M. leprae* putative ribosomal RNA promoter in *Escherichia coli.* Sela, S. and Clark-Curtiss, J. E. ....(A) 684
Cloning and expression of the origin of replication of mycobacteriophage D29 in *M. smegmatis.* Lazraq, R., *et al.* ....(A) 695
Diversity in antigen recognition by *M. tuberculosis*-reactive T cell clones from the synovial fluid of rheumatoid arthritis patients. Res, P. C. M., *et al.* ....(A) 698
Human suppressor T cell clones lack CD28. Li, S. G., *et al.* ....(A) 357
Lymphokine profile of functionally distinct *M. leprae*-reactive CD4+ T-helper and CD8+ T-suppressor clones. Salgame, P., *et al.* ....(A) 713
Selection and characterization of recombinant clones that produce *M. leprae* antigens recognized by antibodies in sera from household contacts of leprosy patients. Hartskeerl, R. A., *et al.* ....(A) 159
Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones; a novel potentially immunoregulatory T-T cell interaction in man. Ottenhoff, T. H. M. and Mutis, T. ....(A) 161

Comores,
Leprosy in the Comores 1981–88. Pattyn, S. R. and Grillone, S. ....(A) 687

Complement,
Activation of the human complement system by phenolic glycolipid of *M. leprae.* Ramanathan, V. D., *et al.* ....(A) 362
Complement activation in pulmonary tuberculosis. Sai Baba, K. S. S., *et al.* ....(A) 185
Inhibition of complement activity in murine leprosy. Rojas-Espinosa, O., *et al.* ....(O) 605
Terminal complement complex in plasma of leprosy patients. Parkash, O., *et al.* ....(A) 516
The human C3b receptor: function and role in human diseases. Tausk, F. and Gigli, I. (A) 164

Congresses,
Dr. Vinita Chaturvedi wins Indian Science Congress 1990 Young Scientists' Award. ..(N) 132
18th World Congress of Dermatology call for abstracts. ....(N) 343
18th World Congress of Dermatology scholarships available. ....(N) 343
International Congress for Infectious Diseases, 1992. ....(N) 662
International Congress of Dermatology, 1992 ....(N) 663
National Leprosy Conference held in Nanchang (China). Ye, G.-Y. ....(N) 131
13th International Congress for Tropical Medicine and Malaria. ....(N) 342

Control of leprosy,
A computerized information system for evaluation of NLEP through monthly progress reports. Krishna Murthy, P., *et al.* ....(A) 687
A rapid survey technique for detection of leprosy. Gupta, S. C., *et al.* ....(A) 523
An evaluation of a microcomputer information system for leprosy control two years post-implementation. Campos-Outcalt, D. ....(A) 500
Disability control in a leprosy control programme. Watson, J. M. ....(A) 175
[Effect of leprosy control in Yulin City of Guangxi Province over 32 years.] Weng, C.-Y., *et al.* ....(A) 525
Evaluation of a computerized field data collection system for health surveys. Forster, D., *et al.* ....(A) 693
Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink, M. ....(O) 558
Impact of multidrug therapy on the treatment and control of leprosy. Gilbody, J. S. ... (E) 458
Leprosy control in Zimbabwe: from a vertical to a horizontal programme. Warndorff, D. K. and Warndorff, J. A. ....(A) 173
Leprosy Control Project Annual Report 1988–1989 (Nepal). ....(N) 137
MDT for all; target oriented leprosy control program in the 1990s. Yuasa, Y. ..... (E) 624
Reduction in caseload after multidrug therapy in an urban leprosy control programme—a retrospective study in Bombay. Revankar, C. R. *et al.* ....(A) 500

What next in basic research? Young, D. B. ..... (E) 95
WHO Interregional Conference on Leprosy Control in Africa. ..... (N) 131

Corticosteroids,
Treatment of leprous neuritis by neurolysis combined with perineural corticosteroid injection. Dandapat, M. C., *et al.* ..... (A) 525

Cuba,
[Some psychosocial and epidemiologic characteristics of the leprosy patient in Artemisa Municipality (Cuba).] Lopez del Rincon, F., *et al.* ..... (A) 174

Cultivation,
Cogitations on the cultivation of *M. leprae.* Why bother? Hanks, J. H. ..... (E) 304
Cultivation *in vitro* of acid-fast nocardioform chemoautotrophic bacteria from mouse foot-pads infected with human strains of leprosy bacillus. Chakrabarty, A. N., *et al.* (A) 166
Mouse footpad pathogenicity of leprosy derived nocardioform bacteria cultivated *in vitro.* Chakrabarty, A. N., *et al.* ..... (A) 683

Cutaneous,
A case of isolated tuberculoid leprosy of brachial cutaneous nerve. Nogueira, L. A. D. (A) 153
Cutaneous lipids and mast cells in murine leprosy. Rojas-Espinosa, O. and Reyes Maldonado, E. ..... (C) 325
Diagnostic and therapeutic considerations for cutaneous *M. haemophilum* infections. McBride, M. E., *et al.* ..... (A) 378
Disseminated *M. chelonae* subspecies *chelonae* infection with cutaneous and osseous manifestations. Drabick, J. J., *et al.* ..... (A) 178

Damien-Dutton Society,
1990 Damien-Dutton Award recipient is Wayne M. Meyers, M.D., Ph.D. ..... (N) 129
1991 Damien-Dutton Award to Dr. Ruth K. M. Pfau. ..... (N) 658

Dapsone (DDS),
A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone. Pattyn, S. R., *et al.* ..... (A) 673
Dapsone as a single agent is suboptimal therapy for *Pneumocystis carinii* pneumonia. Safrin, S., *et al.* ..... (A) 531
Dapsone-induced liver necrosis. Jayalakshmi, P. and Ting, H. C. ..... (A) 147
Effect of dapsone on haemoglobin concentration in patients with leprosy. Byrd, S. R. and Gelber, R. H. ..... (A) 674
Gall-bladder perforation after long-term dapsone therapy. Choy, A. M. and Lang, C. C. (A) 501
[Histological findings in the iris of DDS treated patients.] Shi, Z.-R., *et al.* ..... (A) 507
In vitro effect of dapsone on NADH-methemoglobin reductase. Banzato, C. E. M. and Magna, L. A. ..... (C) 486
Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. Coleman, M. D., *et al.* ..... (A) 146
Longitudinal study on relapses of leprosy in Polynesian multibacillary patients on dapsone monotherapy between 1946 and 1970. Cartel, J.-L., *et al.* ..... (A) 672
Peripheral neuropathy and haemolytic anaemia with cherry red spot on macula in dapsone poisoning. Abhayambika, K., *et al.* ..... (A) 501
Primary dapsone-resistant Hansen's disease in California; experience with over 100 *M. leprae* isolates. Gelber, R. H., *et al.* ..... (A) 345
Self-administered dapsone compliance of leprosy patients in eastern Nepal. van Trier, Y. D. M. and de Soldenhoff, R. ..... (A) 503
Spectrophotometric determination of dapsone by using 9-chloroacridine as a chromogenic reagent. Shoukrallah, I., *et al.* ..... (A) 348
[Study on primary dapsone resistant leprosy.] Cheng, J., *et al.* ..... (A) 146
The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. May, D. G., *et al.* ..... (A) 346
The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden. Hornsten, P., *et al.* ..... (A) 152

The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Coleman, M. D., *et al.* ..... (A) 501

Deformity, disability,

[A study of disabilities caused by leprosy.] Carrazana Hernandez, G. B., *et al.* ..... (A) 349
Disabilities in leprosy patients ascertained in a total population survey in Karonga District, northern Malawi. Ponnighaus, I. M., *et al.* ..... (A) 373
Disability control in a leprosy control programme. Watson, J. M. ..... (A) 175
Disability index of hands and feet of patients attending an urban leprosy clinic. Thappa, D. M., *et al.* ..... (A) 373
[Epidemiological investigation of disability in leprosy. (I) Factors relevant to disability.] Zhang, G.-C., *et al.* ..... (A) 688
[Oral and maxillofacial deformity in leprosy.] Tu, Y., *et al.* ..... (A) 155
[Survey of disability in leprosy.] Zhang, F., *et al.* ..... (A) 175
[Treatment and rehabilitation of deformities in leprosy in a district hospital (Kapolowe, Zaire).] Vuillet, F. and Tschibangu, P. ..... (A) 526

Dermatology,

18th World Congress of Dermatology call for abstracts. ..... (N) 343
18th World Congress of Dermatology scholarships available. ..... (N) 343
International Congress of Dermatology, 1992. ..... (N) 663

DNA,

Development of a highly specific diagnostic 23S rDNA oligonucleotide probe for *M. leprae*. Liesack, W., *et al.* ..... (A) 167

Drugs (see also specific drugs),

A case of relapse with drug-susceptible *M. leprae* after multidrug therapy. Constant-Desportes, M., *et al.* ..... (O) 242
A retrospective study on seven years of multiple drug treatment for paucibacillary and multibacillary leprosy in Bayara General Hospital, Nigeria. Blok, L. M., *et al.* ..... (A) 672
Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy.
A comparison of methods based mainly on skin smears as opposed to clinical methods.
Alternative clinical methods for classification of patients. Becx-Bleumink, M. ..... (O) 292
Antileprosy activity of a newly developed quinolone, fleroxacin. Saito, H. and Tomioka, H. ..... (A) 193
Antileprotic effect of the immunostimulating drug RACA 854 in experimentally infected armadillos. Kazda, J. and Shafik, A. ..... (C) 649
Bactericidal antibiotics of three different classes emerge to treat leprosy; recent developments from the laboratory to the patient. Gelber, R. H., *et al.* ..... (A) 717
Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Cho, S.-N., *et al.* ..... (O) 25
Determination of *in vivo* and *in vitro* drug effects of mycobacteria from the mass spectrometric analysis of single organisms. Haas, M., *et al.* ..... (O) 262
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vitro*. I. Chromosome analysis in bone marrow and spermatocytes. Das, R. K. and Roy, B. ..... (A) 147
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vivo*. II. Micronucleus test in bone marrow and hepatocytes. Roy, B. and Das, R. K. ..... (A) 149
Immunopharmacology of drugs used in leprosy reactions. Girdhar, B. K. ..... (A) 346
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Saito, H., *et al.* ..... (A) 503
New developments in the antimicrobial treatment of leprosy. Gelber, R. H. ..... (A) 147
Pattern of drug compliance in leprosy patients attending urban centers—a longitudinal study. Naik, S. S., *et al.* ..... (A) 347
Probability distribution of drug-resistant mutants in unselected populations of *M. tuberculosis*. David, H. L. ..... (A) 527
Radiolabeling of *M. leprae* lipids with schwannoma cells, a potential drug screening system. Mistry, Y., *et al.* ..... (A) 686
Rifampin in drug-incorporated diet: effect of duration and temperature of storage. Relevance to drug-susceptibility testing in mice inoculated with *M. leprae*. Abraham, B., *et al.* ..... (O) 68

Self-administered drug compliance in Nepali leprosy patients. Roche, P. W., *et al.* ....(A) 503
Shelf life of antileprosy drugs. ....(N) 665
Therapeutic regimens in leprosy. Pattyn, S. R. ....(A) 671
Tuberculostatic activity of henna (*Lawsonia inermis* Linn.). Sharma, V. K. ....(A) 381

Electron microscopy (see also Ultrastructure),
A scanning electron microscope study of mycobacterial developmental stages in commercial BCG vaccines. Devadoss, P. O., *et al.* ....(A) 692

ELISA (enzyme-linked immunosorbent assay) tests,
Association of mycobacterial-specific and *M. leprae* specific antibody levels with clinical activity in tuberculoid leprosy: a comparative study of three serological enzyme-immunoassays. Chaturvedi, V., *et al.* ....(A) 679
Detection of *M. leprae*-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients. Singh, N. B., *et al.* ....(O) 398
Detection of mycobacterial antigens in cerebrospinal fluid by enzyme-linked immunosorbent assay. Wu, C. H., *et al.* ....(A) 187
[Determination of antigen-specific immune complexes by the method of the enzyme immunoassay.] Bobrovnik, S. A. and Lyashchenko, K. P. ....(A) 691
Diagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay to detect mycobacterial antigen and antibody in cerebrospinal fluid. Annamma, M., *et al.* ....(A) 690
ELISA & lepromin skin tests in household contacts of leprosy patients. Dhandayuthapani, S., *et al.* ....(A) 523
[ELISA results in the prevalence of leprosy after monotherapy.] Carrazana Hernandez, G. and Ferra Torres, T. M. ....(A) 353
[Evaluation of an ELISA using A60 antigen from *M. bovis* BCG: specific IgG and IgM during mycobacterial infections.] Cisse, M. F., *et al.* ....(A) 354
Mycobacterial antigens and anti-idiotype antibodies revealed by an enzyme-linked immunosorbent assay in tuberculous patient sera. Stavri, D., *et al.* ....(A) 381
On the value of sequential serology with a *M. leprae*-specific antibody competition ELISA in monitoring leprosy chemotherapy. Chaturvedi, V., *et al.* ....(O) 32
Seroepidemiological study of leprosy in a highly endemic population of South India based on an ELISA using synthetic PGL-1. Krishnamurthy, P., *et al.* ....(O) 426
Serological analysis of human tuberculosis by an ELISA with mycobacterial antigen 60. Baelden, M.-C., *et al.* ....(A) 176
[Study of blocking agents in ELISA for antibodies to leprosy.] Wu, Q.-X., *et al.* ....(A) 520
[The comparative study of gelatin particle agglutination test (GPAT) and PGL-ELISA.] Li, H., *et al.* ....(A) 160
[Use of the microdot enzyme immunoassay for the determination of antibodies to *M. tuberculosis*.] Badukshanova, N. M., *et al.* ....(A) 374

Enzyme(s),
[Antiotensin-converting enzyme in serum of tuberculosis and leprosy patients.] Vinnik, L. A., *et al.* ....(A) 164
Changes in hydrolytic enzyme activities in armadillos infected with *M. leprae*. Dhople, A. M. ....(A) 685
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ....(A) 686

Epidemiology,
A seroepidemiological study of leprosy in high- and low-endemic Indonesian villages. Soebono, H. and Klaster, P. O. ....(O) 416
[Analysis of endemicity of leprosy in Hubai Province (China).] Zhou, S., *et al.* ....(A) 173
[Epidemiological investigation of disability in leprosy. (I) Factors relevant to disability.] Zhang, G.-C., *et al.* ....(A) 688
Epidemiological model and cost-effectiveness of tuberculosis treatment programmes in Indonesia. Joesoef, M. R., *et al.* ....(A) 181
Epidemiological pattern of leprosy in Ethiopia: a review of the control programmes. Berhe, D., *et al.* ....(A) 173
Epidemiological significance of indeterminate leprosy—a hospital based study. Raveendranathan, O., *et al.* ....(A) 687
Evaluation of the leprosy endemicity in Burundi during the years 1981–88. Pattyn, S. R., *et al.* ....(A) 687

[General situation of leprosy in Neimenggu Autonomous Region.] Baodebiligc, *et al.* ..(A) 687
IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Ulrich, M., *et al.* .....(O) 405
Insertion element IS986 from *M. tuberculosis*: a useful tool for diagnosis and epidemiology of tuberculosis. Hermans, P. W. M., *et al.* .....(A) 181
[Leprosy endemicity of Popular Republic of Congo. An epidemiologic and behavioral analysis.] Louis, J. P., *et al.* .....(A) 524
Leprosy in Kuwait: an epidemiological study of new cases. Al-Kandari, S., *et al.* .....(A) 371
Seroepidemiological study of leprosy in a highly endemic population of South India based on an ELISA using synthetic PGL-1. Krishnamurthy, P., *et al.* .....(O) 426
[Some psychosocial and epidemiologic characteristics of the leprosy patient in Artemisa Municipality (Cuba).] Lopez del Rincon, F., *et al.* .....(A) 174
[Some psychosocial and epidemiological characteristics of leprosy patients in the municipality of Artemisa.] de Rojas y Lopez del Rincon, V., *et al.* .....(A) 523
The changing epidemiology of tuberculosis and other mycobacterial infections in the United States: implications for the radiologist. Buckner, C. B., *et al.* .....(A) 692
The face of leprosy in the United States today. Jacobson, R. .....(A) 345
The leprosy endemic in the Golfe Prefecture of Togo in 1987. Edorh, A. A., *et al.* ....(A) 371

Erythema nodosum leprosum (ENL),
[Antibody against PG1 and immunocomplex in the sera of leprosy patients with ENL.] Zhang, X., *et al.* .....(A) 166
Experimental borderline lepromatous leprosy with intraneural erythema nodosum leprosum in a mangabey monkey (*Cercocebus atys*). Baskin, G. B., *et al.* .....(O) 618
Multiple Beau's lines due to recurrent erythema nodosum leprosum. Patki, A. H. .....(A) 153

Escherichia coli,
Analysis of *M. leprae, M. tuberculosis,* and *M. avium* genomic libraries in *M. smegmatis* and *E. coli* using shuttle cosmid vectors. Pane, L., *et al.* .....(A) 200
Cloning and characterization of the *M. leprae* putative ribosomal RNA promoter in *Escherichia coli.* Sela, S. and Clark-Curtiss, J. E. .....(A) 684

Ethambutol,
Cell wall composition of ethambutol susceptible and resistant strains of *M. smegmatis* ATCC 607. Sareen, M. and Khuller, G. K. .....(A) 186
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against *M. avium* complex. Rastogi, N. and Labrousse, V. .....(A) 502

Ethiopia,
A survey of HTLV-I and HIVs in Ethiopian leprosy patients. Tekle-Haimanot, R., *et al.* .....(A) 508
Epidemiological pattern of leprosy in Ethiopia: a review of the control programmes. Berhe, D., *et al.* .....(A) 173
Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink, M. .....(O) 558

Experimental leprosy,
[Effects of ofloxacin and minocycline on experimental leprosy.] Wang, H.-Y., *et al.* ...(A) 673
Gamma interferon in experimental leprosy. Krahenbuhl, J. L., *et al.* .....(A) 514
Naturally acquired and experimental leprosy in nonhuman primates. Meyers, W. M., *et al.* .....(A) 686
Tumor necrosis factor in experimental leprosy. Fukutomi, Y., *et al.* .....(A) 711

Eye(s),
[A survey of eye lesions in leprosy.] Luo, Y.-R., *et al.* .....(A) 351
Corneal sensitivity and correlations between decreased sensitivity and anterior segment pathology in ocular leprosy. Karacorlu, M. A., *et al.* .....(A) 505
Influence of untreated chronic plastic iridocyclitis on intraocular pressure in leprosy patients. Karacorlu, M. A., *et al.* .....(A) 505

Leprotic kerathopathy in India. Lamba, P. A. and Rohatgi, J. ..... (A) 152
Ocular changes in leprosy. Sehgal, V. N. and Lamba, P. A. ..... (A) 154
Progression of eye lesions in leprosy: ten-year follow-up study in The Netherlands. Hogeweg, M. and Faber, W. R. ..... (O) 392
Pupil cycle time and early autonomic involvement in ocular leprosy. Karacorlu, M. A., *et al.* ..... (A) 506
[Severity of leprosy eye lesions in armadillos infected with *M. leprae.*] Zhou, H.-M., *et al.* ..... (A) 360
[Survey of ocular diseases among 1692 cases of leprosy in Guangdong Province (China).] Lu, B., *et al.* ..... (A) 152
The continuing challenge of ocular leprosy. ffytche, T. J. ..... (A) 505
The protective effects of methyl cellulose and conoid shields for lagophthalmos and corneal hypaesthesia in leprosy. Karacorlu, M. A., *et al.* ..... (A) 675
Training for primary eye care in leprosy. Courtright, P., *et al.* ..... (A) 149
Treatment of facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 675

Face,
Facial palsy—a leprosy surgeon's viewpoint. Warren, G. ..... (A) 526
The significance of facial patches and Type 1 reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients. Hogeweg, M., *et al.* ..... (A) 674
Treatment of facial nerve damage with lagophthalmos, using a semi standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 675
Trigeminal trophic syndrome in Hansen's disease. Thomas, J., *et al.* ..... (C) 479

Family,
[Study of genetic markers in the families of patients with tuberculosis.] Rakhimov, A. K. and Pospelov, L. E. ..... (A) 379
Transmission of health information on leprosy from children to their families: another approach to health education. Kumar, R. P., *et al.* ..... (A) 500

Finger(s),
Impairment of fingertip vasomotor reflexes in leprosy patients and apparently healthy contacts. Abbot, N. C., *et al.* ..... (O) 537

Foot,
Disability index of hands and feet of patients attending an urban leprosy clinic. Thappa, D. M., *et al.* ..... (A) 373
Foot soaks for callosities and fissures. Premkumar, R., *et al.* ..... (A) 506
New image-processing system for analysis, display and measurement of static and dynamic foot pressures. Patil, K. M. and Srinath, M. S. ..... (A) 526
Newer designs in foot-wear for leprosy patients. Kulkarni, V. N., *et al.* ..... (A) 525

Foot pad(s),
Mouse footpad pathogenicity of leprosy derived nocardioform bacteria cultivated *in vitro.* Chakrabarty, A. N., *et al.* ..... (A) 683
Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ..... (A) 349

France,
Diplome Universitaire de Leprologie, 1991–1992. ..... (N) 659

Genetics,
Application of HLA-DQ transgenic mice for the analysis of genetic control of the immune response to *M. leprae* antigen. Nishimura, Y., *et al.* ..... (A) 200
Genetic control of immunopathology induced by *M. leprae.* de Vries, R. R. P. ..... (A) 680
Genetic regulation of *M. paratuberculosis* infection in recombinant inbred mice. Frelier, P. F., *et al.* ..... (A) 528
Molecular genetics of mycobacteriophage L5. Hatfull, G. F., *et al.* ..... (A) 196
Nucleotide sequence of the 32kDa-protein gene (antigen 85A) of *M. bovis* BCG. de Wit, M. Y. L., *et al.* ..... (A) 178

[Study of genetic markers in the families of patients with tuberculosis.] Rakhimov, A. K. and Pospelov, L. E. ..... (A) 379
The molecular biology of MHC genes. Accolla, R. S., *et al.* ..... (A) 678

Genome,
A family of dispersed repeats in *M. leprae.* Woods, S. A. and Cole, S. T. ..... (A) 369
An easy and rapid method for isolation of entire mycobacterial genome for application of pulsed-field gel electrophoresis. Charvin, M., *et al.* ..... (A) 684
Analysis of *M. leprae, M. tuberculosis,* and *M. avium* genomic libraries in *M. smegmatis* and *E. coli* using shuttle cosmid vectors. Pane, L., *et al.* ..... (A) 200

Germany,
1991 Damien-Dutton Award to Dr. Ruth K. M. Pfau. ..... (N) 658
German award to AHM Chairman Mr. Maximilian Gruner. ..... (N) 131

Granuloma(s),
Abortion and granulomatous colitis due to *M. avium* complex infection in a horse. Cline, J. M., *et al.* ..... (A) 527
Granuloma disciformis chronica et progressiva (Miescher) mimicking tuberculoid leprosy. Satyawan, I., *et al.* ..... (A) 676
Immunohistological analysis of nerve granulomas in neuritic leprosy. Narayanan, R. B., *et al.* ..... (A) 360
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis.* Orrell, J. M., *et al.* ..... (A) 697
Strain differences in mouse cellular responses to *M. lepraemurium* and BCG subcutaneous infections. I. Analysis of cell surface phenotype in local granulomas. Roch, F. and Bach, M.-A. ..... (A) 170

Hair,
[Contents of 10 kinds of elements in hair and serum of Tibetan leprosy patients in Gansu Province (China).] Shi, C., *et al.* ..... (A) 155
[Selenium contents in hair of normal persons and leprosy patients in Qin and Ba Mountain Regions of Shaanxi Province.] Hu, Y., *et al.* ..... (A) 152

Hand(s),
Carvable silicone rubber prosthetic implant for atrophy of the first web in the hand. Duerksen, F. and Virmond, M. ..... (A) 174
Disability index of hands and feet of patients attending an urban leprosy clinic. Thappa, D. M., *et al.* ..... (A) 373

Histoid leprosy,
Mucosal and genital lesions in histoid leprosy. Nigam, P. K. and Singh, G. ..... (A) 153

HLA (see also Genetics),
Application of HLA-DQ transgenic mice for the analysis of genetic control of the immune response to *M. leprae* antigen. Nishimura, Y., *et al.* ..... (A) 200
Association of pulmonary tuberculosis and HLA in South India. Brahmajothi, V., *et al.* (A) 691
[Clinical importance of HLA phenotype in childhood tuberculosis.] Dovgalyuk, I. F., *et al.* ..... (A) 376
HLA-DQ molecules and the control of *M. leprae*-specific T cell nonresponsiveness in lepromatous leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 361
Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. Salgame, P., *et al.* ..... (A) 518
M. leprae-specific T cells from a tuberculoid leprosy patient suppress HLA-DR3-restricted T cell responses to an immunodominant epitope on 65-kDa hsp of mycobacteria. Haanen, J. B. A. G., *et al.* ..... (A) 356
Molecular mapping of interactions between a *M. leprae*-specific T cell epitope, the restricting HLA-DR2 molecule, and two specific T cell receptors. Anderson, D. C., *et al.* ..... (A) 508
Tuberculosis in patients with various HLA phenotypes. Khomenko, A. G., *et al.* ..... (A) 182

Hypersensitivity,
[Development of delayed hypersensitivity to mycobacterial antigens.] Lyashchenko, K. P., *et al.* ..... (A) 696

Local adoptive transfer of delayed-type hypersensitivity to tuberculin in *M. bovis* (BCG) infected mice. Nikonenko, B. V., *et al.* ..... (A) 184
[Preliminary study of delayed hypersensitivity to leprosy antigen induced by killed leprosy bacilli plus BCG.] Chen, J.-L., *et al.* ..... (A) 354

ILEP (International Federation of Anti-Leprosy Associations),
ILEP 1991 workshop dates. ..... (N) 130
ILEP celebrates 25th anniversary. ..... (N) 664
ILEP General Secretary joins governing membership of UIA. ..... (N) 666

Immune complexes,
[Determination of antigen-specific immune complexes by the method of the enzyme immunoassay.] Bobrovnik, S. A. and Lyashchenko, K. P. ..... (A) 691
Effect of circulating immune complexes of leprosy patients on leukocyte migration inhibition induced by *M. leprae* antigens in healthy volunteers. Tyagi, P., *et al.* ..... (C) 487
Persistent reduced solubilization of immune complexes in lepromatous leprosy patients with reaction. Ramanathan, V. D., *et al.* ..... (O) 5
T lymphocyte subpopulations in leprosy patients and their relation with circulating immune complexes. Bottasso, O. A., *et al.* ..... (A) 157

Immune responses,
Application of HLA-DQ transgenic mice for the analysis of genetic control of the immune response to *M. leprae* antigen. Nishimura, Y., *et al.* ..... (A) 200
Defining protective immune responses to infectious pathogens: lymphokine and cytokine profiles in leprosy lesions. Yamamura, M., *et al.* ..... (A) 712
Immune responses to the 18-kDa protein of *M. leprae*; similar B cell epitopes but different T cell epitopes seen by inbred strains of mice. Doherty, T. M., *et al.* ..... (A) 510
[Influence of treatment with *M. leprae* on the immune response in rats; its evaluation in a model of experimental arthritis.] Bottasso, O., *et al.* ..... (A) 353
Major histocompatibility complex restriction of T-cell suppression of immune response to mycobacteria. Shroff, K. E., *et al.* ..... (O) 49
Spectrum of immune reactivity in mycobacterial (BCG) antigens in healthy hospital contacts in South India. Pitchappan, R. M., *et al.* ..... (A) 698
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186

Immunoglobulins,
Anti-phenolic glycolipid 1 IgM antibodies in leprosy patients and their household contacts. Sulcebe, G. and Nakuci, M. ..... (A) 363
Antiarabinogalactan IgM/IgG ratio: a screening index for leprosy patients. Roy, A., *et al.* ..... (A) 517
Comparison of IgM, IgG and IgA responses to *M. leprae* specific antigens in leprosy. Praputpittaya, K., *et al.* ..... (A) 362
[Detection of IgM anti-PGL-I for the serodiagnosis of leprosy and for the follow up of contact population in Polynesia. A 5 year situation.] Chanteau, S., *et al.* ..... (A) 354
[Evaluation of an ELISA using A60 antigen from *M. bovis* BCG: specific IgG and IgM during mycobacterial infections.] Cisse, M. F., *et al.* ..... (A) 354
IgG and IgM antibodies immunoreacting with a 2,3-diacyl trehalose-2′-sulphate in sera from leprosy patients. Cruaud, P., *et al.* ..... (A) 158
IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Ulrich, M., *et al.* ..... (O) 405
IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from *M. leprae* in sera of leprosy patients and their contacts. Saad, M. H. F., *et al.* ..... (A) 362
Serum IgA1 and IgM antibodies against *M. leprae*-derived phenolic glycolipid-I: a comparative study in leprosy patients and their contacts. Chujor, C. S. N., *et al.* ..... (O) 441
The value of IgM antibodies to PGL-I in the diagnosis of leprosy. Lefford, M. J., *et al.* (O) 432

Immunology,
A clinical, immunological, and histological study of neuritic leprosy patients. Kaur, G., *et al.* ..... (O) 385

A histopathological and immunological profile of a single lesion lepromatous leprosy (LLs). Misra, R. S., *et al.* ..... (E) 645
Autoimmunity, microbial immunity and the immunological humunculus. Cohen, I. R. and Young, D. B. ..... (A) 679
Cytokines and the Koch phenomenon. Rook, G. A. W. and Al Atiyah, R. ..... (A) 531
Effects of cyclosporin A on bacterial growth and immunological responsiveness in BALB/c mice infected with *M. leprae*. Tanaka, M., *et al.* ..... (O) 598
Effects of cyclosporin A on immunological responsiveness in early stages of infection with *M. leprae*. Tanaka, M. and Tanaka, Y. ..... (A) 194
[Immunological characteristics in a different course of lepromatous leprosy.] Saroyants, L. V., *et al.* ..... (A) 363
Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. Salgame, P., *et al.* ..... (A) 518
[Immunology of leprosy, 1987–1990.] Castells Rodellas, A., *et al.* ..... (A) 678
Implications of progressive multifocal leukoencephalopathy and KC virus for the etiology of M.S. Stoner, G. L. ..... (A) 532
Molecular characterization of immunologically reactive proteins of *M. leprae*. Sela, S., *et al.* ..... (A) 715
The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic glycolipids: structure and immunological properties. Puzo, G. ..... (A) 366

Immunoperoxidase,
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis*. Orrell, J. M., *et al.* ..... (A) 697

Immunopharmacology,
Immunopharmacology of drugs used in leprosy reactions. Girdhar, B. K. ..... (A) 346

Immunotherapy,
Immunotherapy with *M. vaccae* as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Stanford, J. L., *et al.* ..... (A) 163
Improved immunotherapy for pulmonary tuberculosis with *M. vaccae*. Bahr, G. M., *et al.* ..... (A) 374
M. vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Stanford, J. L., *et al.* ..... (A) 518
Serological monitoring of previously treated lepromatous patients during a course of multiple immunotherapy treatments with heat-killed *M. leprae* and BCG. Douglas, J. T., *et al.* ..... (A) 355

Indeterminate leprosy,
Epidemiological significance of indeterminate leprosy—a hospital based study. Raveendranathan, O., *et al.* ..... (A) 687
Indeterminate leprosy: histopathologic and histochemical predictive parameters involved in its possible change to paucibacillary or multibacillary leprosy. Takahashi, M. D., *et al.* ..... (O) 12

India,
Acworth Leprosy Hospital Research Society, Bombay, celebrates 20th anniversary. ... (N) 131
Association of pulmonary tuberculosis and HLA in South India. Brahmajothi, V., *et al.* (A) 691
Birla Award to Dr. D. K. Dastur. ..... (N) 659
Bombay Leprosy Project starts extension center at Sion Medical College. ..... (N) 132
Bombay Leprosy Project starts integrated rehabilitation clinic for leprosy patients. .... (N) 496
Comparative leprosy vaccine trial launched in south India. ..... (N) 660
Conference of Voluntary Leprosy Institutions of Maharashtra. ..... (N) 660
December 1991 Workshop to be held at Dhoolpet. ..... (N) 497
Dharmendra. Ramu, G. ..... (Ob) 494
Dharmendra death notice. ..... (N) 143
Dr. (Mrs.) K. Katoch wins Dr. C. G. S. Iyer 1989 Oration Award. ..... (N) 132
Dr. Ganapati honored with Eighth Annual Fr. Maschio Humanitarian Award. ..... (N) 339
Dr. Kiran Katoch receives Dr. C. G. S. Iyer Oration Award 1989. ..... (N) 496
Dr. V. M. Katoch gives 8th (1991) Erwin Stindl Memorial Oration. ..... (N) 339

Dr. Vinita Chaturvedi wins Indian Science Congress 1990 Young Scientists' Award. ..(N) 132
Drs. Saha and Rao receive International Mitsuda Award. ..(N) 497
Evaluation of an MDT workshop. ..(N) 660
Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India. Balasubramanian, R., *et al.* ..(A) 375
Geographic distribution of phage types among cultures of *M. tuberculosis.* II. Cultures from India and South Africa. Jones, W. D., Jr. ..(A) 377
Ghandi Memorial Leprosy Foundation 39th (1989–90) Annual Report. ..(N) 339
Indian Journal of Leprosy office moves to Madras. ..(N) 133
Indian Journal of Leprosy permanent address. ..(N) 661
International Mitsuda Award to Dr. K. N. Rao and Dr. K. Saha. ..(N) 133
JALMA Trust Fund 1989 Oration Award to Dr. U. Sengupta. ..(N) 133
Largest vaccine trial yet. ..(N) 661
"Leprosy—Diagnosis and Management" 4th edition. ..(N) 661
Leprotic keratopathy in India. Lamba, P. A. and Rohatgi, J. ..(A) 152
New appointment for Dr. V. P. Bharadwaj. Kumar, S. ..(N) 133
1988–89 Annual Report of the Director-General, Indian Council of Medical Research. (N) 136
1990 Best Scientific Film award. Mehta, J. ..(N) 133
1990 Padma Shri awards to two leprosy scientists—Dr. Antia and Dr. Deo. ..(N) 134
Prevalence study of tuberculous infection over fifteen years in a rural population of Chingleput district (south India). Mayurnath, S., *et al.* ..(A) 696
Proposals for research in leprosy during VIII plan period. ..(N) 134
Reactions in leprosy; a study of 250 patients in a multidrug therapy project, Baroda District, Gujarat, India. Chopra, N. K. *et al.* ..(A) 149
Role of topical phenytoin in trophic ulcers of leprosy in India. Malhotra, Y. K. and Amin, S. S. ..(C) 337
Seroepidemiological study of leprosy in a highly endemic population of South India based on an ELISA using synthetic PGL-1. Krishnamurthy, P., *et al.* ..(O) 426
XVII Indian Association of Leprologists Conference. ..(N) 661
Southern regional IAL conference on MDT. ..(N) 662
Spectrum of immune reactivity to mycobacterial (BCG) antigens in healthy hospital contacts in South India. Pitchappan, R. M., *et al.* ..(A) 698
"Wall Journal" on leprosy at Sion Medical College. ..(N) 662

Indonesia,
A seroepidemiological study of leprosy in high- and low-endemic Indonesian villages. Soebono, H. and Klatser, P. R. ..(O) 416
Epidemiological model and cost-effectiveness of tuberculosis treatment programmes in Indonesia. Joesoef, M. R., *et al.* ..(A) 181

Inoculation,
[Mycobacteria isolated from armadillos (*Dasypus novemcinctus*) inoculated with *M. leprae.*] Coelmo, A. A. M., *et al.* ..(A) 169
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ..(A) 532
Rifampin in drug-incorporated diet: effect of duration and temperature of storage. Relevance to drug-susceptibility testing in mice inoculated with *M. leprae.* Abraham, B., *et al.* ..(O) 68
Susceptibility of severe combined immunodeficient (SCID) mice to *M. leprae*: multiplication of *M. leprae* inoculated into both hind feet at an early stage. Yogi, Y., *et al.* (A) 722
The evolution of antibody response in armadillos inoculated with *M. leprae.* Vadiee, A. R., *et al.* ..(A) 171

Interferon,
A comparative study on the activation of J-774 macrophage-like cells by gamma-interferon, 1,25-dihydroxyvitamin D3 and lipopeptide RP-56142: ability to kill intracellularly multiplying *M. tuberculosis* and *M. avium.* Rastogi, N. and Blom-Potar, M.-C. ..(A) 379
Effect of glucocorticoids and interferon-gamma on the oxidative responses of monocytes from leprosy patients and normal donors. Vachula, M., *et al.* ..(O) 41

Gamma interferon in experimental leprosy. Krahenbuhl, J. L., *et al.* ..... (A) 514
M. leprae- and BCG-induced chemiluminescence response of monocytes from leprosy patients and healthy subjects: effects of gamma-interferon and GM-CSF. Launois, P., *et al.* ..... (O) 582
[Systemic use of interferon-gamma in lepromatous leprosy.] Sagaro Delgado, B., *et al.* (A) 362
Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma. Nathan, C., *et al.* ..... (A) 361

Interleukin(s),
Cell changes and soluble interleukin-2 receptors (Tac peptide) in leprosy reversal reactions using section-induced blisters. Theetranont, C., *et al.* ..... (A) 363
Detection of interleukin-3 in the serum of mice infected with *M. lepraemurium.* Resnick, M., *et al.* ..... (A) 380
In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis *in vitro.* Hancock, G. E., *et al.* ..... (A) 511
Interleukins, mycobacteria, and listeriae. Kaufmann, S. H. E. ..... (A) 681
Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Converse, P., *et al.* ..... (A) 158
M. avium-intracellulare induced interleukin-6 from human monocytes and large granular lymphocytes. Blanchard, D. K., *et al.* ..... (A) 690
Role of recombinant human IL-2 in immune modulation of leprosy. Kaplan, G. and Cohn, Z. A. ..... (A) 198
Serum levels of tumour necrosis factor-alpha and interleukin-β during leprosy reactional states. Sarno, E. N., *et al.* ..... (A) 506
Target cell lysis and IL-2 secretion by gamma/delta T lymphocytes after activation with bacteria. Munk, M. E., *et al.* ..... (A) 359
The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 513

International Journal of Leprosy (IJL),
New address for IJL Editorial Office. ..... (—) 655
Reviewers. ..... (—) 724
Special Grantors and Sustaining Members. ..... (—) 729
Statement of Financial Condition. ..... (—) 726
Statement of Ownership, Management and Circulation. ..... (—) 725
The 1990 Journal—a continuing perspective. Hastings, R. C. ..... (E) 102

International Leprosy Association (ILA),
Members. ..... (—) 207
Officers and Councillors. ..... (—) 206

Intestine(s),
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186

Isoniazid,
Effect of the initial isoniazid resistance on response to chemotherapy of tuberculosis: a review of clinical trials. Al-Orainey, I. O. M. ..... (A) 689
Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Crowle, A. J. and May, M. H. ..... (A) 376
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. Shafer, R. W. and Jones, W. D. ..... (A) 699
Smear-negative, culture-positive pulmonary tuberculosis; six-month chemotherapy with isoniazid and rifampin. Dutt, A. K., *et al.* ..... (A) 179
Sustained release of isoniazid *in vivo* from a single implant of a biodegradable polymer. Gangadharam, P. R. J., *et al.* ..... (A) 694
Transformation of *M. aurum* by electroporation: the use of glycine, lysozyme and isoecotinic acid hydrazide in enhancing transformation efficiency. Hermans, J., *et al.* ..... (A) 365

Kidney(s),
Glomerular diseases in the tropics. Chugh, K. S. and Sakhuja, V. ..... (A) 509
Renal alterations in murine leprosy. Rojas-Espinosa, O. and Reyes Maldonado, E. ..... (C) 652
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 686

Kuwait,
Leprosy in Kuwait: an epidemiological study of new cases. Al-Kandari, S., *et al.* ..... (A) 371

Leishmaniasis,
Post-kala-azar dermal leishmaniasis: a case report strikingly resembling lepromatous leprosy. Ramesh, V., *et al.* ..... (A) 676
[Treatment of American cutaneous leishmaniasis by means of vaccine.] Mayrink, W., *et al.* ..... (A) 696

Lepromatous leprosy,
An unusual presentation of lepromatous leprosy: a case report. Sharma, Y., *et al.* ..... (A) 677
CD1-positive epidermal Langerhans cells in regressed tuberculoid and lepromatous leprosy lesions. Narayanan, R. B., *et al.* ..... (A) 360
[Changes in carbohydrate metabolism in lepromatous leprosy.] Castano Hernandez, S. T. and Carrazana Hernandez, G. B. ..... (A) 349
Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Katoch, K., *et al.* ..... (O) 248
Effect of treatment on immune responsiveness in lepromatous leprosy patients. Esquenazi, D. A., *et al.* ..... (A) 158
Evaluation of PCR analysis in monitoring antileprosy chemotherapy in lepromatous leprosy patients. Williams, D. L., *et al.* ..... (A) 719
Fine structures of macrophages and/or leprosy bacilli in lepromatous leprosy lesions of human skin. Hirata, T. ..... (A) 195
Hepatic ultrasonography in patients with lepromatous leprosy. Taneja, K., *et al.* ..... (A) 508
HLA-DQ molecules and the control of *M. leprae*-specific T cell nonresponsiveness in lepromatous leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 361
[Immunological characteristics in a different course of lepromatous leprosy.] Saroyants, L. V., *et al.* ..... (A) 363
Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Converse, P., *et al.* ..... (A) 158
Lepromatous leprosy and seropositivity for HTLV-I. Harle, J.-R., *et al.* ..... (A) 350
Minocycline has impressive activity against lepromatous leprosy. Gelber, R. H. and Rea, T. H. ..... (A) 193
Persistent reduced solubilization of immune complexes in lepromatous leprosy patients with reactions. Ramanathan, V. D., *et al.* ..... (O) 5
Positive Mitsuda lepromin reactions in long-term treated lepromatous leprosy. Waters, M. F. R., *et al.* ..... (A) 364
Post-kala-azar dermal leishmaniasis: a case report strikingly resembling lepromatous leprosy. Ramesh, V., *et al.* ..... (A) 676
Response to phytohemagglutinin of LL patients' lymphocytes preincubated in culture media. Fafutis-Morris, M., *et al.* ..... (C) 480
Restoration of defective cytokine activity within lepromatous leprosy lesions. Volc-Platzer, B., *et al.* ..... (A) 164
Studies on lymphokine production in lepromatous leprosy patients. Munno, I., *et al.* ..... (A) 360
[Systemic use of interferon-gamma in lepromatous leprosy.] Sagaro Delgado, B., *et al.* (A) 362
The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 513
Therapeutic implications of morphological study of nerves from treated or untreated tuberculoid or lepromatous leprosy. Dastur, D. K., *et al.* ..... (C) 122
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ..... (A) 169
Transmission of *M. leprae* from lepromatous leprosy patients to the skin of mice through intermittent feeding. Banerjee, R., *et al.* ..... (A) 369
Transmission of viable *M. leprae* by *Aedes aegypti* from lepromatous leprosy patients to the skin of mice through interrupted feeding. Banerjee, R., *et al.* ..... (A) 523

Tuberculoid relapse in lepromatous leprosy. Waters, M. F. R. and Ridley, D. S. .....(A) 364
Vitiligo and lepromatous leprosy. Pavithran, K. .....(C) 120

Lepromin,
ELISA & lepromin skin tests in household contacts of leprosy patients. Dhandayuthapani, S., *et al.* .....(A) 523
Induction of lepromin positivity in monkeys by a candidate antileprosy vaccine: *M. habana*. Singh, N. B., *et al.* .....(C) 317
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* .....(A) 159
Positive Mitsuda lepromin reactions in long-term treated lepromatous leprosy. Waters, M. F. R., *et al.* .....(A) 364
Quantitative relationship between anti-PGL-I-specific antibody levels and the lepromin reaction. David, H. L., *et al.* .....(C) 332

Lesion(s),
A histopathological and immunological profile of a single lesion lepromatous leprosy (LLs). Misra, R. S., *et al.* .....(E) 645
[A survey of eye lesions in leprosy.] Luo, Y.-R., *et al.* .....(A) 351
CD1-positive epidermal Langerhans cells in regressed tuberculoid and lepromatous leprosy lesions. Narayanan, R. B., *et al.* .....(A) 360
Defining protective immune responses to infectious pathogens: lymphokine and cytokine profiles in leprosy lesions. Yamamura, M., *et al.* .....(A) 712
[Determination of Langerhans' cells in the skin lesions of leprosy cases with immunohistochemical technique using wheat-germ agglutinin.] Liang, Z., *et al.* .....(A) 161
Fine structures of macrophages and/or leprosy bacilli in lepromatous leprosy lesions of human skin. Hirata, T. .....(A) 195
Histoid lesion in nerve of a lepromatous patient. Girdhar, A., *et al.* .....(A) 151
Hypopigmented lesions in early leprosy—a clinical and histological study. Agarwal, U. S., *et al.* .....(A) 504
Hypothesis: solar ultraviolet radiation and the initial skin lesion of leprosy. Patki, A. H. (C) 492
In situ demonstration of *M. leprae* in leprosy lesions using monoclonal antibodies. Narayanan, R. B., *et al.* .....(A) 161
Keratosis spinulosa developing in borderline tuberculoid lesions during type I lepra reaction: two case reports. Thankappan, T. P. and Sulochana, G. .....(A) 508
Leprotic involvement of peripheral nerves in the absence of skin lesions; case report and literature review. Jenkins, D., *et al.* .....(A) 350
Measurement of some biophysical parameters in skin lesions of leprosy. Gupta, A. B., *et al.* .....(A) 350
Mucosal and genital lesions in histoid leprosy. Nigam, P. K. and Singh, G. .....(A) 153
Multibacillary leprosy presenting as a solitary skin lesion; report of three cases and its significance in control programs. Ramesh, V., *et al.* .....(O) 1
Progression of eye lesions in leprosy: ten-year follow-up study in The Netherlands. Hogeweg, M. and Faber, W. R. .....(O) 392
Residual sight-threatening lesions in leprosy patients completing multidrug therapy and sulphone monotherapy. ffytche, T. J. .....(A) 504
Restoration of defective cytokine activity within lepromatous leprosy lesions. Volc-Platzer, B., *et al.* .....(A) 164
[Severity of leprosy eye lesions in armadillos infected with *M. leprae*.] Zhou, H.-M., *et al.* .....(A) 360
Subcellular localization of *M. leprae*-specific PGL-I antigen in human leprosy lesions and in *M. leprae* isolated from armadillo liver. Boddingius, J. and Dijkman, H. ....(A) 369
[Surgical treatment for neurotrophic lesions of leprosy: application to other types of neuropathy.] Bourrel, P. .....(A) 174
The anatomical distribution of single leprosy lesions in an African population, and its implications for the pathogenesis of leprosy. Ponnighaus, J. M., *et al.* .....(A) 154

Leukocyte(s),
Effect of circulating immune complexes of leprosy patients on leukocyte migration inhibition induced by *M. leprae* antigens in healthy volunteers. Tyagi, P., *et al.* .....(C) 487
Widespread intradermal accumulation of mononuclear leukocytes in lepromatous lep-

rosy patients treated systemically with recombinant interferon gamma. Nathan, C., *et al.* ..... (A) 361

Lipid(s),
Cutaneous lipids and mast cells in murine leprosy. Rojas-Espinosa, O. and Reyes Maldonado, E. ..... (C) 325
Radiolabeling of *M. leprae* lipids with schwannoma cells, a potential drug screening system. Mistry, Y., *et al.* ..... (A) 686
The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic glycolipids: structure and immunological properties. Puzo, G. ..... (A) 366

Lipoarabinomannan (LAM),
Distribution of anti-LAM antibodies in leprosy patients and household contacts. Izumi, S., *et al.* ..... (A) 721
Structural features of the arabinan component of the lipoarabinomannan of *M. tuberculosis.* Chatterjee, D., *et al.* ..... (A) 678

Liposome,
Targeting of plant glycoside-bearing liposomes to specific cellular and subcellular sites. Medda, S., *et al.* ..... (A) 697

Liver,
Dapsone-induced liver necrosis. Jayalakshmi, P. and Ting, H. C. ..... (A) 147
Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. Coleman, M. D., *et al.* ..... (A) 146
Subcellular localization of *M. leprae*-specific antigen in human leprosy lesions and in *M. leprae* isolated from armadillo liver. Boddingius, J. and Dijkman, H. ..... (A) 369

Lucio phenomenon,
[Virchowian hanseniasis, Lucio's phenomenon, cryptococcosis.] Fleury, R. N. and Opromolla, D. V. A. ..... (A) 151

Lupus,
Characteristics of antineuronal antibodies in systemic lupus erythematosus patients with and without central nervous system involvement: the role of mycobacterial cross-reacting antigens. Avinoach, I., *et al.* ..... (A) 176
Comparative study of idiotypes of monoclonal antibodies derived from patients with lupus and leprosy and from normal individuals. Mackworth-Young, C. G., *et al.* ..... (A) 358

Lymph node(s),
Immunohistochemical study of bovine lymph nodes with antibodies against S100 protein subunits: comparison between lymph nodes of healthy and *M. paratuberculosis*-infected cattle. Momotani, E., *et al.* ..... (A) 697

Lymphocyte(s),
Determination of different populations of blood lymphocytes in Brazilian patients with hanseniasis. Azulay, R. D. ..... (A) 156
Flow cytometric analysis of CD2 modulation on human peripheral blood T lymphocytes by Dharmendra preparation of *M. leprae.* Sheela, R., *et al.* ..... (A) 518
Leprosy and AIDS: a review of the literature and speculations on the impact of CD4+ lymphocyte depletion on immunity to *M. leprae.* Miller, R. A. ..... (E) 639
Lymphocyte arginase activity in leprosy—a preliminary report. Suri Babu, C. S. S., *et al.* ..... (A) 163
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* ..... (A) 159
M. avium-intracellulare induced interleukin-6 from human monocytes and large granular lymphocytes. Blanchard, D. K., *et al.* ..... (A) 690
Nonspecific esterase staining of lymphocyte subsets in leprosy. Macedo, H. W. and Quirico-Santos, T. ..... (A) 516
Response to phytohemagglutinin of LL patients' lymphocytes preincubated in culture media. Fafutis-Morris, M., *et al.* ..... (C) 480
Specificity of lymphocytotoxic autoantibodies (LCAbs) found in the serum of leprosy patients: class I MHC antigens. Rasheed, F. N., *et al.* ..... (A) 517

T lymphocyte subpopulations in leprosy patients and their relation with circulating immune complexes. Bottasso, O. A., *et al.* ..... (A) 157
Target cell lysis and IL-2 secretion by gamma/delta T lymphocytes after activation with bacteria. Munk, M. E., *et al.* ..... (A) 359

Macrophage(s),
A comparative study on the activation of J-774 macrophage-like cells by gamma-interferon, 1,25-dihydroxyvitamin D3 and lipopeptide RP-56142: ability to kill intracellularly multiplying *M. tuberculosis* and *M. avium*. Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
Activities of clarithromycin, sulfisoxazole, and rifabutin against *M. avium* complex multiplication within human macrophages. Perrone, C., *et al.* ..... (A) 378
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of *M. avium* complex within human macrophages. Perrone, C., *et al.* ..... (A) 698
Differential handling of bacterial antigens in macrophages infected with *M. leprae* as studied by immunogold labeling of ultrathin sections. Rastogi, N., *et al.* ..... (O) 278
Effect of antimicrobial agents on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ..... (A) 194
Effect of tuftsin stimulation on the microbicidal activity exerted by blood monocyte-macrophages of leprosy patients. Iyer, R. R., *et al.* ..... (A) 511
Fine structures of macrophages and/or leprosy bacilli in lepromatous leprosy lesions of human skin. Hirata, T. ..... (A) 195
Identification of genes involved in the resistance of mycobacteria to killing by macrophages. Sathish, M. and Shinnick, T. M. ..... (A) 711
[Immunoregulatory properties of monocytes/macrophages in patients with pulmonary tuberculosis.] Seledtsova, G. V. and Koslov, V. A. ..... (A) 699
In vivo modulation of atypical mycobacterial infection: adjuvant therapy increases resistance to *M. avium* by enhancing macrophage effector functions. Denis, M. (A) 692
Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Crowle, A. J. and May, M. H. ..... (A) 376
Intracellular bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* H37Rv multiplying in the J-774 macrophage cell line. Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
Macrophages infected with *M. leprae* or treated with mycobacterial constituents release factors that modulate afferent and efferent macrophage function. Fukutomi, Y., *et al.* (A) 712
Modulation of human lepromatous monocyte-macrophage functions *in vitro* by tuftsin. Iyer, R. R., *et al.* ..... (A) 511
Modulation of *M. lepraemurium* growth in murine macrophages: beneficial effect of tumor necrosis factor alpha and granulocyte-macrophage colony-stimulating factor. Denis, M. ..... (A) 510
Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill *M. avium* complex. Bermudez, L. E. M. and Young, L. S. ..... (A) 176
Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. Crowle, A. J. and Elkins, N. ..... (A) 527
Role of the L-arginine-dependent pathway of activated macrophages on the metabolic activity of *M. leprae*. Adams, L., *et al.* ..... (A) 198

Malawi,
Disabilities in leprosy patients ascertained in a total population survey in Karonga District, northern Malawi. Ponnighaus, I. M., *et al.* ..... (A) 373
Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi. Boerrigter, G., *et al.* ..... (O) 255
HIV seropositivity and tuberculosis in a rural Malawi hospital. Kelly, P., *et al.* ..... (A) 378
Setting up HIV serology for the Karonga leprosy vaccine trial in Malawi. Shaw, M. A., *et al.* ..... (A) 507

Maldives,
Unique prevention trial. ..... (N)) 663

Mali,
[Anti-HIV seroconversion among patients with leprosy in Mali.] Tounkara, A., *et al.* ..(A) 678

Metabolism,
[Changes in carbohydrate metabolism in lepromatous leprosy.] Castano Hernandez, S. T. and Carrazana Hernandez, G. B. .....(A) 349
Role of the L-arginine-dependent pathway of activated macrophages on the metabolic activity of *M. leprae.* Adams, L., *et al.* .....(A) 198

Mice, murine,
Activities of pefloxacin and ofloxacin against mycobacteria: *in vitro* and mouse experiments. Truffot-Pernot, C., *et al.* .....(A) 533
Activities of various macrolide antibiotics against *M. leprae* infection in mice. Gelber, R. H., *et al.* .....(A) 522
Anti-*M. leprae* activity of several quinolones studied in the mouse. Pattyn, S. R. .....(O) 613
Antileprosy activity of ofloxacin in combination with rifampin and diaminodiphenylsulfone in mice and *in vitro* activities of new quinolones and rifamycin derivatives. Saito, H., *et al.* .....(A) 718
Application of HLA-DQ transgenic mice for the analysis of genetic control of the immune response to *M. leprae* antigen. Nishimura, Y., *et al.* .....(A) 200
Biological properties of factors secreted by antigen-reactive suppressor cells in mice infected with *M. lepraemurium.* Forget, A. and Turcotte, R. .....(A) 370
Characterization of murine B-cell epitopes on the *M. leprae* proline-rich antigen by use of synthetic peptides. Klatser, P. R., *et al.* .....(A) 514
Cutaneous lipids and mast cells in murine leprosy. Rojas-Espinosa, O. and Reyes Maldonado, E. .....(C) 325
Detection of interleukin-3 in the serum of mice infected with *M. lepraemurium.* Resnick, M., *et al.* .....(A) 380
Early accumulation of suppressor cell precursors in the spleen of *M. lepraemurium*-infected mice and analysis of their *in vitro*-induced maturation. Lemieux, S., *et al.* ..(A) 169
Effect of antimicrobial agents on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. .....(A) 194
Effect of low-level and intermittent minocycline therapy on the growth of *M. leprae* in mice. Gelber, R. H., *et al.* .....(A) 673
Effectiveness of clarithromycin and minocycline alone and in combination against experimental *M. leprae* infection in mice. Ji, B., *et al.* .....(A) 501
Effects of cyclosporin A on bacterial growth and immunological responsiveness in BALB/c mice infected with *M. leprae.* Tanaka, M., *et al.* .....(O) 598
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vitro.* I. Chromosome analysis in bone marrow and spermatocytes. Das, R. K. and Roy, B. .....(A) 147
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vivo.* II. Micronucleus test in bone marrow and hepatocytes. Roy, B. and Das, R. K. .....(A) 149
Genetic regulation of *M. paratuberculosis* infection in recombinant inbred mice. Frelier, P. F., *et al.* .....(A) 528
Immune responses to the 18-kDa protein of *M. leprae*; similar B cell epitopes but different T cell epitopes seen by inbred strains of mice. Doherty, T. M., *et al.* .....(A) 510
Inhibition of complement activity in murine leprosy. Rojas-Espinosa, O., *et al.* .....(O) 605
Intramacrophage growth of *M. avium* during infection of mice. Frehel, C., *et al.* .....(A) 693
Local adoptive transfer of delayed-type hypersensitivity to tuberculin in *M. bovis* (BCG) infected mice. Nikonenko, B. V., *et al.* .....(A) 184
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis.* Orrell, J. M., *et al.* .....(A) 697
Memory T cell-mediated resistance to *M. tuberculosis* infection in innately susceptible and resistant mice. Hubbard, R. D., *et al.* .....(A) 694
Modulation of *M. lepraemurium* growth in murine macrophages: beneficial effect of tumor necrosis factor alpha and granulocyte-macrophage colony-stimulating factor. Denis, M. .....(A) 510
Nucleotide sequence of mouse HSP60 (chaperonin, GroEl homolog) cDNA. Venner, T. J. and Gupta, R. S. .....(A) 519
Production and characterization of antibody against cord factor (trehalose 6,6′-dimy-

colate) in mice and its application to rapid serodiagnosis of human mycobacteriosis including tuberculosis and leprosy. He, H., *et al.* ..... (A) 709
Proliferative response to seven affinity purified mycobacterial antigens in eight strains of inbred mice. Andersen, P., *et al.* ..... (O) 58
Renal alterations in murine leprosy. Rojas-Espinosa, O. and Reyes Maldonado, E. .... (C) 652
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 686
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ..... (A) 532
Rifampin in drug-incorporated diet: effect of duration and temperature of storage. Relevance to drug-susceptibility testing in mice inoculated with *M. leprae.* Abraham, B., *et al.* ..... (O) 68
Strain differences in mouse cellular responses to *M. lepraemurium* and BCG subcutaneous infections. I. Analysis of cell surface phenotype in local granulomas. Roch, F. and Bach, M.-A. ..... (A) 170
Susceptibility of severe combined immunodeficient (SCID) mice to *M. leprae*: multiplication of *M. leprae* inoculated into both hind feet at an early stage. Yogi, Y., *et al.* (A) 722
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ..... (A) 169
Transmission of *M. leprae* from lepromatous leprosy patients to the skin of mice through intermittent feeding. Banerjee, R., *et al.* ..... (A) 369
Transmission of viable *M. leprae* by *Aedes aegypti* from lepromatous leprosy patients to the skin of mice through interrupted feeding. Banerjee, R., *et al.* ..... (A) 523

Mice, nude,
Mode of transmission of *M. leprae* infection in nude mice. McDermott-Lancaster, R. D. and McDougall, A. C. ..... (A) 170
Studies on the development of novel antileprous chemotherapeutics using nude mice with special reference to a new quinolone carboxylic acid, AT-4140. Tsutsumi, S. and Gidoh, M. ..... (A) 673
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ..... (A) 169

Minocycline,
Effect of low-level and intermittent minocycline therapy on the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (A) 673
Effectiveness of clarithromycin and minocycline and in combination against experimental *M. leprae* infection in mice. Ji, B., *et al.* ..... (A) 501
[Effects of ofloxacin and minocycline on experimental leprosy.] Wang, H.-Y., *et al.* ... (A) 673
Minocycline has impressive activity against lepromatous leprosy. Gelber, R. H. and Rea, T. H. ..... (A) 193

Molecular biology,
A family of dispersed repeats in *M. leprae.* Woods, S. A. and Cole, S. T. ..... (A) 369
An antigenic complex that restores ability in leprosy patients to kill *M. leprae*—the probable molecular events identified in *in vitro* experiments. Mahadevan, P. R. and Robinson, P. ..... (A) 359
Characterization of a *M. tuberculosis* insertion sequence belonging to the IS3 family. McAdam, R. A., *et al.* ..... (A) 530
HLA-DQ molecules and the control of *M. leprae*-specific T cell nonresponsiveness in lepromatous leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 361
Host and bacterial molecules mediating phagocytosis of *M. leprae* of mass 14 kDa and 35 kDa. Rivoire, B., *et al.* ..... (A) 715
Identification, characterization, and expression of the major proteins of *M. leprae* by human mononuclear phagocytes. Schlesinger, L. S. and Horwitz, M. A. ..... (A) 719
Molecular characterization of immunologically reactive proteins of *M. leprae.* Sela, S., *et al.* ..... (A) 715
Molecular genetics of mycobacteriophage L5. Hatfull, G. F., *et al.* ..... (A) 196

Molecular mapping of interactions between a *M. leprae*-specific T cell epitope, the restricting HLA-DR2 molecule, and two specific T cell receptors. Anderson, D. C., *et al.* ..... (A) 508
Nucleotide sequence of the 32 kDa-protein gene (antigen 85A) of *M. bovis* BCG. de Wit, M. Y. L., *et al.* ..... (A) 178
Phylogenetic analysis and identification of different serovars of *M. intracellulare* at the molecular level. Boddinghaus, B., *et al.* ..... (A) 375
Studies on alpha-antigen gene of *M. leprae*: molecular biological studies of *M. leprae*-specific epitopes of alpha-antigen. Makino, M. and Suzuki, Y. ..... (A) 711

Monkey(s),
Experimental borderline lepromatous leprosy with intraneural erythema nodosum leprosum in a mangabey monkey (*Cercocebus atys*). Baskin, G. B., *et al.* ..... (O) 618
Induction of lepromin positivity in monkeys by a candidate antileprosy vaccine: *M. habana*. Singh, N. B., *et al.* ..... (C) 317
Intraocular pressure changes and postural changes of intraocular pressure in experimentally induced Hansen's disease of rhesus, mangabey, and African green monkeys. Hussein, N., *et al.* ..... (A) 370

Monocyte(s),
A rapid [3H]glycerol radioassay for determination of monocyte-mediated growth inhibition of *M. avium*. Blanchard, D. K., *et al.* ..... (A) 375
Effect of glucocorticoids and interferon-gamma on the oxidative responses of monocytes from leprosy patients and normal donors. Vachula, M., *et al.* ..... (O) 41
Effect of tuftsin stimulation on the microbicidal activity exerted by blood monocyte-macrophages of leprosy patients. Iyer, R. R., *et al.* ..... (A) 511
[Immunoregulatory properties of monocytes/macrophages in patients with pulmonary tuberculosis.] Seledtsova, G. V. and Koslov, V. A. ..... (A) 699
M. avium-intracellulare induced interleukin-6 from human monocytes and large granular lymphocytes. Blanchard, D. K., *et al.* ..... (A) 690
M. leprae- and BCG-induced chemiluminescence response of monocytes from leprosy patients and healthy subjects: effects of gamma-interferon and GM-CSF. Launois, P., *et al.* ..... (O) 582
Modulation of human lepromatous monocyte-macrophage functions *in vitro* by tuftsin. Iyer, R. R., *et al.* ..... (A) 511

Morocco,
[Synthesis of seven years of systematic surveys on leprosy in Morocco.] Sekkat, A., *et al.* ..... (A) 172

Multidrug therapy (MDT),
A case of relapse with drug-susceptible *M. leprae* after multidrug therapy. Constant-Desportes, M., *et al.* ..... (O) 242
Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Katoch, K., *et al.* ..... (O) 248
Effect of three-year multidrug therapy in multibacillary leprosy patients. Li, W.-H., *et al.* ..... (A) 148
Evaluation of an MDT workshop. ..... (N) 660
Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink, M. ..... (O) 558
Fixed duration MDT in paucibacillary leprosy. Mathai, R., *et al.* ..... (O) 237
Health education for the successful implementation of MDT. Wele, D. S. ..... (A) 348
Histological changes in tuberculoid leprosy after fixed duration multidrug therapy of six months. Lavania, R. K., *et al.* ..... (A) 160
[Histopathological changes in the skin of MB leprosy after MDT.] Miao, Z.-H., *et al.* (A) 347
Impact of multidrug therapy on the treatment and control of leprosy. Gilbody, J. S. ... (E) 458
MDT for all; target oriented leprosy control program in the 1990s. Yuasa, Y. ..... (E) 624
Multidrug therapy for treatment of paucibacillary leprosy in western Kenya—preliminary communications. Orege, P. A., *et al.* ..... (A) 502
[Observations on effect of MDT in multibacillary leprosy for five years.] Li, W., *et al.* (A) 147

Reactions in leprosy; a study of 250 patients in a multidrug therapy project, Baroda District, Gujarat, India. Chopra, N. K., *et al.* ....(A) 149
Reduction in caseload after multidrug therapy in an urban leprosy control programme—a retrospective study in Bombay. Revankar, C. R., *et al.* ....(A) 500
Relapse in leprosy after multidrug therapy and its differential diagnosis with reversal reaction. Kesava Reddy, P. and Cherian, A. ....(A) 673
Relapse rate in paucibacillary leprosy patients after multidrug therapy in North Arcot District. Ekambaram, V. and Rao, M. K. ....(A) 672
Residual sight-threatening lesions in leprosy patients completing multidrug therapy and sulphone monotherapy. ffytche, T. J. ....(A) 504
Southern regional IAL conference on MDT. ....(N) 662
[Three year follow-up after completing two year MDT for MB.] Yu, X., *et al.* ....(A) 149

Muscle(s),
Denatured muscle grafts for nerve repair; an experimental model of nerve damage in leprosy. Pereira, J. H., *et al.* ....(A) 373

Mycobacteria (see also individual species),
[A comparative study of the various staining methods for mycobacteria.] Costa, H. C., *et al.* ....(A) 167
A monoclonal antibody to the mycobacterial 65 kDa heat shock protein (ML 30) binds to cells in normal and arthritic joints of rats. Kleinau, S., *et al.* ....(A) 514
A novel mycolic acid in a *Mycobacterium* sp. from the environment. Luquin, M., *et al.* (A) 521
A scanning electron microscope study of mycobacterial developmental stages in commercial BCG vaccines. Devadoss, P. O., *et al.* ....(A) 692
Activities of pefloxacin and ofloxacin against mycobacteria: *in vitro* and mouse experiments. Truffot-Pernot, C., *et al.* ....(A) 553
An easy and rapid method for isolation of entire mycobacterial genome for application of pulsed-field gel electrophoresis. Charvin, M., *et al.* ....(A) 684
Association of mycobacterial-specific and *M. leprae* specific antibody levels with clinical activity in tuberculoid leprosy: a comparative study of three serological enzyme-immunoassays. Chaturvedi, V., *et al.* ....(A) 679
Characteristics of antineuronal antibodies in systemic lupus erythematosus patients with and without central nervous system involvement: the role of mycobacterial cross-reacting antigens. Avinoach, I., *et al.* ....(A) 176
Characterization of a 65-kDa heat-shock protein of mycobacteria. Nomaguchi, H., *et al.* ....(A) 197
Detection and identification of mycobacteria by amplification of rRNA. Boddinghaus, B., *et al.* ....(A) 177
Detection of mycobacteria using PCR and specific DNA probes. Venkataraman, S. and Barker, R. H., Jr. ....(A) 201
Detection of mycobacterial antigens in cerebrospinal fluid by enzyme-linked immunosorbent assay. Wu, C. H., *et al.* ....(A) 187
Detection and identification of *Mycobacterium* species using gene amplification techniques and RFLP analysis. Plikaytis, B. B., *et al.* ....(A) 202
Determination of *in vivo* and *in vitro* drug effects of mycobacteria from the mass spectrometric analysis of single organisms. Haas, M., *et al.* ....(O) 262
[Development of delayed hypersensitivity to mycobacterial antigens.] Lyashchenko, K. P., *et al.* ....(A) 696
Diagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay to detect mycobacterial antigen and antibody in cerebrospinal fluid. Annamma, M., *et al.* ....(A) 690
Establishment of a foreign antigen secretion system in mycobacteria. Matsuo, K., *et al.* (A) 359
[Evaluation of an ELISA using A60 antigen from *M. bovis* BCG: specific IgG and IgM during mycobacterial infections.] Cisse, M. F., *et al.* ....(A) 354
Evidence that the capsule around mycobacteria grown in axenic media contains mycobacterial antigens: implications at the level of cell envelope architecture. Rastogi, N. and Hellio, R. ....(A) 366
Fatty acid oxidation and the beta-oxidation complex in *M. leprae* and two axenically cultivable mycobacteria that are pathogens. Wheeler, P. R., *et al.* ....(A) 685
[Features of qualitative changes in mycobacterial population in new elderly and senile cases of pulmonary tuberculosis during their treatment.] Dorozhkova, I. R., *et al.* ...(A) 178

Genotypic identification of pathogenic *Mycobacterium* species by using a nonradioactive oligonucleotide probe. Lim, S. D., *et al.* ..... (A) 696
Genus- and species-specific DNA probes to identify mycobacteria using the polymerase chain reaction. Fries, J. W. U., *et al.* ..... (A) 179
Growth physiology of mycobacteria in modified Dubos liquid medium. Tsukamura, M. (A) 685
Identification of genes involved in the resistance of mycobacteria to killing by macrophages. Sathish, M. and Shinnick, T. M. ..... (A) 711
[Identification of mycobacteria by gas-liquid chromatography.] Vorobyev, A. A., *et al.* (A) 187
Immunity to mycobacteria. Kaufmann, S. H. E. ..... (A) 513
In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565). Dickinson, J. M. and Mitchison, D. A. ..... (A) 376
In vivo modulation of atypical mycobacterial infection: adjuvant therapy increases resistance to *M. avium* by enhancing macrophage effector functions. Denis, M. ..... (A) 692
Induction of arthritis in rats by aqueous suspensions of mycobacteria without the use of oil. Levine, S. and Saltzman, A. ..... (A) 515
Interleukins, mycobacteria, and listeriae. Kaufmann, S. H. E. ..... (A) 681
Iron-regulated envelope proteins of mycobacteria grown *in vitro* and their occurrence in *M. avium* and *M. leprae* grown *in vivo*. Sritharan, M. and Ratledge, C. ..... (A) 367
[Isolation of a strain of *M. tuberculosis* which is considered to be rifampicin-dependent, from a patient with long-lasted smear positive and culture difficult (SPCD) mycobacteria.] Nakamura, M., *et al.* ..... (A) 531
Isolation of auxotrophic mutants of mycobacteria using shuttle mutagenesis. Ganjam, K., *et al.* ..... (A) 196
M. leprae-specific T cells from a tuberculoid leprosy patient suppress HLA-DR3-restricted T cell responses to an immunodominant epitope on 65-kDa hsp of mycobacteria. Haanen, J. B. A. G., *et al.* ..... (A) 356
Macrophages infected with *M. leprae* or treated with mycobacterial constituents release factors that modulate afferent and efferent macrophage function. Fukutomi, Y., *et al.* (A) 712
Major histocompatibility complex restriction of T-cell suppression of immune response to mycobacteria. Shroff, K. E., *et al.* ..... (O) 49
Mycobacteria and human autoimmune disease: direct evidence of cross-reactivity between human lactoferrin and the 65-kilodalton protein of tubercle and leprosy bacilli. Esaguy, N., *et al.* ..... (A) 510
Mycobacteria glycolipids as potential pathogenicity effectors: alteration of model and natural membranes. Sut, A., *et al.* ..... (A) 368
Mycobacteria in nerve trunks of long-term treated leprosy patients. Pereira, J. H., *et al.* (A) 681
[Mycobacteria isolated from armadillos (*Dasypus novemcinctus*) inoculated with *M. leprae*.] Coelmo, A. A. M., *et al.* ..... (A) 169
Mycobacteria other than tubercle bacilli in sputum specimens from patients in Manaus (Amazonia, Brazil). Salem, J. I., *et al.* ..... (A) 380
Mycobacteria, cytokines and antibiotics. Rook, G. A. W. ..... (A) 163
Mycobacterial antigens and anti-idiotype antibodies revealed by an enzyme-linked immunosorbent assay in tuberculous patient sera. Stavri, D., *et al.* ..... (A) 381
Mycobacterial antigens stimulate rheumatoid mononuclear cells to cartilage proteoglycan depletion.] Wilbrink, B., *et al.* ..... (A) 187
Mycobacterial cell surface proteins revealed by labeling with 125I. Deuskar, N. J. and Deo, M. G. ..... (C) 482
Mycobacterial flora of the skin in leprosy. Fandinho, F. C. O., *et al.* ..... (O) 569
Mycobacterial subcutaneous arteritis. Rodrigues, C. J., *et al.* ..... (A) 531
Mycobacterial-induced cytoxic T cells as well as nonspecific killer cells derived from healthy individuals and leprosy patients. Kaleab, B., *et al.* ..... (A) 512
Nontuberculous mycobacterial infections of the skin. Street, M. L., *et al.* ..... (A) 532
Polyclonal antibodies raised against bacillus Calmette-Guérin, *M. duvalii*, and *M. paratuberculosis* used to detect mycobacteria in tissue with the use of immunohistochemical techniques. Wiley, E. L., *et al.* ..... (A) 364
Production and characterization of antibody against cord factor (trehalose 6,6'-dimycolate) in mice and its application to rapid serodiagnosis of human mycobacteriosis including tuberculosis and leprosy. He, H., *et al.* ..... (A) 709
Proliferative response to seven affinity purified mycobacterial antigens in eight strains of inbred mice. Andersen, P., *et al.* ..... (O) 58

Recognition of mycobacterial antigens by gamma/delta T cells. Band, H., *et al.* .....(A) 678
Role of TNF alpha in the pathogenesis of mycobacterial infections; mechanism of modulation by thalidomide. Kaplan, G. and Sampaio, E. P. .....(A) 714
Serological analysis of human tuberculosis by an ELISA with mycobacterial antigen 60. Baelden, M.-C., *et al.* .....(A) 176
[Serotyping of strains of non-tuberculous mycobacteria.] Obregon Fuentes, A. M., *et al.* (A) 184
Spectrum of immune reactivity to mycobacterial (BCG) antigens in healthy hospital contacts in South India. Pitchappan, R. M., *et al.* .....(A) 698
Susceptibility of mycobacteria to fusidic acid. Hoffner, S. E., *et al.* .....(A) 181
Synovial cells responding to a 65-kDa mycobacterial heat shock protein have a high proportion of a TcR gamma/delta subtype uncommon in peripheral blood. Soderstrom, K., *et al.* .....(A) 700
T cell activation by mycobacterial antigens in inflammatory synovitis. Pope, R. M., *et al.* .....(A) 517
T cell reactivity to an epitope of the mycobacterial 65-kDa heat-shock protein (hsp 65) corresponds with arthritis susceptibility in rats and is regulated by hsp 65-specific cellular responses. Hogervorst, E. J. M., *et al.* .....(A) 680
The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic glycolipids: structure and immunological properties. Puzo, G. .....(A) 366
The changing epidemiology of tuberculosis and other mycobacterial infections in the United States: implications for the radiologist. Buckner, C. B., *et al.* .....(A) 692
The diagnostic value of an enzyme-linked immune sorbent assay using adsorbed mycobacterial sonicates in children. Rosen, E. U. .....(A) 185
The mycobacterial GroEL stress protein: a common target of T-cell recognition in infection and autoimmunity. Lamb, J. R., *et al.* .....(A) 160
The T-cell receptor repertoire in mycobacterial infection. Modlin, R. L., *et al.* .....(A) 721
Transformation of distinct mycobacterial species by shuttle vectors derived from *M. fortuitum* pAL5000 plasmid. Lazraq, R., *et al.* .....(A) 520

Mycobacterium aurum,

Cell-free synthesis of mycolic acids in *M. aurum*: radioactivity distribution in newly synthesized acids and presence of cell wall in the system. Lacave, C., *et al.* .....(A) 183
Formation of progesterone and 1-dehydroprogesterone from cholesterol in fermentation cultures of *M. aurum.* Horhold, C. and Bohme, K.-H. .....(A) 181
Transformation of *M. aurum* by electroporation: the use of glycine, lysozyme and isonicotinic acid hydrazide in enhancing transformation efficiency. Hermans, J., *et al.* ....(A) 365

Mycobacterium avium,

A comparative study on the activation of J-774 macrophage-like cells by gamma-interferon, 1,25-dihydroxyvitamin D3 and lipopeptide RP-56142: ability to kill intracellularly multiplying *M. tuberculosis* and *M. avium.* Rastogi, N. and Blom-Potar, M.-C. .....(A) 379
A rapid [3H]glycerol radioassay for determination of monocyte-mediated growth inhibition of *M. avium.* Blanchard, D. K., *et al.* .....(A) 375
Analysis of *M. leprae, M. tuberculosis,* and *M. avium* genomic libraries in *M. smegmatis* and *E. coli* using shuttle cosmid vectors. Pane, L., *et al.* .....(A) 200
Arylsulfatase activity for differentiating *M. avium* and *M. intracellulare.* Tomioka, H., *et al.* .....(A) 186
In vivo modulation of atypical mycobacterial infection: adjuvant therapy increases resistance to *M. avium* by enhancing macrophage effector functions. Denis, M. .....(A) 692
Intramacrophage growth of *M. avium* during infection of mice. Frehel, C., *et al.* .....(A) 693
Iron-regulated envelope proteins of mycobacteria grown *in vitro* and their occurrence in *M. avium* and *M. leprae* grown *in vivo.* Sritharan, M. and Ratledge, C. .....(A) 367
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* .....(A) 186
The avian tubercle bacillus and its relatives. Grange, J. M., *et al.* .....(A) 180

***Mycobacterium avium* complex,**

Abortion and granulomatous colitis due to *M. avium* complex infection in a horse. Cline, J. M., *et al.* .....(A) 527

Action of 1-isonicotinyl-2-palmitoyl hydrazine against *M. avium* complex and enhancement of its activity by m-fluorophenylalanine. Rastogi, N. and Goh, K. S. ..... (A) 380
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of *M. avium* complex within human macrophages. Perrone, C., *et al.* ..... (A) 698
Analysis of cellular fatty acids and proteins by capillary gas chromatography and sodium dodecyl sulphate polyacrylamide gel electrophoresis to differentiate *M. avium, M. intracellulare* and *M. scrofulaceum* (MAIS) complex species. Fourche, J., *et al.* ..... (A) 528
Early days in the use of DNA probes for *M. tuberculosis* and *M. avium* complexes. Andrew, P. W. and Boulnois, G. J. ..... (A) 166
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against *M. avium* complex. Rastogi, N. and Labrousse, V. ..... (A) 502
In vitro susceptibility of *M. avium* complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Yajko, D. M., *et al.* ..... (A) 381
M. avium-intracellulare induced interleukin-6 from human monocytes and large granular lymphocytes. Blanchard, D. K., *et al.* ..... (A) 690
Plasmid analysis of *M. avium-intracellulare* (MAI) isolated in the United Kingdom from patients with and without AIDS. Hellyer, T. J., *et al.* ..... (A) 694
Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill *M. avium* complex. Bermudez, L. E. M. and Young, L. S. ..... (A) 176

***Mycobacterium bovis* (see also BCG),**
Cell mass of *M. bovis* BCG estimated by gas chromatography. Olsen, W. P., *et al.* ..... (A) 184
[Evaluation of an ELISA using A60 antigen from *M. bovis* BCG: specific IgG and IgM during mycobacterial infections.] Cisse, M. F., *et al.* ..... (A) 354
Fusion protein based epitope mapping of the MPB57 protein from *M. bovis* BCG and its epitope insertion into the native protein. Yamaguchi, R., *et al.* ..... (A) 533
Local adoptive transfer of delayed-type hypersensitivity to tuberculin in *M. bovis* (BCG) infected mice. Nikonenko, B. V., *et al.* ..... (A) 184
Nucleotide sequence of the 32 kDa-protein gene (antigen 85A) of *M. bovis* BCG. de Wit, M. Y. L., *et al.* ..... (A) 178
Quantitative and qualitative studies on the major extracellular antigen of *M. tuberculosis* H37Rv and *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 165
Rapid confirmatory identification of *M. bovis* using a dot blotting immunodetection technique. Veerman, G. M., *et al.* ..... (A) 187

Mycobacterium chelonei,
High-performance liquid chromatography patterns of mycolic acids as criteria for identification of *M. chelonae, M. fortuitum,* and *M. smegmatis.* Butler, W. R. and Kilburn, J. O. ..... (A) 177
Disseminated *M. chelonae* subspecies *chelonae* infection with cutaneous and osseous manifestations. Drabick, J. J., *et al.* ..... (A) 178
Rapid characterization of *M. fortuitum-chelonei* complex by restriction fragment length polymorphism or ribosomal RNA genes. Kanaujia, G. V., *et al.* ..... (A) 695
Susceptibilities of *M. fortuitum* biovar. *fortuitum* and the two subgroups of *M. chelonae* to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Wallace, R. J., Jr., *et al.* ..... (A) 533
Ofloxacin and imipenem in the treatment of *M. fortuitum* and *M. chelonae* lung infections. Yew, W. W., *et al.* ..... (A) 188

Mycobacterium cookii,
M. cookii sp. nov. Kazda, J., *et al.* ..... (A) 182

Mycobacterium duvalii,
Polyclonal antibodies raised against bacillus Calmette-Guérin, *M. duvalii,* and *M. paratuberculosis* used to detect mycobacteria in tissue with the use of immunohistochemical techniques. Wiley, E. L., *et al.* ..... (A) 364

Mycobacterium fortuitum,
Characterization of a beta-lactamase produced in *M. fortuitum* D316. Amicosante, G., *et al.* ..... (A) 374

High-performance liquid chromatography patterns of mycolic acids as criteria for identification of *M. chelonae, M. fortuitum,* and *M. smegmatis.* Butler, W. R. and Kilburn, J. O. ..... (A) 177
Ofloxacin and imipenem in the treatment of *M. fortuitum* and *M. chelonae* lung infections. Yew, W. W., *et al.* ..... (A) 188
Rapid characterization of *M. fortuitum-chelonei* complex by restriction fragment length polymorphism or ribosomal RNA genes. Kanaujia, G. V., *et al.* ..... (A) 695
Susceptibilities of *M. fortuitum* biovar. *fortuitum* and the two subgroups of *M. chelonae* to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Wallace, R. J., Jr., *et al.* ..... (A) 533
Transformation of distinct mycobacterial species by shuttle vectors derived from *M. fortuitum* pAL5000 plasmid. Lazraq, R., *et al.* ..... (A) 520

Mycobacterium habana,
Induction of lepromin positivity in monkeys by a candidate antileprosy vaccine: *M. habana.* Singh, N. B., *et al.* ..... (C) 317

Mycobacterium intracellulare,
Arylsulfatase activity for differentiating *M. avium* and *M. intracellulare.* Tomioka, H., *et al.* ..... (A) 186
Phylogenetic analysis and identification of different serovars of *M. intracellulare* at the molecular level. Boddinghaus, B., *et al.* ..... (A) 375

Mycobacterium kansasii,
Carbohydrate epitope structural elucidation of 1H-NMR spectroscopy of a new *M. kansasii* phenolic glycolipid antigen. Gilleron, M., *et al.* ..... (A) 377
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186

Mycobacterium leprae,
A case of relapse with drug-susceptible *M. leprae* after multidrug therapy. Constant-Desportes, M., *et al.* ..... (O) 242
A family of dispersed repeats in *M. leprae.* Woods, S. A. and Cole, S. T. ..... (A) 369
[A study of subclinical infection with *M. leprae.* I. Paired analysis of contacts with leprosy.] Shu, H.-W., *et al.* ..... (A) 688
Activation of the human complement system by phenolic glycolipid of *M. leprae.* Ramanathan, V. D., *et al.* ..... (A) 362
Activities of various macrolide antibiotics against *M. leprae* infection in mice. Gelber, R. H., *et al.* ..... (A) 522
An antigenic complex that restores ability in leprosy patients to kill *M. leprae*—the probable molecular events identified in *in vitro* experiments. Mahadevan, P. R. and Robinson, P. ..... (A) 359
An n.m.r. and conformational analysis of the terminal glycolipid of *M. leprae* in different solvents. Bock, K., *et al.* ..... (A) 166
Analysis of *M. leprae, M. tuberculosis,* and *M. avium* genomic libraries in *M. smegmatis* and *E. coli* using shuttle cosmid vectors. Pane, L., *et al.* ..... (A) 200
Anti-*M. leprae* activity of several quinolones studied in the mouse. Pattyn, S. R. ..... (O) 613
Antibodies to phenolic glycolipid-1 of *M. leprae* in urine of leprosy patients. Patil, S. A., *et al.* ..... (A) 162
Application of a polymerase chain reaction for the detection of *M. leprae* in skin tissues. de Wit, M. Y. L., *et al.* ..... (A) 520
Application of HLA-DQ transgenic mice for the analysis of genetic control of the immune response to *M. leprae* antigen. Nishimura, Y., *et al.* ..... (A) 200
Association of mycobacterial-specific and *M. leprae* specific antibody levels with clinical activity in tuberculoid leprosy: a comparative study of three serological enzyme-immunoassays. Chaturvedi, V., *et al.* ..... (A) 679
Changes in hydrolytic enzyme activities in armadillos infected with *M. leprae.* Dhople, A. M. ..... (A) 685
Characterization of cell-wall associated 10-kDa heat-shock protein of *M. leprae* which is a major T-cell antigen. Mehra, V. L., *et al.* ..... (A) 710

Characterization of murine B-cell epitopes on the *M. leprae* proline-rich antigen by use of synthetic peptides. Klatser, P. R., *et al.* ..... (A) 514
Cloning and characterization of the *M. leprae* putative ribosomal RNA promoter in *Escherichia coli*. Sela, S. and Clark-Curtiss, J. E. ..... (A) 684
Cogitations on the cultivation of *M. leprae*. Why bother? Hanks, J. H. ..... (E) 304
Comparison of IgM, IgG and IgA responses to *M. leprae* specific antigens in leprosy. Praputpittaya, K., *et al.* ..... (A) 362
Complete nucleotide sequence of the *M. leprae* 23 S and 5 S rRNA genes plus flanking regions and their potential in designing diagnostic oligonucleotide probes. Liesack, W., *et al.* ..... (A) 684
Correlation between the chemical structure of the carbohydrate part of *M. leprae* PGL-I and its activity to the monoclonal antibodies. Fujiwara, T., *et al.* ..... (A) 199
Detection of antibodies to 35 kD determinant of *M. leprae* in urine and serum of leprosy patients. Path, S. ..... (A) 162
Detection of *M. leprae* antigens in the sera of leprosy patients by sandwich immunoradiometric assay using monoclonal antibodies. Patil, S. A., *et al.* ..... (A) 361
Detection of *M. leprae*-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients. Singh, N. B., *et al.* ..... (O) 398
Development of a highly specific diagnostic 23S rDNA oligonucleotide probe for *M. leprae*. Liesack, W., *et al.* ..... (A) 167
Differential handling of bacterial antigens in macrophages infected with *M. leprae* as studied by immunogold labeling of ultrathin sections. Rastogi, N., *et al.* ..... (O) 278
Early infection with *M. leprae* and antibodies to phenolic glycolipid-I in the nine-banded armadillo. Job, C. K., *et al.* ..... (A) 169
Effect of antimicrobial agents on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ..... (A) 194
Effect of circulating immune complexes of leprosy patients on leukocyte migration inhibition induced by *M. leprae* antigens in healthy volunteers. Tyagi, P., *et al.* ..... (C) 487
Effect of low-level and intermittent minocycline therapy on the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (A) 673
Effectiveness of clarithromycin and minocycline alone and in combination against experimental *M. leprae* infection in mice. Ji, B., *et al.* ..... (A) 501
Effects of cyclosporin A on bacterial growth and immunological responsiveness in BALB/c mice infected with *M. leprae*. Tanaka, M., *et al.* ..... (O) 598
Effects of cyclosporin A on immunological responsiveness in early stages of infection with *M. leprae*. Tanaka, M. and Tanaka, Y. ..... (A) 194
Evidence that coating of *M. leprae* surface antigens reduces its ability to hinder host microbicidal functions. Rastogi, N. and Frehel, C. ..... (A) 162
Expression of antigenic determinants of *M. leprae* in an avirulent *Salmonella typhimurium* vaccine delivery system. Clark-Curtiss, J. E., *et al.* ..... (A) 196
Expression of *M. tuberculosis* and *M. leprae* proteins by vaccinia virus. Lyons, J., *et al.* (A) 358
Factors influencing the *in vitro* growth of *M. leprae*: effect of sulfhydryl compounds. Dhople, A. M. and Lamoureux, L. C. ..... (A) 684
Fatty acid oxidation and the beta-oxidation complex in *M. leprae* and two axenically cultivable mycobacteria that are pathogens. Wheeler, P. R., *et al.* ..... (A) 685
Flow cytometric analysis of CD2 modulation on human peripheral blood T lymphocytes by Dharmendra preparation of *M. leprae*. Sheela, R., *et al.* ..... (A) 518
Genetic control of immunopathology induced by *M. leprae*. de Vries, R. R. P. ..... (A) 680
Geographically distinct isolates of *M. leprae* exhibit no genotypic diversity by restriction fragment-length polymorphism analysis. Williams, D. L., *et al.* ..... (A) 368
Growth of *M. leprae* under low oxygen tension. Ishaque, M. ..... (A) 365
HLA-DQ molecules and the control of *M. leprae*-specific T cell nonresponsiveness in lepromatous leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 361
Host and bacterial molecules mediating phagocytosis of *M. leprae* by human mononuclear phagocytes. Schlesinger, L. S. and Horwitz, M. A. ..... (A) 719
Identification, characterization, and expression of the major proteins of *M. leprae* of molecular mass 14 kDa and 35 kDa. Rivorie, B., *et al.* ..... (A) 715
Identification, sequencing, and expression of *M. leprae* superoxide dismutase, a major antigen. Thangaraj, H. S., *et al.* ..... (A) 168

IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from *M. leprae* in sera of leprosy patients and their contacts. Saad, M. H. F., *et al.* ..... (A) 362
Immune responses to the 18-kDa protein of *M. leprae*; similar B cell epitopes but different T cell epitopes seen by inbred strains of mice. Doherty, T. M., *et al.* ..... (A) 510
In situ demonstration of *M. leprae* in leprosy lesions using monoclonal antibodies. Narayanan, R. B., *et al.* ..... (A) 161
In vitro activities of aminoglycosides, lincosamides, and rifamycins against *M. leprae.* Franzblau, S. G. ..... (A) 684
In vitro and *in vivo* effects of N-methyl-3,5-dichlorobenzylamine hydrochloride on *M. leprae.* Dhople, A. M., *et al.* ..... (A) 672
[Influence of treatment with *M. leprae* on the immune response in rats; its evaluation in a model of experimental arthritis.] Bottasso, O., *et al.* ..... (A) 353
Intrabacterial sodium-to-potassium ratios and ATP contents of *M. leprae* from ofloxacin-treated patients. Dietz, M., *et al.* ..... (O) 548
Iron-regulated envelope proteins of mycobacteria grown *in vitro* and their occurrence in *M. avium* and *M. leprae* grown *in vivo.* Sritharan, M. and Ratledge, C. ..... (A) 367
Is leprosy bacillus a chemoautotrophic nocardio-form organisms? Pal, D., *et al.* ..... (A) 366
Isolation and structural characteristics of a monoclonal antibody-defined crossreactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J.-J., *et al.* ..... (A) 355
Leprosy and AIDS: a review of the literature and speculations on the impact of CD4+ lymphocyte depletion on immunity to *M. leprae.* Miller, R. A. ..... (E) 639
Light- and electron-microscopic immunohistochemistry using anti-PGL-I antibody specific for *M. leprae.* Goto, M. and Izumi, S. ..... (A) 195
Lymphokine profile of functionally distinct *M. leprae*-reactive CD4+ T-helper and CD8+ T-suppressor clones. Salgame, P., *et al.* ..... (A) 713
M. leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells. Steinhoff, U., *et al.* ..... (A) 519
M. leprae- and BCG-induced chemiluminescence response of monocytes from leprosy patients and healthy subjects: effects of gamma-interferon and GM-CSF. Launois, P., *et al.* ..... (O) 582
M. leprae-specific T cells from a tuberculoid leprosy patient suppress HLA-DR3-restricted T cell responses to an immunodominant epitope on 65-kDa hsp of mycobacteria. Haanen, J. B. A. G., *et al.* ..... (A) 356
Macrophages infected with *M. leprae* or treated with mycobacterial constituents release factors that modulate afferent and efferent macrophage function. Fukutomi, Y., *et al.* (A) 712
Mode of transmission of *M. leprae* infection in nude mice. McDermott-Lancaster, R. D. and McDougall, A. C. ..... (A) 170
Molecular characterization of immunologically reactive proteins of *M. leprae.* Sela, S., *et al.* ..... (A) 715
Molecular mapping of interactions between a *M. leprae*-specific T cell epitope, the restricting HLA-DR2 molecule, and two specific T cell receptors. Anderson, D. C., *et al.* ..... (A) 508
Nucleotide and deduced amino acid sequence of a *M. leprae* 12K protein. Hartskeerl, R. A., *et al.* ..... (A) 167
Observations on nerve tissue infected with *M. leprae.* Bhatia, V. N. ..... (A) 520
On the pathologic significance of the receptor for Beta-glucuronidase (BGR) of *M. leprae* in relationship to its other antigen. Matsuo, E., *et al.* ..... (A) 716
On the value of sequential serology with a *M. leprae*-specific antibody competition ELISA in monitoring leprosy chemotherapy. Chaturvedi, V., *et al.* ..... (O) 32
Phenolic glycolipid-I from *M. leprae* inhibits oxygen free radical production by human mononuclear cells. Launois, P., *et al.* ..... (A) 515
Primary dapsone-resistant Hansen's disease in California; experience with over 100 *M. leprae* isolates. Gelber, R. H., *et al.* ..... (A) 345
Protein antigens of *M. leprae.* Clark-Curtiss, J. E., *et al.* ..... (A) 509
Radiolabeling of *M. leprae* lipids with schwannoma cells, a potential drug screening system. Mistry, Y., *et al.* ..... (A) 686
Rapid and sensitive detection of *M. leprae* using a nested-primer gene amplification assay. Plikaytis, B. B., *et al.* ..... (A) 168
Reactions to antigens from actinomycetes including *M. leprae* in leprosy patients. Ohman, R., *et al.* ..... (C) 320

Recent research into the physiology of *M. leprae*. Wheeler, P. R. ..... (A) 521
Recombinant fusion protein identified by lepromatous sera mimics native *M. leprae* in T-cell responses across the leprosy spectrum. Laal, S., *et al.* ..... (A) 515
Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ..... (A) 349
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 686
Rifampin in drug-incorporated diet: effect of duration and temperature of storage. Relevance to drug-susceptibility testing in mice inoculated with *M. leprae*. Abraham, B., *et al.* ..... (O) 68
Role of the L-arginine-dependent pathway of activated macrophages on the metabolic activity of *M. leprae*. Adams, L., *et al.* ..... (A) 198
Selection and characterization of recombinant clones that produce *M. leprae* antigens recognized by antibodies in sera from household contacts of leprosy patients. Hartskeerl, R. A., *et al.* ..... (A) 159
Serological monitoring of previously treated lepromatous patients during a course of multiple immunotherapy treatments with heat-killed *M. leprae* and BCG. Douglas, J. T., *et al.* ..... (A) 355
Serum IgA1 and IgM antibodies against *M. leprae*-derived phenolic glycolipid-I: a comparative study in leprosy patients and their contacts. Chujor, C. S. N., *et al.* ..... (O) 441
[Severity of leprosy eye lesions in armadillos infected with *M. leprae*.] Zhou, H.-M., *et al.* ..... (A) 360
Some possible interactions of *M. leprae* and HIV in the peripheral nerves. Patki, A. H. (C) 331
Studies on alpha-antigen gene of *M. leprae*: molecular biological studies of *M. leprae*-specific epitopes of alpha-antigen. Makino, M. and Suzuki, Y. ..... (A) 711
Sub-clinical infection with *M. leprae* in household contacts of leprosy. Bhatia, V. N., *et al.* ..... (A) 348
Subcellular localization of *M. leprae*-specific PGL-I antigen in human leprosy lesions and in *M. leprae* isolated from armadillo liver. Boddingius, J. and Dijkman, H. ..... (A) 369
Susceptibility of severe combined immunodeficient (SCID) mice to *M. leprae*: multiplication of *M. leprae* inoculated into both hind feet at an early stage. Yogi, Y., *et al.* (A) 722
The evolution of antibody response in armadillos inoculated with *M. leprae*. Vadiee, A. R., *et al.* ..... (A) 171
The response of human B cells to *M. leprae*. Identification of target antigens following polyclonal activation *in vitro*. Mahon, A. C., *et al.* ..... (A) 359
The response to chemotherapy of serum *M. leprae*-specific antigen in multibacillary leprosy patients. Roche, P. W., *et al.* ..... (A) 676
The use of a specific DNA probe and polymerase chain reaction for the detection of *M. leprae*. Williams, D. L., *et al.* ..... (A) 168
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ..... (A) 169
Toward a thorough resolution and structural definition of the major antigens of *M. leprae*. Brennan, P. J., *et al.* ..... (A) 202
Transmission of *M. leprae* from lepromatous leprosy patients to the skin of mice through intermittent feeding. Banerjee, R., *et al.* ..... (A) 369
Transmission of viable *M. leprae* by *Aedes aegypti* from lepromatous leprosy patients to the skin of mice through interrupted feeding. Banerjee, R., *et al.* ..... (A) 523
[Trial of a skin test with the soluble antigen of *M. leprae* in a group at risk.] Maestre Mesa, J. L. and Gonzalez Segredo, A. ..... (A) 681
Use of flanking sequences to study secondary structure-activity correlations of *M. leprae* T cell epitope. Anderson, D. C., *et al.* ..... (A) 352
Workshop on PCR Technology for the Detection of *M. leprae*. ..... (N) 498

Mycobacterium lepraemurium,

Application of monoclonal antibodies to differentiate the morphological forms of *M. lepraemurium* Hawaiian strain. Elangeswaran, N., *et al.* ..... (A) 716
Biological properties of factors secreted by antigen-reactive suppressor cells in mice infected with *M. lepraemurium*. Forget, A. and Turcotte, R. ..... (A) 370

Detection of interleukin-3 in the serum of mice infected with *M. lepraemurium.* Resnick, M., *et al.* ..... (A) 380
Early accumulation of suppressor cell precursors in the spleen of *M. lepraemurium*-infected mice and analysis of their *in vitro*-induced maturation. Lemieux, S., *et al.* ..(A) 169
Modulation of *M. lepraemurium* growth in murine macrophages: beneficial effect of tumor necrosis factor alpha and granulocyte-macrophage colony-stimulating factor. Denis, M. ..... (A) 510
Strain differences in mouse cellular responses to *M. lepraemurium* and BCG subcutaneous infections. I. Analysis of cell surface phenotype in local granulomas. Roch, R. and Bach, M.-A. ..... (A) 170

Mycobacterium paratuberculosis,
A DNA probe for the detection of *M. paratuberculosis.* Ambrosio, R. E., *et al.* ..... (A) 689
Genetic regulation of *M. paratuberculosis* infection in recombinant inbred mice. Frelier, P. F., *et al.* ..... (A) 528
Identification of two groups of *M. paratuberculosis* strains by restriction endonuclease analysis and DNA hybridization. Collins, D. M., *et al.* ..... (A) 178
Immunohistochemical study of bovine lymph nodes with antibodies against S100 protein subunits: comparison between lymph nodes of healthy and *M. paratuberculosis*-infected cattle. Momotani, E., *et al.* ..... (A) 697
M. paratuberculosis and Crohn's disease. Tanaka, K., *et al.* ..... (A) 532
Polyclonal antibodies raised against bacillus Calmette-Guérin, *M. duvalii,* and *M. paratuberculosis* used to detect mycobacteria in tissue with the use of immunohistochemical techniques. Wiley, E. L., *et al.* ..... (A) 364
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186

Mycobacterium scrofulaceum,
On the possible cross-immunoreactivity of the beta-glucuronidase receptor of *M. scrofulaceum* HI-75 with that in globi in lepromas; an immunohistologic study. Matsuo, E., *et al.* ..... (A) 195

Mycobacterium smegmatis,
Analysis of *M. leprae, M. tuberculosis,* and *M. avium* genomic libraries in *M. smegmatis* and *E. coli* using shuttle cosmid vectors. Pane, L., *et al.* ..... (A) 200
Cell wall composition of ethambutol susceptible and resistant strains of *M. smegmatis* ATCC 607. Sareen, M. and Khuller, G. K. ..... (A) 186
Cloning and expression of the origin of replication of mycobacteriophage D29 in *M. smegmatis.* Lazraq, R., *et al.* ..... (A) 695
High-performance liquid chromatography patterns of mycolic acids as criteria for identification of *M. chelonae, M. fortuitum,* and *M. smegmatis.* Butler, W. R. and Kilburn, J. O. ..... (A) 177
Isolation and characterization of efficient plasmid transformation mutants of *M. smegmatis.* Snapper, S. B., *et al.* ..... (A) 367
Presence of gamma glutamyl transferase in *M. smegmatis.* Kumar, S., *et al.* ..... (A) 183
Purification and characterization of dihydrofolate reductase from wild-type and trimethoprim-resistant *M. smegmatis.* Sirawaraporn, W., *et al.* ..... (A) 699

Mycobacterium tuberculosis,
A comparative study on the activation of J-774 macrophage-like cells by gamma-interferon, 1,25-dihydroxyvitamin D3 and lipopeptide RP-56142: ability to kill intracellularly multiplying *M. tuberculosis* and *M. avium.* Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
Activation of human neutrophils by *M. tuberculosis*-derived sulfolipid-1. Zhang, L., *et al.* ..... (A) 683
Analysis of *M. leprae, M. tuberculosis,* and *M. avium* genomic libraries in *M. smegmatis* and *E. coli* using shuttle cosmid vectors. Pane, L., *et al.* ..... (A) 200
Characterization of a *M. tuberculosis* insertion sequence belonging to the IS3 family. McAdam, R. A., *et al.* ..... (A) 530
[Characterization of the spectrum of antibody response to *M. tuberculosis* determinants by the method of immunoblotting.] Kioshka, V. S., *et al.* ..... (A) 695

[Clinical value of *M. tuberculosis* L-form detection in subjects with residual tuberculous changes in the lungs.] Dorozhkova, I. R., *et al.* ..... (A) 527
Cloning and characterization of the aroA gene from *M. tuberculosis.* Garbe, T., *et al.* .. (A) 365
Detection and identification of *M. tuberculosis* by DNA amplification. Pao, C. C., *et al.* (A) 184
Diversity in antigen recognition by *M. tuberculosis*-reactive T cell clones from the synovial fluid of rheumatoid arthritis patients. Res, P. C. M., *et al.* ..... (A) 698
Early days in the use of DNA probes for *M. tuberculosis* and *M. avium* complexes. Andrew, P. W. and Boulnois, G. J. ..... (A) 166
Efficacies of selected disinfectants against *M. tuberculosis.* Best, M., *et al.* ..... (A) 177
Expression of *M. tuberculosis* and *M. leprae* proteins by vaccinia virus. Lyons, J., *et al.* (A) 358
In-vitro activity of ofloxacin against *M. tuberculosis* and its clinical efficacy in multiple resistant pulmonary tuberculosis. Yew, W. W., *et al.* ..... (A) 188
Insertion element IS986 from *M. tuberculosis*: a useful tool for diagnosis and epidemiology of tuberculosis. Hermans, P. W. M., *et al.* ..... (A) 181
Intracellular bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* H37Rv multiplying in the J-774 macrophage cell line. Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
IS6110: conservation of sequence in the *M. tuberculosis* complex and its utilization in DNA fingerprinting. Cave, M. D., *et al.* ..... (A) 692
Isolation and structural characteristics of a monoclonal antibody-defined crossreactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J.-J., *et al.* ..... (A) 355
[Isolation of a strain of *M. tuberculosis* which is considered to be rifampicin-dependent, from a patient with long-lasted smear positive and culture difficult (SPCD) mycobacteria.] Nakamura, M., *et al.* ..... (A) 531
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis.* Orrell, J. M., *et al.* ..... (A) 697
Memory T cell-mediated resistance to *M. tuberculosis* infection in innately susceptible and resistant mice. Hubbard, R. D., *et al.* ..... (A) 694
Polymerase chain reaction for detection of *M. tuberculosis.* Sjobring, U., *et al.* ..... (A) 186
Probability distribution of drug-resistant mutants in unselected populations of *M. tuberculosis.* David, H. L. ..... (A) 527
Proteins released from *M. tuberculosis* during growth. Andersen, P., *et al.* ..... (A) 689
Quantitative and qualitative studies on the major extracellular antigen of *M. tuberculosis* H37Rv and *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 165
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ..... (A) 532
Structural features of the arabinan component of the lipoarabinomannan of *M. tuberculosis.* Chatterjee, D., *et al.* ..... (A) 678
Synthesis of carbohydrate-antigenic structures of *M. tuberculosis* using an iodonium ion promoted glycosidation approach. Veeneman, G. H., *et al.* ..... (A) 701
T-cellular immune reactions (in macrophage inhibition factor assay) against *M. paratuberculosis, M. kansasii, M. tuberculosis, M. avium* in patients with chronic inflammatory bowel disease. Seldenrijk, C. A., *et al.* ..... (A) 186
[The influence of agonists and antagonists of the histamine H1- and H2-receptor on the growth of *M. tuberculosis* H37Ra.] Meindl, W., *et al.* ..... (A) 184
Trace elements incorporated into the culture medium of *M. tuberculosis* promote the presence of tuberculoprotein C in the preparation of purified protein derivatives. Affronti, L. F., *et al.* ..... (A) 374
[Use of the microdot enzyme immunoassay for the determination of antibodies to *M. tuberculosis.*] Badukshanova, N. M., *et al.* ..... (A) 374

Mycobacterium vaccae,
Immunotherapy with *M. vaccae* as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Stanford, J. L., *et al.* ..... (A) 163
Improved immunotherapy for pulmonary tuberculosis with *M. vaccae.* Bahr, G. M., *et al.* ..... (A) 374
M. vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Stanford, J. L., *et al.* ..... (A) 518

Mycobacterium w,
Immuno-blot analysis of antigens of *Mycobacterium w*: a candidate antileprosy vaccine using monoclonal antibodies and patient sera. Ganju, L., *et al.* ....(A) 356
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w*. Singh, I. G., *et al.* ....(A) 532

Nepal,
Leprosy Control Project Annual Report 1988–1989. ....(N) 137
Self-administered dapsone compliance of leprosy patients in eastern Nepal. van Trier, Y. D. M. and de Soldenhoff, R. ....(A) 503
Self-administered drug compliance in Nepali leprosy patients. Roche, P. W., *et al.* ....(A) 503

Nerve(s),
A case of isolated tuberculoid leprosy of brachial cutaneous nerve. Nogueira, L. A. D. (A) 153
Denatured muscle grafts for nerve repair; an experimental model of nerve damage in leprosy. Pereira, J. H., *et al.* ....(A) 373
Giant nerve abscesses in leprosy. Saxena, U., *et al.* ....(A) 351
Histoid lesion in nerve of a lepromatous patient. Girdhar, A., *et al.* ....(A) 151
Immunohistological analysis of nerve granulomas in neuritic leprosy. Narayanan, R. B., *et al.* ....(A) 360
Isolation and characterization of infiltrates in the nerves of patients with neuritic leprosy. Kumar, V., *et al.* ....(A) 160
Leprotic involvement of peripheral nerves in the absence of skin lesions; case report and literature review. Jenkins, D., *et al.* ....(A) 350
Mycobacteria in nerve trunks of long-term treated leprosy patients. Pereira, J. H., *et al.* (A) 681
Nodularity of nerves in treated leprosy. Saxena, U., *et al.* ....(A) 154
Observations on nerve tissue infected with *M. leprae*. Bhatia, V. N. ....(A) 520
Serological responses in primary neuritic leprosy. Roche, P. W., *et al.* ....(A) 681
Some possible interactions of *M. leprae* and HIV in the peripheral nerves. Patki, A. H. (C) 331
[Surgical exploration of swollen peripheral nerves in 55 cases.] Dong, L., *et al.* ....(A) 150
The significance of facial patches and type 1 reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients. Hogeweg, M., *et al.* ....(A) 674
Therapeutic implications of morphological study of nerves from treated or untreated tuberculoid or lepromatous leprosy. Dastur, D. K., *et al.* ....(C) 122
Treatment of facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Kiran, K. U., *et al.* ....(A) 675

Netherlands, The,
Progression of eye lesions in leprosy: ten-year follow-up study in The Netherlands. Hogeweg, M. and Faber, W. R. ....(O) 392

Neuritis,
Treatment of leprous neuritis by neurolysis combined with perineural corticosteroid injection. Dandapat, M. C., *et al.* ....(A) 525

Neuropathy,
Peripheral neuropathy and haemolytic anaemia with cherry red spot on macula in dapsone poisoning. Abhayambika, K., *et al.* ....(A) 501
[Surgical treatment for neurotrophic lesions of leprosy: application to other types of neuropathy.] Bourrel, P. ....(A) 174

Neutrophil(s),
Activation of human neutrophils by *M. tuberculosis*-derived sulfolipid-1. Zhang, L., *et al.* ....(A) 683

New Zealand,
New name for Leprosy Trust Board. ....(N) 663

Nigeria,
A retrospective study on seven years of multiple drug treatment for paucibacillary and multibacillary leprosy in Bayara General Hospital, Nigeria. Blok, L. M., *et al.* ....(A) 672
LEPRA in Nigeria. ....(N) 138

Moniaya Tuberculosis and Leprosy (TBL) Control Services 1989 Annual Report. Bourdillon, C. ..... (N) 138
New cases of leprosy in the Cross River Region, Nigeria. Brightmer, M. I. ..... (A) 172

Nose,
Detection of *M. leprae*-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients. Singh, N. B., *et al.* ..... (O) 398

Nutrition,
A study on nutrition, growth and development of a high-risk group of children of urban leprosy patients. Saha, K., *et al.* ..... (A) 372

Obituaries,
Dharmendra by Ramu, G. ..... (Ob) 494
Jagadisan, T. N. by Srinivasan, H. ..... (Ob) 656
Weddell, Alexander Graham by Rees, R. J. W. ..... (Ob) 127

Ofloxacin,
Activities of pefloxacin and ofloxacin against mycobacteria: *in vitro* and mouse experiments. Truffot-Pernot, C., *et al.* ..... (A) 533
Antileprosy activity of ofloxacin in combination with rifampin and diaminodiphenylsulfone in mice and *in vitro* activities of new quinolones and rifamycin derivatives. Saito, H., *et al.* ..... (A) 718
[Effects of ofloxacin and minocycline on experimental leprosy.] Wang, H.-Y., *et al.* ... (A) 673
In-vitro activity of ofloxacin against *M. tuberculosis* and its clinical efficacy in multiple resistant pulmonary tuberculosis. Yew, W. W., *et al.* ..... (A) 188
Intrabacterial sodium-to-potassium ratios and ATP contents of *M. leprae* from ofloxacin-treated patients. Dietz, M., *et al.* ..... (O) 548
Intracellular bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* H37Rv multiplying in the J-774 macrophage cell line. Rastogi, N. and Blom-Potar, M.-C. ..... (A) 379
Ofloxacin and imipenem in the treatment of *M. fortuitum* and *M. chelonae* lung infections. Yew, W. W., *et al.* ..... (A) 188
Ofloxacin trials. ..... (N) 667

Pathology,
Corneal sensitivity and correlations between decreased sensitivity and anterior segment pathology in ocular leprosy. Karacorlu, M. A., *et al.* ..... (A) 505
Reply: the use of xylene (xylol) in medical laboratories. Ridley, M. D. ..... (A) 521

Pefloxacin,
Activities of pefloxacin and ofloxacin against mycobacteria: *in vitro* and mouse experiments. Truffot-Pernot, C., *et al.* ..... (A) 533

Phagocyte(s),
Host and bacterial molecules mediating phagocytosis of *M. leprae* by human mononuclear phagocytes. Schlesinger, L. S. and Horwitz, M. A. ..... (A) 719
M. leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells. Steinhoff, U., *et al.* ..... (A) 519

Pharmacokinetic(s),
The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. May, D. G., *et al.* ..... (A) 346

Phenolic glycolipid(s),
Activation of the human complement system by phenolic glycolipid of *M. leprae*. Ramanathan, V. D., *et al.* ..... (A) 362
Anti-phenolic glycolipid 1 IgM antibodies in leprosy patients and their household contacts. Sulcebe, G. and Nakuci, M. ..... (A) 363
Antibodies to phenolic glycolipid-1 of *M. leprae* in urine of leprosy patients. Patil, S. A., *et al.* ..... (A) 162
Carbohydrate epitope structural elucidation of 1H-NMR spectroscopy of a new *M. kansasii* phenolic glycolipid antigen. Gilleron, M., *et al.* ..... (A) 377
Correlation between the chemical structure of the carbohydrate part of *M. leprae* PGL-I and its activity to the monoclonal antibodies. Fujiwara, T., *et al.* ..... (A) 199

[Detection of IgM anti-PGL-I for the serodiagnosis of leprosy and for the follow up of contact population in Polynesia. A 5 year situation.] Chanteau, S., *et al.* ..... (A) 354
Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Cho, S.-N., *et al.* ..... (O) 25
Distribution of anti-PGL-I antibody in household contacts from endemic countries. Izumi, S., *et al.* ..... (A) 199
Early infection with *M. leprae* and antibodies to phenolic glycolipid-I in the nine-banded armadillo. Job, C. K., *et al.* ..... (A) 169
IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Ulrich, M., *et al.* ..... (O) 405
IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from *M. leprae* in sera of leprosy patients and their contacts. Saad, M. H. F., *et al.* ..... (A) 362
Light- and electron-microscopic immunohistochemistry using anti-PGL-I antibody specific for *M. leprae.* Goto, M. and Izumi, S. ..... (A) 195
Phenolic glycolipid-I from *M. leprae* inhibits oxygen free radical production by human mononuclear cells. Launois, P., *et al.* ..... (A) 515
Quantitative relationship between anti-PGL-I-specific antibody levels and the lepromin reaction. David, H. L., *et al.* ..... (C) 332
Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ..... (A) 349
Seroepidemiological study of leprosy in a highly endemic population of South India based on an ELISA using synthetic PGL-1. Krishnamurthy, P., *et al.* ..... (O) 426
Serum IgA1 and IgM antibodies against *M. leprae*-derived phenolic glycolipid-I: a comparative study in leprosy patients and their contacts. Chujor, C. S. N., *et al.* ..... (O) 441
Subcellular localization of *M. leprae*-specific PGL-I antigen in human leprosy lesions and in *M. leprae* isolated from armadillo liver. Boddingius, J. and Dijkman, H. .... (A) 369
The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic glycolipids: structure and immunological properties. Puzo, G. ..... (A) 366
[The comparative study of gelatin particle agglutination test (GPAT) and PGL-ELISA.] Li, H., *et al.* ..... (A) 160
The value of IgM antibodies to PGL-I in the diagnosis of leprosy. Lefford, M. J., *et al.* (O) 432
Urinary phenolic glycolipid 1 in the diagnosis and management of leprosy. Mahon, A. C., *et al.* ..... (A) 516

Phenotype(s),
[Clinical importance of HLA phenotype in childhood tuberculosis.] Dovgalyuk, I. F., *et al.* ..... (A) 376
Strain differences in mouse cellular responses to *M. lepraemurium* and BCG subcutaneous infections. I. Analysis of cell surface phenotype in local granulomas. Roch, F. and Bach, M.-A. ..... (A) 170
Tuberculosis in patients with various HLA phenotypes. Khomenko, A. G., *et al.* ..... (A) 182

Phospholipid(s),
Isolation and structural characteristics of a monoclonal antibody-defined crossreactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J.-J., *et al.* ..... (A) 355

Phytohemagglutinin (PHA),
Response to phytohemagglutinin of LL patients' lymphocytes preincubated in culture media. Fafutis-Morris, M., *et al.* ..... (C) 480

Poland,
International Congress of Dermatology, 1992. ..... (N) 663

Polynesia,
[Detection of IgM anti-PGL-I for the serodiagnosis of leprosy and for the follow up of contact population in Polynesia. A 5 year situation.] Chanteau, S., *et al.* ..... (A) 354
Longitudinal study on relapses of leprosy in Polynesian multibacillary patients on dapsone monotherapy between 1946 and 1970. Cartel, J.-L., *et al.* ..... (A) 672

Prosthetic(s),
Carvable silicone rubber prosthetic implant for atrophy of the first web in the hand. Duerksen, F. and Virmond, M. ..... (A) 174

Protein(s),
A monoclonal antibody to the mycobacterial 65kDa heat shock protein (ML 30) binds to cells in normal and arthritic joints of rats. Kleinau, S., *et al.* ..... (A) 514
Analysis of cellular fatty acids and proteins by capillary gas chromatography and sodium dodecyl sulphate polyacrylamide gel electrophoresis to differentiate *M. avium, M. intracellulare* and *M. scrofulaceum* (MAIS) complex species. Fourche, J., *et al.* ..... (A) 528
Characterization of a 65-kDa heat-shock protein of mycobacteria. Nomaguchi, H., *et al.* ..... (A) 197
Characterization of cell-wall associated 10-kDa heat-shock protein of *M. leprae* which is a major T-cell antigen. Mehra, V. L., *et al.* ..... (A) 710
Distribution in tissue sections of the human groEL stress-protein homologue. Evans, D. J., *et al.* ..... (A) 158
Epitopes on protein antigens: misconceptions and realities. Laver, W. G., *et al.* ..... (A) 515
Expression of *M. tuberculosis* and *M. leprae* proteins by vaccinia virus. Lyons, J., *et al.* (A) 358
Fusion protein based epitope mapping of the MPB57 protein from *M. bovis* BCG and its epitope insertion into the native protein. Yamaguchi, R., *et al.* ..... (A) 533
Heat-shock proteins as antigens of pathogenic microorganisms. Shinnick, T. M. ..... (A) 203
Identification, characterization, and expression of the major proteins of *M. leprae* of molecular mass 14 kDa and 35 kDa. Rivoire, B., *et al.* ..... (A) 715
Immune responses to the 18-kDa protein of *M. leprae*; similar B cell epitopes but different T cell epitopes seen by inbred strains of mice. Doherty, T. M., *et al.* ..... (A) 510
Immunohistochemical study of bovine lymph nodes with antibodies against S100 protein subunits: comparison between lymph nodes of healthy and *M. paratuberculosis*-infected cattle. Momotani, E., *et al.* ..... (A) 697
Iron-regulated envelope proteins of mycobacteria grown *in vitro* and their occurrence in *M. avium* and *M. leprae* grown *in vivo*. Sritharan, M. and Ratledge, C. ..... (A) 367
Molecular characterization of immunologically reactive proteins of *M. leprae*. Sela, S., *et al.* ..... (A) 715
Mycobacteria and human autoimmune disease: direct evidence of cross-reactivity between human lactoferrin and the 65-kilodalton protein of tubercle and leprosy bacilli. Esaguy, N., *et al.* ..... (A) 510
Mycobacterial cell surface proteins revealed by labeling with 125I. Deuskar, N. J. and Deo, M. G. ..... (C) 482
Nucleotide and deduced amino acid sequence of a *M. leprae* 12K protein. Hartskeerl, R. A., *et al.* ..... (A) 167
Nucleotide sequence of the 32 kDa-protein gene (antigen 85A) of *M. bovis* BCG. de Wit, M. Y. L., *et al.* ..... (A) 178
Protein antigens of *M. leprae*. Clark-Curtiss, J. E., *et al.* ..... (A) 509
Proteins released from *M. tuberculosis* during growth. Andersen, P., *et al.* ..... (A) 689
Recombinant fusion protein identified by lepromatous sera mimics native *M. leprae* in T-cell responses across the leprosy spectrum. Laal, S., *et al.* ..... (A) 515
S-100 protein marker. Lefford, M. J. ..... (C) 122
Synovial cells responding to a 65-kDa mycobacterial heat shock protein have a high proportion of a TcR gamma/delta subtype uncommon in peripheral blood. Soderstrom, K., *et al.* ..... (A) 700
T cell reactivity to an epitope of the mycobacterial 65-kDa heat-shock protein (hsp 65) corresponds with arthritis susceptibility in rats and is regulated by hsp 65-specific cellular responses. Hogervorst, E. J. M., *et al.* ..... (A) 680
The major native proteins of the leprosy bacillus. Hunter, S. W., *et al.* ..... (A) 167
The mycobacterial GroEL stress protein: a common target of T-cell recognition in infection and autoimmunity. Lamb, J. R., *et al.* ..... (A) 160
Trace elements incorporated into the culture medium of *M. tuberculosis* promote the presence of tuberculoprotein C in the preparation of purified protein derivatives. Affronti, L. F., *et al.* ..... (A) 374

Psychosocial,
[Some psychosocial and epidemiologic characteristics of the leprosy patient in Artemisa Municipality (Cuba).] Lopez del Rincon, F., *et al.* ..... (A) 174
[Some psychosocial and epidemiological characteristics of leprosy patients in the municipality of Artemisa.] de Rojas y Lopez del Rincon, V., *et al.* ..... (A) 523

Purification,
Purification and characterization of dihydrofolate reductase from wild-type and trimethoprim-resistant *M. smegmatis.* Sirawaraporn, W., *et al.* ..... (A) 699

Purified protein derivative (PPD),
Trace elements incorporated into the culture medium of *M. tuberculosis* promote the presence of tuberculoprotein C in the preparation of purified protein derivatives. Affronti, L. F., *et al.* ..... (A) 374

Qatar,
Leprosy in Qatar. Mahmoud, S. F. and Azadeh, B. ..... (A) 524

Rat(s),
Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. Coleman, M. D., *et al.* ..... (A) 146

Reaction, leprosy,
Additional markers for the type I reactional states of borderline leprosy. Lazaro-Medina, A., *et al.* ..... (A) 357
Cell changes and soluble interleukin-2 receptors (Tac peptide) in leprosy reversal reactions using section-induced blisters. Theetranont, C., *et al.* ..... (A) 363
Immunopharmacology of drugs used in leprosy reactions. Girdhar, B. K. ..... (A) 346
Keratosis spinulosa developing in borderline tuberculoid lesions during type I lepra reaction: two case reports. Thankappan, T. P. and Sulochana, G. ..... (A) 508
[Late reversal reactions of leprosy.] Flageul, B., *et al.* ..... (A) 150
Persistent reaction in paucibacillary leprosy: case reports. Saxena, U., *et al.* ..... (A) 677
Persistent reduced solubilization of immune complexes in lepromatous leprosy patients with reactions. Ramanathan, V. D., *et al.* ..... (O) 5
Reactional states in Hansen's disease: practical aspects of emergency management. Goodless, D. R., *et al.* ..... (A) 505
Reactions in leprosy; a study of 250 patients in a multidrug therapy project, Baroda District, Gujarat, India. Chopra, N. K., *et al.* ..... (A) 149
Reactions to antigens from actinomycetes including *M. leprae* in leprosy patients. Ohman, R., *et al.* ..... (C) 320
Relapse in leprosy after multidrug therapy and its differential diagnosis with reversal reaction. Kesava Reddy, P. and Cherian, A. ..... (A) 673
Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states. Sarno, E. N., *et al.* ..... (A) 506
Serum zinc/copper ratio in subtypes of leprosy and effect of oral zinc therapy on reactional states. George, J., *et al.* ..... (O) 20
Thalidomide in type-2 lepra reaction—a clinical experience. Jadhav, V. H., *et al.* ..... (A) 350
The significance of facial patches and type 1 reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients. Hogeweg, M., *et al.* ..... (A) 674

Rehabilitation,
Bombay Leprosy Project starts integrated rehabilitation clinic for leprosy patients. ..... (N) 496
[Preliminary observation on 74 leprosy patients undergoing a rehabilitation plan for a year.] Zhou, S.-N., *et al.* ..... (A) 526
[Treatment and rehabilitation of deformities in leprosy in a district hospital (Kapolowe, Zaire).] Vuillet, F. and Tschibangu, P. ..... (A) 526
Vibration sense and tarsal disintegration. Klenerman, P., *et al.* ..... (A) 506

Relapse(s),
A case of relapse with drug-susceptible *M. leprae* after multidrug therapy. Constant-Desportes, M., *et al.* ..... (O) 242
Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Cho, S.-N., *et al.* ..... (O) 25
Longitudinal study on relapses of leprosy in Polynesian multibacillary patients on dapsone monotherapy between 1946 and 1970. Cartel, J.-L., *et al.* ..... (A) 672
Precautionary note for observing signs of activity (or relapse) in treated leprosy patients. Ramesh, V. ..... (C) 322

Relapse in leprosy after multidrug therapy and its differential diagnosis with reversal reaction. Kesava Reddy, P. and Cherian, A. ..... (A) 673
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. Shafer, R. W. and Jones, W. D. ..... (A) 699
Relapse rate in paucibacillary leprosy patients after multidrug therapy in North Arcot District. Ekambaram, V. and Rao, M. K. ..... (A) 672
Tuberculoid relapse in lepromatous leprosy. Waters, M. F. R. and Ridley, D. S. ..... (A) 364

Rifampin,
A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone. Pattyn, S. R., *et al.* ..... (A) 673
Addisonian crisis induced by treatment with rifampicin. Wilkins, E. G. L., *et al.* ..... (A) 348
Antileprosy activity of ofloxacin in combination with rifampin and diaminodiphenylsulfone in mice and *in vitro* activities of new quinolones and rifamycin derivatives. Saito, H., *et al.* ..... (A) 718
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against *M. avium* complex. Rastogi, N. and Labrousse, V. ..... (A) 502
Fleroxacin combined with rifampin. Zhang, Y.-X. and Neu, H. C. ..... (A) 534
[Isolation of a strain of *M. tuberculosis* which is considered to be rifampicin-dependent, from a patient with long-lasted smear positive and culture difficult (SPCD) mycobacteria.] Nakamura, M., *et al.* ..... (A) 531
[Potentiometric procedure for assay of rifampicin.] Ovcharova, G. D., *et al.* ..... (A) 148
Rifampicin-induced immune hemolytic anemia: therapeutic relevance of plasma exchange. Govoni, M., *et al.* ..... (A) 501
Rifampin in drug-incorporated diet: effect of duration and temperature of storage. Relevance to drug-susceptibility testing in mice inoculated with *M. leprae*. Abraham, B., *et al.* ..... (O) 68
Smear-negative, culture-positive pulmonary tuberculosis; six-month chemotherapy with isoniazid and rifampin. Dutt, A. K., *et al.* ..... (A) 179

Rifamycin,
Antileprosy activity of ofloxacin in combination with rifampin and diaminodiphenylsulfone in mice and *in vitro* activities of new quinolones and rifamycin derivatives. Saito, H., *et al.* ..... (A) 718
In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565). Dickinson, J. M. and Mitchison, D. A. ..... (A) 376
In vitro activities of aminglycosides, lincosamides, and rifamycins against *M. leprae*. Franzblau, S. G. ..... (A) 684

Sarcoidosis,
Sarcoidosis masquerading as leprosy, pulmonary tuberculosis and urolithiasis. Singh, K., *et al.* ..... (A) 507

Saudi Arabia,
Leprosy in Saudi Arabia. Ibrahim, M. A., *et al.* ..... (A) 371

Screening,
Antiarabinogalactan IgM/IgG ratio: a screening index for leprosy patients. Roy, A., *et al.* ..... (A) 517
Radiolabeling of *M. leprae* lipids with schwannoma cells, a potential drug screening system. Mistry, Y., *et al.* ..... (A) 686
Screening of registered leprosy cases and its effects on prevalance rate. Rao, P. S. and Sirumban, P. ..... (A) 172
The glutaraldehyde test as a rapid screening method for pulmonary tuberculosis; a preliminary report. Larsson, S., *et al.* ..... (A) 529

Senegal,
Formation Pratique pour la Prevention des Invalidites et la Readaptation dans la Lepre. (N) 663

Serodiagnosis, serology,

A seroepidemiological study of leprosy in high- and low-endemic Indonesian villages. Soebono, H. and Klatser, P. O. ..... (O) 416

[Detection of IgM anti-PGL-I for the serodiagnosis of leprosy and for the follow up of contact population in Polynesia. A 5 year situation.] Chanteau, S., *et al.* ..... (A) 354

Production and characterization of antibody against cord factor (trehalose 6,6′-dimycolate) in mice and its application to rapid serodiagnosis of human mycobacteriosis including tuberculosis and leprosy. He, H., *et al.* ..... (A) 709

Seroepidemiological study of leprosy in a highly endemic population of South India based on an ELISA using synthetic PGL-1. Krishnamurthy, P., *et al.* ..... (O) 426

Serum,

[Antibody against PG1 and immunocomplex in the sera of leprosy patients with ENL.] Zhang, X., *et al.* ..... (A) 166

Antineural antibodies in sera of leprosy patients. Thomas, B. M. and Mukherjee, R. .. (A) 364

[Antiotensin-converting enzyme in serum of tuberculosis and leprosy patients.] Vinnik, L. A., *et al.* ..... (A) 164

[Contents of 10 kinds of elements in hair and serum of Tibetan leprosy patients in Gansu Province (China).] Shi, C., *et al.* ..... (A) 155

Detection of antibodies to 35 kD determinant of *M. leprae* in urine and serum of leprosy patients. Path, S. ..... (A) 162

Detection of interleukin-3 in the serum of mice infected with *M. lepraemurium.* Resnick, M., *et al.* ..... (A) 380

Detection of *M. leprae* antigens in the sera of leprosy patients by sandwich immunoradiometric assay using monoclonal antibodies. Patil, S. A., *et al.* ..... (A) 361

Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Cho, S.-N., *et al.* ..... (O) 25

Enzyme immunoassay of phagocytosis stimulating tetrapeptide "tuftsin" in normal and leprosy sera. Kaur, J., *et al.* ..... (O) 576

IgG and IgM antibodies immunoreacting with a 2,3-diacyl trehalose-2′-sulphate in sera from leprosy patients. Cruaud, P., *et al.* ..... (A) 158

IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from *M. leprae* in sera of leprosy patients and their contacts. Saad, M. H. F., *et al.* ..... (A) 362

Immuno-blot analysis of antigens of *Mycobacterium w*: a candidate antileprosy vaccine using monoclonal antibodies and patient sera. Ganju, L., *et al.* ..... (A) 356

[Level of G6PD in the sera of 81 leprosy patients (China).] Zhou, S., *et al.* ..... (A) 156

Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis.* Orrell, J. M., *et al.* ..... (A) 697

Mycobacterial antigens and anti-idiotype antibodies revealed by an enzyme-linked immunosorbent assay in tuberculous patient sera. Stavri, D., *et al.* ..... (A) 381

Recombinant fusion protein identified by lepromatous sera mimics native *M. leprae* in T-cell responses across the leprosy spectrum. Laal, S., *et al.* ..... (A) 515

Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ..... (A) 349

Selection and characterization of recombinant clones that produce *M. leprae* antigens recognized by antibodies in sera from household contacts of leprosy patients. Hartskeerl, R. A., *et al.* ..... (A) 159

Serum antibodies against peripheral nervous system antigens in leprosy. Chujor, C. S. N., *et al.* ..... (O) 590

Serum IgA1 and IgM antibodies against *M. leprae*-derived phenolic glycolipid-I: a comparative study in leprosy patients and their contacts. Chujor, C. S. N., *et al.* ..... (O) 441

Serum iron and total iron binding capacity in leprosy patients. Saxena, N., *et al.* ..... (A) 154

Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states. Sarno, E. N., *et al.* ..... (A) 506

Specificity of lymphocytotoxic autoantibodies (LCAbs) found in the serum of leprosy patients: class I MHC antigens. Rasheed, F. N., *et al.* ..... (A) 517

The response to chemotherapy of serum *M. leprae*-specific antigen in multibacillary leprosy patients. Roche, P. W., *et al.* ..... (A) 676

[The role of precipitating antibodies in the serum of tuberculosis patients.] Klyshev, T. L., *et al.* ..... (A) 695

Skin,
Application of a polymerase chain reaction for the detection of *M. leprae* in skin tissues. de Wit, M. Y. L., *et al.* ..... (A) 520
[Determination of Langerhans' cells in the skin lesions of leprosy cases with immunohistochemical technique using wheat-germ agglutinin.] Liang, Z., *et al.* ..... (A) 161
Fine structures of macrophages and/or leprosy bacilli in lepromatous leprosy lesions of human skin. Hirata, T. ..... (A) 195
[Histopathological changes in the skin of MB leprosy after MDT.] Miao, Z.-H., *et al.* (A) 347
Hypothesis: solar ultraviolet radiation and the initial skin lesion of leprosy. Patki, A. H. ..... (C) 492
Inside the skin: the local immune and inflammatory milieu in leprosy. Scollard, D. M. (A) 682
Leprotic involvement of peripheral nerves in the absence of skin lesions; case report and literature review. Jenkins, D., *et al.* ..... (A) 350
Low-magnification electron micrography of leproma in human skin based on semithin and ultrathin sectioning. Hirata, T. ..... (A) 159
Measurement of some biophysical parameters in skin lesions of leprosy. Gupta, A. B., *et al.* ..... (A) 350
Multibacillary leprosy presenting as a solitary skin lesion; report of three cases and its significance in control programs. Ramesh, V., *et al.* ..... (O) 1
Mycobacterial flora of the skin in leprosy. Fandinho, F. C. O., *et al.* ..... (O) 569
Nontuberculous mycobacterial infections of the skin. Street, M. L., *et al.* ..... (A) 532
Skin changes in the tuberculin test. Beck, J. S. ..... (A) 690
Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. Job, C. K., *et al.* ..... (A) 147
Transmission of *M. leprae* from lepromatous leprosy patients to the skin of mice through intermittent feeding. Banerjee, R., *et al.* ..... (A) 369
Transmission of viable *M. leprae* by *Aedes aegypti* from lepromatous leprosy patients to the skin of mice through interrupted feeding. Banerjee, R., *et al.* ..... (A) 523

Skin smear(s),
Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy.
A comparison of methods based mainly on skin smears as opposed to clinical methods.
Alternative clinical methods for classification of patients. Becx-Bleumink, M. ..... (O) 292
Inter- and intra-laboratory variation in the reporting of skin smears in leprosy. Abraham, B. and Cariappa, A. ..... (O) 76
Slit-skin smear in leprosy. Sehgal, V. N. and Joginder ..... (A) 154
Some observations on skin smear examination. Bhatia, V. N., *et al.* ..... (A) 365

Skin test(s),
ELISA & lepromin skin tests in household contacts of leprosy patients. Dhandayuthapani, S., *et al.* ..... (A) 523
Induction of lepromin positivity in monkeys by a candidate antileprosy vaccine: *M. habana*. Singh, N. B., *et al.* ..... (C) 317
Local adoptive transfer of delayed-type hypersensitivity to tuberculin in *M. bovis* (BCG) infected mice. Nikonenko, B. V., *et al.* ..... (A) 184
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* ..... (A) 159
Positive Mitsuda lepromin reactions in long-term treated lepromatous leprosy. Waters, M. F. R., *et al.* ..... (A) 364
Quantitative relationship between anti-PGL-I-specific antibody levels and the lepromin reaction. David, H. L., *et al.* ..... (C) 332
Sensitivity to sensitins and tuberculin in Swedish children. I. A study of school children in an urban area. Lind, A., *et al.* ..... (A) 530
Sensitivity to sensitins and tuberculin in Swedish children. II. A study of preschool children. Larsson, L. O., *et al.* ..... (A) 529
Skin changes in the tuberculin test. Beck, J. S. ..... (A) 690

The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. Friedland, I. R. ..... (A) 179
[Trial of a skin test with the soluble antigen of *M. leprae* in a group at risk.] Maestre Mesa, J. L. and Gonzalez Segredo, A. ..... (A) 681

South Africa,
Geographic distribution of phage types among cultures of *M. tuberculosis*. II. Cultures from India and South Africa. Jones, W. D., Jr. ..... (A) 377

Spain,
Fontilles 1991 International Courses. ..... (N) 341
[Leprosy in Andalucia.] Rodriguez Idigoras, M. I. and Petit, C. ..... (A) 372
Pattern of leprosy: STUH experience. Go-Estrada, K. L. ..... (A) 671

Sperm,
Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice *in vitro*. I. Chromosome analysis in bone marrow and spermatocytes. Das, R. K. and Roy, B. ..... (A) 147

Spleen,
Early accumulation of suppressor cell precursors in the spleen of *M. lepraemurium*-infected mice and analysis of their *in vitro*-induced maturation. Lemieux, S., *et al.* ..(A) 169

Stain(s),
[A comparative study of the various staining methods for mycobacteria.] Costa, H. C., *et al.* ..... (A) 167
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis*. Orrell, J. M., *et al.* ..... (A) 697
Nonspecific esterase staining of lymphocyte subsets in leprosy. Macedo, H. W. and Quirico-Santos, T. ..... (A) 516

Steroid(s),
Treatment of facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 675

Streptomycin,
Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Crowle, A. J. and May, M. H. ..... (A) 376

Subclinical,
[A study of subclinical infection with *M. leprae*. I. Paired analysis of contacts with leprosy.] Shu, H.-W., *et al.* ..... (A) 688
Sub-clinical infection with *M. leprae* in household contacts of leprosy. Bhatia, V. N., *et al.* ..... (A) 348

Sulfone(s),
Residual sight-threatening lesions in leprosy patients completing multidrug therapy and sulphone monotherapy. ffytche, T. J. ..... (A) 504

Superoxide,
Identification, sequencing, and expression of *M. leprae* superoxide dismutase, a major antigen. Thangaraj, H. S., *et al.* ..... (A) 168
The influence of structural modifications of dihydrophenazines on arachidonic acid mobilization and superoxide generation by human neutrophils. Zeis, B. M., *et al.* ...(A) 165

Suppression,
Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. Salgame, P., *et al.* ..... (A) 518
Major histocompatibility complex restriction of T-cell suppression of immune response to mycobacteria. Shroff, K. E., *et al.* ..... (O) 49
On the mechanism of human T cell suppression. Salgame, P., *et al.* ..... (A) 682

Surgery,
Beneficial effect of thalidomide and cyclosporin combination in heterotopic cardiac transplantation in rats. Emre, S., *et al.* ..... (A) 528

Facial palsy—a leprosy surgeon's viewpoint. Warren, G. ..... (A) 526
Recent advances in restorative surgery of extremities in leprosy. Malaviya, G. N. ..... (A) 525
[The actual situation of surgery and the global treatment of hanseniasis.] Virmond, M. and Duerksen, F. ..... (A) 175
The results of arthrodesis of the ankle for leprotic neuroarthropathy. Shibata, T., *et al.* (A) 174

Sweden,
The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden. Hornsten, P., *et al.* ..... (A) 152

Switzerland,
Council for International Organizations of Medical Services (CIOMS) holds XXIV Round Table Conference. ..... (N) 138
44th World Health Assembly calls for elimination of leprosy by year 2000. ..... (N) 497
Global intensification of work against leprosy. ..... (N) 664
ILEP celebrates 25th anniversary. ..... (N) 664
Industry and WHO collaborate in tropical disease research. ..... (N) 341
Shelf life of antileprosy drugs. ..... (N) 665
TDR call for applications for support of research training (1991). ..... (N) 342
TDR calls for applications for support of research training (1992). ..... (N) 665
WHO Consultation on early diagnosis of leprosy. ..... (N) 666
WHO Tropical Diseases Research (TDR) budgets cut. ..... (N) 666

Synovitis,
T cell activation by mycobacterial antigens in inflammatory synovitis. Pope, R. M., *et al.* ..... (A) 517

Testing,
Rifampin in drug-incorporated diet: effect of duration and temperature of storage. Relevance to drug-susceptibility testing in mice inoculated with *M. leprae.* Abraham, B., *et al.* ..... (O) 68
The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. Friedland, I. R. ..... (A) 179

Thailand,
Problems of tuberculosis treatment in Thailand. Jittinandana, A. ..... (A) 181
13th International Congress for Tropical Medicine and Malaria. ..... (N) 342
Workshop on PCR Technology for the Detection of *M. leprae.* ..... (N) 498

Thalidomide,
Beneficial effect of thalidomide and cyclosporin combination in heterotopic cardiac transplantation in rats. Emre, S., *et al.* ..... (A) 528
Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Revuz, J., *et al.* ..... (A) 185
Role of TNF alpha in the pathogenesis of mycobacterial infections; mechanism of modulation by thalidomide. Kaplan, G. and Sampaio, E. P. ..... (A) 714
Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Youle, M., *et al.* ..... (A) 188
Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Gorin, I., *et al.* ..... (A) 180
Thalidomide in the treatment of graft-versus-host disease. Henry, D., *et al.* ..... (A) 180
Thalidomide in type-2 lepra reaction—a clinical experience. Jadhav, V. H., *et al.* ..... (A) 350
The potential use of thalidomide in the therapy of graft-versus-host disease—a review of clinical and laboratory information. Wood, P. M. D. and Proctor, S. J. ..... (A) 187
Treatment of severe colitis in Behcet's syndrome with thalidomide. Larsson, H. ..... (A) 529

Therapy (see also Chemotherapy),
A case of relapse with drug-susceptible *M. leprae* after multidrug therapy. Constant-Desportes, M., *et al.* ..... (O) 242
Dapsone as a single agent is suboptimal therapy for *Pneumocystis carinii* pneumonia. Safrin, S., *et al.* ..... (A) 531
Effect of low-level and intermittent minocycline therapy on the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (A) 673
Effect of three-year multidrug therapy in multibacillary leprosy patients. Li, W.-H., *et al.* ..... (A) 148

Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink, M. ....(O) 558
Gall-bladder perforation after long-term dapsone therapy. Choy, A. M. and Lang, C. C. (A) 501
Histological changes in tuberculoid leprosy after fixed duration multidrug therapy of six months. Lavania, R. K., *et al.* ....(A) 160
Impact of multidrug therapy on the treatment and control of leprosy. Gilbody, J. S. ... (E) 458
"Implementing Multiple Drug Therapy for Leprosy" to be reprinted. ....(N) 342
In vivo modulation of atypical mycobacterial infection: adjuvant therapy increases resistance to *M. avium* by enhancing macrophage effector functions. Denis, M. ....(A) 692
Multidrug therapy for treatment of paucibacillary leprosy in western Kenya—preliminary communications. Orege, P. A., *et al.* ....(A) 502
Persistence mechanisms in *Pseudomonas aeruginosa* from cystic fibrosis patients undergoing ciprofloxacin therapy. Diver, J. M., *et al.* ....(A) 693
Reactions in leprosy; a study of 250 patients in a multidrug therapy project, Baroda District, Gujarat, India. Chopra, N. K., *et al.* ....(A) 149
Reduction in caseload after multidrug therapy in an urban leprosy control programme—a retrospective study in Bombay. Revankar, C. R., *et al.* ....(A) 500
Relapse in leprosy after multidrug therapy and its differential diagnosis with reversal reaction. Kesava Reddy, P. and Cherian, A. ....(A) 673
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. Shafer, R. W. and Jones, W. D. ....(A) 699
Relapse rate in paucibacillary leprosy patients after multidrug therapy in North Arcot District. Ekambaram, V. and Rao, M. K. ....(A) 672
Residual slight-threatening lesions in leprosy patients completing multidrug therapy and sulphone monotherapy. ffytche, T. J. ....(A) 504
Serum zinc/copper ratio in subtypes of leprosy and effect of oral zinc therapy on reactional states. George, J., *et al.* ....(O) 20
Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. Job, C. K., *et al.* ....(A) 147
Therapeutic regimens in leprosy. Pattyn, S. R. ....(A) 671

Tissue(s),
Application of a polymerase chain reaction for the detection of *M. leprae* in skin tissues. de Wit, M. Y. L., *et al.* ....(A) 520
Distribution in tissue sections of the human groEL stress-protein homologue. Evans, D. J., *et al.* ....(A) 158
Measurement of the tissue distribution of immunoperoxidase staining with polyclonal anti-BCG serum in lung granulomata of mice infected with *M. tuberculosis.* Orrell, J. M., *et al.* ....(A) 697
Observations on nerve tissue infected with *M. leprae.* Bhatia, V. N. ....(A) 520
Polyclonal antibodies raised against bacillus Calmette-Guérin, *M. duvalii,* and *M. paratuberculosis* used to detect mycobacteria in tissue with the use of immunohistochemical techniques. Wiley, E. L., *et al.* ....(A) 364
Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ....(A) 349

Training,
ALM International education and training materials. ....(N) 142
TAMILEP—Catalog of teaching and learning materials. ....(N) 343
TDR call for applications for support of research training (1991). ....(N) 342
TDR calls for applications for support of research training (1992). ....(N) 665
[Teaching of hansenology in the universities.] Opromolla, D. V. A. ....(A) 146
Training for primary eye care in leprosy. Courtright, P., *et al.* ....(A) 149

Trial(s),
A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone. Pattyn, S. R., *et al.* ....(A) 673

Comparative leprosy vaccine trial launched in south India. ....(N) 660
Effect of the initial isoniazid resistance on response to chemotherapy of tuberculosis: a review of clinical trials. Al-Orainey, I. O. M. ....(A) 689
Largest vaccine trial yet. ....(N) 661
Ofloxacin trials. ....(N) 667
Relationships between PGL-I antigen in serum, tissue and viability of *M. leprae* as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Chanteau, S., *et al.* ....(A) 349
Setting up HIV serology for the Karonga leprosy vaccine trial in Malawi. Shaw, M. A., *et al.* ....(A) 507
[Trial forecast of incidence with grey calculation in leprosy.] Cen, Y., *et al.* ....(A) 172
[Trial of a skin test with the soluble antigen of *M. leprae* in a group at risk.] Maestre Mesa, J. L. and Gonzalez Segredo, A. ....(A) 681
Unique prevention trial. ....(N) 663

Tuberculin,
Local adoptive transfer of delayed-type hypersensitivity to tuberculin in *M. bovis* (BCG) infected mice. Nikonenko, B. V., *et al.* ....(A) 184
Sensitivity to sensitins and tuberculin in Swedish children. I. A study of school children in an urban area. Lind, A., *et al.* ....(A) 530
Sensitivity to sensitins and tuberculin in Swedish children. II. A study of preschool children. Larsson, L. O., *et al.* ....(A) 529
Skin changes in the tuberculin test. Beck, J. S. ....(A) 690
The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. Friedland, I. R. ....(A) 179

Tuberculoid leprosy,
A case of isolated tuberculoid leprosy of brachial cutaneous nerve. Nogueira, L. A. D. (A) 153
A case of tuberculoid leprosy in Rhode Island. Frankel, E. H. and Teng, B. P. ....(A) 671
Association of mycobacterial-specific and *M. leprae* specific antibody levels with clinical activity in tuberculoid leprosy: a comparative study of three serological enzyme-immunoassays. Chaturvedi, V., *et al.* ....(A) 679
Granuloma disciformis chronica et progressiva (Miescher) mimicking tuberculoid leprosy. Satyawan, I., *et al.* ....(A) 676
Histological changes in tuberculoid leprosy after fixed duration multidrug therapy of six months. Lavania, R. K., *et al.* ....(A) 160
M. leprae-specific T cells from a tuberculoid leprosy patient suppress HLA-DR3-restricted T cell responses to an immunodominant epitope on 65-kDa hsp of mycobacteria. Haanen, J. B. A. G., *et al.* ....(A) 356
Tuberculoid leprosy: a case report. Mezebish, D. S., *et al.* ....(A) 506

Tuberculosis,
[Antiotensin-converting enzyme in serum of tuberculosis and leprosy patients.] Vinnik, L. A., *et al.* ....(A) 164
Association of pulmonary tuberculosis and HLA in South India. Brahmajothi, V., *et al.* (A) 691
BCG, tuberculosis, and leprosy. Kaklamani, E., *et al.* ....(A) 512
[Clinical importance of HLA phenotype in childhood tuberculosis.] Dovgalyuk, I. F., *et al.* ....(A) 376
Complement activation in pulmonary tuberculosis. Sai Baba, K. S. S., *et al.* ....(A) 185
Effect of the initial isoniazid resistance on response to chemotherapy of tuberculosis: a review of clinical trials. Al-Orainey, I. O. M. ....(A) 689
Epidemiological model and cost-effectiveness of tuberculosis treatment programmes in Indonesia. Joesoef, M. R., *et al.* ....(A) 181
Evaluation of a polymerase chain reaction for the diagnosis of tuberculosis. Manjunath, N., *et al.* ....(A) 530
[Features of qualitative changes in mycobacterial population in new elderly and senile cases of pulmonary tuberculosis during their treatment.] Dorozhkova, I. R., *et al.* ...(A) 178
Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India. Balasubramanian, R., *et al.* ....(A) 375
HIV seropositivity and tuberculosis in a rural Malawi hospital. Kelly, P., *et al.* ....(A) 378
[Immunoregulatory properties of monocytes/macrophages in patients with pulmonary tuberculosis.] Seledtsova, G. V. and Koslov, V. A. ....(A) 699

Immunotherapy with *M. vaccae* as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Stanford, J. L., *et al.* ....(A) 163
[Impact of acute respiratory viral infection on the immunity parameters of pulmonary tuberculosis patients.] Kossiy, N. M., *et al.* ....(A) 183
Improved immunotherapy for pulmonary tuberculosis with *M. vaccae.* Bahr, G. M., *et al.* ....(A) 374
In-vitro activity of ofloxacin against *M. tuberculosis* and its clinical efficacy in multiple resistant pulmonary tuberculosis. Yew, W. W., *et al.* ....(A) 188
Insertion element IS986 from *M. tuberculosis*: a useful tool for diagnosis and epidemiology of tuberculosis. Hermans, P. W. M., *et al.* ....(A) 181
M. vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Stanford, J. L., *et al.* ....(A) 518
Natural killer cell activity in patients with pulmonary tuberculosis and in healthy controls. Restrepo, L. M., *et al.* ....(A) 162
New strategies for leprosy and tuberculosis and for development of bacillus Calmette-Guérin into a multivaccine vehicle. Bloom, B. R. ....(A) 157
Prevalence study of tuberculous infection over fifteen years, in a rural population in Chingleput district (south India). Mayurnath, S., *et al.* ....(A) 696
Problems of tuberculosis treatment in Thailand. Jittinandana, A. ....(A) 181
Production and characterization of antibody against cord factor (trehalose 6,6′-dimycolate) in mice and its application to rapid serodiagnosis of human mycobacteriosis including tuberculosis and leprosy. He, H., *et al.* ....(A) 709
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. Shafer, R. W. and Jones, W. D. ....(A) 699
[Relation of sensitization to specific and nonspecific antigens to an individual type of immune reaction in pulmonary tuberculosis patients.] Ginda, S. S. ....(A) 377
Sarcoidosis masquerading as leprosy, pulmonary tuberculosis and urolithiasis. Singh, K., *et al.* ....(A) 507
Serodiagnostic tests for tuberculosis: a need for assessment of their operational predictive accuracy and acceptability. Grange, J. M. and Laszlo, A. ....(A) 377
Smear-negative, culture-positive pulmonary tuberculosis; six-month chemotherapy with isoniazid and rifampin. Dutt, A. K., *et al.* ....(A) 179
[Specific tuberculosis prophylaxis by BCG vaccine in young subjects.] Bubochkin, B. P. and Ivanova, E. S. ....(A) 691
[Study of genetic markers in the families of patients with tuberculosis.] Rakhimov, A. K. and Pospelov, L. E. ....(A) 379
The changing epidemiology of tuberculosis and other mycobacterial infections in the United States: implications for the radiologist. Buckner, C. B., *et al.* ....(A) 692
The Heiser Program for Research in Leprosy and Tuberculosis, 1992. ....(N) 668
[The role of precipitating antibodies in the serum of tuberculosis patients.] Klyshev, T. L., *et al.* ....(A) 695
Tuberculosis and leprosy. Rees, R. J. W. ....(A) 345
Tuberculosis in patients with various HLA phenotypes. Khomenko, A. G., *et al.* ....(A) 182

U.K.,
ILEP General Secretary joins governing membership of UIA. ....(N) 666
"Implementing Multiple Drug Therapy for Leprosy" to be reprinted. ....(N) 342
New course on health education/promotion. ....(N) 666
Ofloxacin trials. ....(N) 667
Plasmid analysis of *M. avium-intracellulare* (MAI) isolated in the United Kingdom from patients with and without AIDS. Hellyer, T. J., *et al.* ....(A) 694
TAMILEP—Catalog of teaching and learning materials. ....(N) 343
TAMILEP English Language Booklist 1990. ....(N) 140
Wellesley Bailey Scholarship closed. ....(N) 142

Ulcer(s),
Methods of treating plantar ulcers. Birke, J. A., *et al.* ....(A) 372
Role of topical phenytoin in trophic ulcers of leprosy in India. Malhotra, Y. K. and Amin, S. S. ....(C) 337

Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Youle, M., *et al.* ..... (A) 188
Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Gorin, I., *et al.* ..... (A) 180

Urine,
Antibodies to phenolic glycolipid-1 of *M. leprae* in urine of leprosy patients. Patil, S. A., *et al.* ..... (A) 162
Assessment of cure in schistosomiasis patients after chemotherapy with praziquantel by quantitation of circulating anodic antigen (CAA) in urine. Van Lieshout, L., *et al.* ..(A) 700
Detection of antibodies to 35 kD determinant of *M. leprae* in urine and serum of leprosy patients. Path, S. ..... (A) 162
Detection of *M. leprae*-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients. Singh, N. B., *et al.* ..... (O) 398

U.S.A.,
ALM International education and training materials. ..... (N) 142
Carville Seminar Dates 1992–1993. ..... (N) 667
18th World Congress of Dermatology call for abstracts. ..... (N) 343
18th World Congress of Dermatology scholarships available. ..... (N) 343
Hansen's disease (leprosy): the North Carolina experience. Fleischer, A. B., Jr., *et al.* ..(A) 145
Heiser Program's first decade. ..... (N) 142
INMED's health education materials (EDTEC) program. ..... (N) 667
Leprosy poster from ALM International and Wellcome. ..... (N) 343
New leprosy cases in 1990. ..... (N) 143
The changing epidemiology of tuberculosis and other mycobacterial infections in the United States: implications for the radiologist. Buckner, C. B., *et al.* ..... (A) 692
The face of leprosy in the United States today. Jacobson, R. ..... (A) 345
The Heiser Program for Research in Leprosy and Tuberculosis, 1992. ..... (N) 668

U.S.–Japan Cooperative Medical Science Program,
U.S.–Japan Cooperative Medical Science Program, Seattle, Washington, U.S.A., 6–9 August 1991. ..... (—) 702
U.S.–Japan Twenty-fifth Joint Leprosy Research Conference, Sapporo, Japan, 27 and 29 August 1990. ..... (—) 189

Vaccination,
Leprosy vaccines. Fine, P. and Dockrell, H. ..... (A) 680
The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. Friedland, I. R. ..... (A) 179

Venezuela,
IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Ulrich, M., *et al.* ..... (O) 405

Viet Nam,
Leprosy and BCG in southern Vietnam. Abel, L., *et al.* ..... (A) 171

Vitamin(s),
Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Crowle, A. J. and May, M. H. ..... (A) 376

World Health Organization (WHO),
Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Becx-Bleumink, M. ..... (O) 558
Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi. Boerrigter, G., *et al.* ..... (O) 255
Industry and WHO collaborate in tropical disease research. ..... (N) 341
WHO Consultation on early diagnosis of leprosy. ..... (N) 666
WHO Interregional Conference on Leprosy Control in Africa. ..... (N) 131
WHO Tropical Diseases Research (TDR) budgets cut. ..... (N) 666

Yemen,
Prevalence of HIV infection among patients with leprosy in African countries and Yemen. Leonard, G., *et al.* ..... (A) 351

Zaire,
[Evaluation of an antileprosy program in Ueles (Zaire) (1975–1989).] Tonglet, R., *et al.* (A) 172
The reduction of the leprosy endemicity in northeastern Zaire. Tonglet, R., *et al.* ..... (A) 524
[Treatment and rehabilitation of deformities in leprosy in a district hospital (Kapolowe, Zaire).] Vuillet, F. and Tschibangu, P. ..... (A) 526

Zimbabwe,
Leprosy control in Zimbabwe: from a vertical to a horizontal programme. Warndorff, D. K. and Warndorff, J. A. ..... (A) 173

Zinc,
Serum zinc/copper ratio in subtypes of leprosy and effect of oral zinc therapy on reactional states. George, J., *et al.* ..... (O) 20

ERRATUM: Vol. 58, No. 4, "The Chemotherapy of Leprosy. Part 1" by Gordon Ellard: Page 706, 2nd column, 2nd paragraph, line 9, 10^4 should be 10^6 bacilli. Page 712, 1st column, 2nd paragraph, line 14, mouse[7] should be mouse[71]. Page 716, footnote[135], Lepr. Rev. **25** should read Lepr. Rev. **55**.

ERRATUM: Vol. 59, No. 1, "Persistent Reduced Solubilization of Immune Complexes in Lepromatous Leprosy Patients with Reactions" by V. D. Ramanathan, *et al.* The reference list printed on page 11 is incomplete, and should have included those references listed below. We apologize to the authors for this oversight.

10. Ramanathan, V. D., Parkash, O., Ramu, G., Parker, D., Curtis, J., Sengupta, U. and Turk, J. L. Isolation and analysis of circulating immune complexes in leprosy. Clin. Immunol. Immunopathol. **32** (1984) 261–268.
11. Ramanathan, V. D., Parkash, O., Tyagi, P., Sengupta, U. and Ramu, G. Activation of the human complement system by phenolic glycolipid 1 of *Mycobacterium leprae*. Microb. Pathog. **8** (1990) 403–410.
12. Ramanathan, V. C., Sharma, P., Ramu, G. and Sengupta, U. Reduced complement mediated immune complex solubilization in leprosy patients. Clin. Exp. Immunol. **60** (1985) 553–558.
13. Ramu, G. and Dharmendra. Acute exacerbations (reactions) in leprosy. In: *Leprosy. Vol. I.* Dharmendra, ed. New Delhi: Kothari Publishing Co., 1978, pp. 108–139.
14. Ridley, D. S. and Jopling, W. H. Classification of leprosy according to immunity; a five-group system. Int. J. Lepr. **34** (1966) 255–273.
15. Saha, K., Chakrabarty, A. K., Sharma, V. K. and Sehgal, V. N. An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Lepr. Rev. **53** (1982) 253–260.
16. Sehgal, S. and Kumar, B. Circulating and tissue immune complexes in leprosy. Int. J. Lepr. **49** (1981) 294–301.
17. Takahashi, M., Takahashi, S. and Hirose, S. Solubilization of antigen-antibody complexes; a new function of complement as a regulator of immune reactions. Prog. Allergy **27** (1980) 134–166. (47 refs)
18. Valentijn, R. M., Faber, W. R., Lai A Fat, R. F., Chan Pin Jie, J. C., Daha, M. R. and van Es, L. A. Immune complexes in leprosy patients from an endemic and a nonendemic area and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum. Clin. Immunol. Immunopathol. **22** (1982) 194–202.
19. Wemambu, S. N. C., Turk, J. L., Waters, M. F. R. and Rees, R. J. W. Erythema nodosum leprosum; a clinical manifestation of the Arthus phenomenon. Lancet **2** (1969) 933–935.